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Abstract 
 
This work seeks to contribute to the discipline of neuropharmacology by way of 
structure activity relationship from the standpoint of an organic chemist.  More specifically, 
we sought to develop robust synthetic methodology able to efficiently produce an array of 
compounds for the purpose of systematic evaluation of their interaction with specific sights 
within the central nervous system (CNS) in order to better understand the mind and to 
develop drugs that may have beneficial effects on neurological function.   
The focus of these studies has been toward the development of novel molecules, 
using a structure-activity relationship approach, that exhibit binding affinity at specific 
targets within the CNS.  The merit of such studies is twofold: primarily, new compounds are 
produced that provide valuable scientific insight about their physiological targets, and 
secondarily, new synthetic methodologies that may arise in order to produce these 
compounds, thereby contributing to the whole of organic chemistry. 
As a result of the research described herein, the development of one high affinity 
and several moderate affinity compounds at the cannabinoid receptor subtype 1 (CB1) has 
been accomplished.  The research demonstrates that a diaryl ether molecular scaffold 
represents a successful motif in the cannabinoid pharmacophore.  The production of the 
compounds in the SAR studies also introduced a novel general synthetic methodology for 
the synthesis of diaryl ethers around a phloroglucinol core. 
A second project was initiated in order to explore the synthetic methods required to 
develop a general process for the synthesis of rigid aminobenzocyclobutane analogs of 
x 
 
known phenethylamines with activity at monoaminergic neurotransmitter sites.  Using the 
synthetic approach devised here, four novel aminobenzocyclobutane isomeric analogs of a 
known pharmacologically active phenethylamine, (RS)-phenylpropan-amine were 
synthesized and are currently being evaluated for pharmacological potential. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Neuroscience, CNS-Active drugs, Cannabinoids, CB1 Receptor, Biogenic Amines, 
Serotonin, Dopamine, Norepinephrine, Drug Abuse, Addiction Pharmacotherapy, Organic 
Synthesis, Drug design   
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1 
Introduction 
 
1.1 CNS-active drugs, organic chemistry and the study of the mind  
 
 This introduction begins with a broad historical overview citing some early 
milestones in CNS-drug development and their relation to the interwoven collaborative 
efforts between early chemists and pharmacologists.  In doing so, our motivation in 
completing this work of chemistry and pharmacology shall hopefully become partially 
revealed.  As this introduction progresses, the focus will narrow accordingly and ultimately 
lead into the tiny sliver of new information contributed by the subsequent chapters. The 
discussion begins with a broad overview of the first synthetic CNS-active drugs and the 
interesting early history of these compounds.  The development of the first synthetic CNS-
active drugs was paralleled by the emerging support of the receptor theory of drugs, which 
will subsequently be reviewed.  Receptor theory leads to a review of the pharmacodynamic 
techniques used to access the activity of drugs followed by an analysis of the specific 
receptor family which nearly all known CNS active drugs affect, the G-protein coupled 
receptors.  Finally, two specific GPCR sites in the CNS and their corresponding ligands—the 
cannabinoids and monoamine neurotransmitters—will be discussed in some detail.  The 
goal of this introduction is to funnel the reader into the ultimate rationale behind 
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completing the work described in this dissertation, along with providing suitable 
background information to support the subsequent chapters.  
 
1.1.1 Why develop compounds that affect the CNS? 
 
A CNS-active drug may be broadly defined as a compound able to cross the blood-
brain barrier and cause changes in perception, mood, consciousness, cognition, and 
behavior.  One of the simplest methods for studying the underlying mechanisms and 
functioning of the brain is by observing physiological responses elicited by external 
chemical influences, or drugs that function as “molecular probes.”  A wealth of knowledge 
about the body and brain has been acquired in the last century by studying the correlation 
between the structural features of chemical species and how they interact with the CNS, 
both at the cellular level and universally.   In doing so, we have begun to develop at least a 
partial understanding of the endogenous mechanisms by which the CNS functions under 
normal physiological conditions.  In turn, we are provided with valuable information for 
understanding the pathophysiology of the mind when affected by disease; subsequently, 
we are provided with potential treatments for easing the suffering associated with these 
conditions.  Studying the underlying mechanisms of the CNS by way of “chemical probes” 
contributes valuable information towards understanding one of the greatest puzzles in 
science: the human brain.  
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1.1.2 A Brief History of the First CNS-Active Drugs 
 
Humans have been utilizing plants, herbs and other naturally occurring substances 
to treat illness and manipulate physiological functions for thousands of years. However, it 
was the almost concurrent advent of organic chemistry and modern pharmacology in the 
late nineteenth century that has provided a systematic means by which to study and 
understand how exogenous organic compounds affect the mind and body.  The roots of this 
revolution can be traced back to approximately 1804 with the extraction and isolation of 
the principle active component of the opium poppy, morphine, by Austrian pharmacist 
Friedrich Wilhelm Sertürner.1 Using the principles of acid/base extraction, a technique that 
is still ubiquitous in any modern organic chemistry laboratory, morphine became the first 
isolated active ingredient from an herb or other plant. Application of the scientific method 
to isolating and purifying natural products, obtaining new compounds by chemical 
synthesis, and observing their physiological attributes have since become central themes in 
the disciplines of organic chemistry and pharmacology.   
The development of early CNS-active drugs owes it beginnings in part to antibiotics 
and Fleming’s discovery of penicillin in the 1920’s as well as World War II for increasing 
the demand for the substance, as these factors provided the basis for the pharmaceutical 
industry that exists today.  Once an effective antibiotic was identified in a naturally 
occurring source, organic chemists were employed to develop variations of the structure 
by chemical modification in order to produce patentable compounds with improved safety 
and efficacy that could be produced on large scale.  The structure-activity relationship 
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methodology became a universal approach for the development of new drugs, including 
CNS-medications.2  
A series of chance discoveries between the 1930’s and 1960’s helped set the stage 
for the development of many drugs that helped scientists understand and treat disorders of 
the mind.  A classic example of one of these serendipitous discoveries was the development 
of chlorpromazine (1.3), the first effective treatment for schizophrenia, from a commonly 
used industrial dye.3 The dye, methylene blue (1.1), introduced a new class of molecules 
called phenothiazines in the late 1800’s, which had interesting properties aside from 
turning things blue. Specifically, methylene blue demonstrated antimalarial properties 
when ingested.4 Efforts in the early 1940’s to synthetically modify phenothiazines to 
produce more effective antimalarial agents largely failed, but the researchers noticed that 
some of the compounds synthesized had antiemetic and sedative properties in individuals 
on which they were tested (many years later, these drugs would collectively become 
known as antihistamines).4   One of the most effective compounds at inducing sedation was 
called promethazine (1.2).  In an attempt to further exploit the favorable sedative 
properties of promethazine and produce something useful for inducing anesthesia before 
surgery, Paul Charpentier working for Rhône-Poulenc (a French pharmaceutical company) 
synthesized a series of related compounds including one to become known as 
chlorpromazine (1.3) in 1950.  In a clinical setting, physician Henri Laborit observed that 
chlorpromazine produced, “a tendency to sleep and disinterest in the surroundings.”5,6 In 
the same report, Laborit mentioned that this calming property might potentially be useful 
for treating individuals afflicted with schizophrenia, and subsequently, chlorpromazine 
was made available to professionals in psychiatry.  The therapeutic potential of 
5 
 
chlorpromazine was immediately realized and within three years (1953-1955), 
chlorpromazine was being used around the world as a treatment for schizophrenia.7   
 
Scheme 1.1 From blue dye to the first pharmacological treatments for schizophrenia 
 
1.1 1.2 1.3 
 
The drug imipramine (1.4) came about as a result of further modification of the 
chlorpromazine scaffold to produce a new class of compounds based on an iminodibenzyl 
system.  Unlike chlorpromazine, it was found to not be particularly useful as an 
antipsychotic drug and actually made the symptoms of agitated psychotic patients slightly 
worse, with the exception being patients who exhibited symptoms of depression.  To the 
researchers’ surprise, it was noted that depressed individuals became more animated upon 
treatment with imipramine.  These observations ultimately led to a new class of drugs 
known as tricyclic anti-depressants (TCAs), which are still prescribed today.7  
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Scheme 1.2. From chlorpromazine to the first tricyclic antidepressants 
 
                                            1.3                            1.4 
 
Around the same time as the development of imipramine, research was underway to 
develop hydrazine-derived compounds that could potentially treat tuberculosis.  While its 
use as a treatment for tuberculosis largely failed, it was discovered that patients who were 
administered the drug ipronazid (1.5) became “inappropriately happy.”8 Along with 
imipramine, ipronazid became one of the first pharmacological treatments for depression.  
It would eventually be discovered that ipronazid acted by inhibiting the enzyme 
monoamine oxidase and years later would lead to the discovery of an entire class of drugs 
that behaved similarly; these drugs are collectively known as monoamine oxidase 
inhibitors or MAOIs.9   
 
Figure 1.1. Ipronazid, the first MAOI antidepressant 
 
1.5 
 
In addition to chlorpromazine, iproniazid, and imipramine, CNS-active drugs such as 
lithium and the barbiturates also gained popularity during the first half of the twentieth 
 century. These compounds helped to validate the pioneering work of researchers such as 
Otto Loewi, who in 1921, demonstrated for the first time that ne
communicate by chemical messengers
contributing to our basic understanding of the mind, these compounds served as probes 
into brain function and fundamentally changed the way medical profe
psychiatric syndromes, providing
understood.2   
 
Figure 1.2. Timeline of CNS drug development
 
With the solidification of receptor occupancy theory in the 1950’s (discussed below) 
and experimental evidence describing the e
7 
urons were able to 
, later dubbed neurotransmitters.  In addition to 
ssionals viewed 
 a chemical basis by which psychiatric disorders could be 
2 
xistence of neurotransmitters, a new era of 
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drug design began to emerge where novel drugs could be discovered by a means other than 
luck, serendipity, and ethically questionable human clinical trials.  The concept of a 
receptor provided a target at which chemists could aim and a theoretical basis upon which 
compounds could be designed.  As illustrated by Figure 1.2, the chance discoveries 
between the 1930’s and 1960’s that introduced tricyclic antidepressants and monoamine 
oxidase inhibitors set the stage for scientists to devise new theories about how these 
compounds affected the brain.  As a result, these compounds helped to solidify many 
concepts underlying CNS functioning via neurotransmitters and the mechanisms by which 
they mediate specific processes in the body.   
A comprehensive review of the subsequent advances in CNS-active drug design that 
occurred from the 1960’s to present day and contributed to our current understanding of 
the mind would be a daunting task well beyond the scope of this work.  The remainder of 
this introduction shall focus on the tenets of rational drug design and its founding 
principles followed by a discussion of the current state of the art in two frontiers in the 
study of the mind: the biogenic amines and the cannabinoids. This will conveniently 
transition into the research that is the subject of this dissertation in the subsequent 
chapters.   
 
1.2 Early History of Pharmacology and Receptor Theory 
During the first half of the twentieth century, where the previously mentioned 
compounds and many others were being discovered by luck, serendipity, and basic 
scientific experimentation, the actions of these compounds were only explained vaguely 
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and with reference to affinities to certain organs and tissues or even extraordinary 
chemical powers.10 In an effort to provide a more rigorous and formal explanation 
regarding the actions of drugs, the discipline of pharmacology developed alongside these 
milestone drug discoveries during this time period.    
The emergence of drug-receptor theory came about as a result of several 
conclusions published by Cambridge physiologist John Newport Langley (1852-1925) and 
the Berlin immunologist Paul Ehrlich (1854-1925).  In 1905, following nearly 30 years of 
observations, Langley concluded that the naturally derived toxins nicotine and curare act 
on “receptive substances on muscle cells.”11 Meanwhile, based partially on his observations 
of the interactions of dyes with cells (histological staining), Ehrlich proposed the existence 
of “chemoreceptors” for drugs in 1907.12 However, until about 1930, receptor theory was 
otherwise not well supported theoretically or experimentally and therefore was not widely 
accepted, and several alternative theories had been proposed during this time.13   
Quantitative analysis of drug action on cells by British pharmacologist Alfred Joseph 
Clark  (1885-1941) helped garner significant support for the concept of drug receptors in 
the early 1930’s.  In his 1933 publication, The Mode of Action of Drugs on Cells, Clark sought 
to apply concepts of physical chemistry to the interactions between drugs and cells.14 He 
reasoned that from calculations describing the relatively small size of molecules such as 
adrenaline and acetylcholine at sparse physiological concentrations compared to the 
relatively large surface area of the heart cells that they affected, they were likely to “…exert 
their action by uniting with certain specific receptors in or on heart cells,” and furthermore, 
that these receptors formed only an insignificant proportion of the total surface of cells.  
His approach recognized that the Law of Mass Action probably governed the rate at which 
10 
 
drugs reversibly bound to receptors in cells as an equilibrium process.  He noted that the 
relation between drug concentration and the elicited biological effect followed a simple 
hyperbolic function in the same way that a gas reversibly adsorbs onto a metal surface at 
different concentrations, which was a principle already well studied in physical chemistry.  
Clark concluded that the equilibrium between a drug present in excess that reacts with a 
finite number of cell receptors to form an easily dissociable compound would produce the 
same hyperbolic curve as gas adsorption on a metal surface.  His work would collectively 
become known as receptor occupancy theory.  With R. P. Stephenson’s introduction of the 
concept of efficacy (the ability to induce an effect after binding) to receptor occupancy 
theory in 1956, the basis of modern pharmacodynamic analysis had been established.14,15 
Further advances in providing the experimental evidence to support receptor 
occupancy theory relied heavily on the collaboration between organic chemists and 
pharmacologists, as the ability to study the pharmacological properties of receptors relied, 
by definition, on the availability of compounds able to selectively stimulate or antagonize 
the effects elicited by the receptors.  Furthermore, perhaps the greatest contribution that 
organic chemistry has made to the study of pharmacology and the establishment of 
receptor theory was the synthesis of the first radioactively labeled drugs that provided the 
necessary probes able to demonstrate the existence of and visualize the receptors within 
the plasma membrane in the 1960-70’s.16,17   In the sections that follow, the focus will 
narrow upon the experimental and theoretical elements necessary for understanding and 
quantifying the actions of drugs on receptors, and in turn, how we may strategically design 
drugs targeting specific receptors based on these principles.   
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1.2.1 Binding affinity  
The mathematics introduced by the Law of Mass Action to describe the 
concentration-response data provided a strong theoretical basis to describe the actions of 
drugs. A macroscopic static representation of this concept is shown in Figure 1.3, where a 
free ligand (L) at some concentration may bind reversibly with a receptor (R) forming 
receptor ligand complex (RL). Experimentally, if one quantified and plotted the cellular or 
physiological response elicited by varying concentrations of ligand (L), a hyperbolic curve 
would result.  Conventionally, the logarithm of concentration is used for these plots, 
producing the sigmoidal dose-response curve shown in Figure 1.4.  If the binding affinity 
of ligand (L) is defined by the chemical forces that cause the drug to associate with the 
receptor, then this property can be viewed in terms of the equilibrium of bound and 
unbound state to the receptor at given concentrations.  The term Kd is called the 
dissociation constant and its value, with units of concentration, reflects the affinity of the 
ligand to the receptor, described by the relation Kd = [R][L] / [RL].  The value Kd is defined 
as the concentration of ligand that occupies 50% of the receptors at equilibrium, i.e. when 
[R] = [RL]; Kd = [L], and therefore, a smaller concentration of Kd reflects a higher affinity of 
ligand L for receptor R. 
 
 Figure 1.3. Schematic of ligand receptor binding
 
Figure 1.4. Sigmoidal dose-response curve of ligand receptor action
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For the purpose of this dissertation, the binding affinities of novel compounds were 
determined by an experimental technique called a radioligand competitive binding assay.  
This procedure allowed us to determine the binding affinity of unknown compounds by 
measuring their ability to displace a radioactive tritium-labeled compound with a known 
dissociation constant at a specific receptor site of interest.  Experimentally, this assay was 
conducted by adding a range of concentrations of the unknown compound to a radioligand 
bound to receptors at a fixed concentration.  The output of this type of experiment was 
ideally a sigmoidal curve of the form shown in Figure 1.5, where the vertical axis 
represented the amount of radioligand bound to receptors and the horizontal axis 
represented increasing concentrations of unknown compound.  From the curve, the IC50 
value of the novel compound may be determined, which is the concentration of unlabeled 
drug that displaced 50% of the radioligand.  From the IC50 value and known data about the 
radioligand, the Cheng-Prusoff equation (Figure 1.5) was used to produce the Ki value, or 
inhibition constant, for the drug, which represents an absolute value defined as the 
concentration of drug that would occupy 50% of receptors in the absence of radioligand.  
The experimentally determined Ki value should therefore be equal to the Kd value for the 
same compound, meaning the lower the value of this concentration, the higher the affinity 
of the compound for the receptor.  
 
 Figure 1.5. (Left) Characteristic sigmoidal curve produced by a radioligand competition binding assay. 
(Right) The Cheng-Prusoff equation:  IC
radioligand concentration and dissociation constant, respectively.  
 
1.2.2 Drug efficacy 
The word efficacy, also known as intrinsic activity, is a somewhat relative term that 
describes the degree by which a drug
is, if compound A produces a diminished physiological response compared to compound B
at the same receptor site, compound A is said to have lower efficacy than compound B.
terms agonist, partial agonist, neutral antagonist, and inverse agonist are use
drug efficacy.  A graphical representation in terms of dose
displayed in Figure 1.6. An expanded
below in Section 1.3 with specific regard to the cellular response elicited by G
coupled receptors. 
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Figure 1.6. Comparison of drugs with the same binding affinity but different efficacies  
 
 
1.2.3 G-Protein coupled receptors 
The elucidation of GPCRs began around the early 1960’s. The legacy left by the early 
pioneers of pharmacology such as Langley, Ehrlich, Stephenson, and Clark to the field of 
GPCR study was the concept of affinity and efficacy and the quantitative methods by which 
these properties could be understood.  This theory combined with a diverse array of 
compounds able to differentially interact with the receptors has provided many of the 
experimental tools necessary in constructing our understanding of these receptors.  Today, 
approximately 40-50% of drugs that are used clinically in humans and nearly 60-70% of 
those in development today target a G-Protein coupled receptor.18–21  
The G-protein coupled receptor (GPCR) family represents the most diverse and 
versatile group of cell surface receptors known.   These proteins serve as sensors capable of 
transducing an extracellular stimulus across the cell membrane barrier to activate 
intracellular signaling cascades. GPCRs consist of lipid bilayer spanning proteins and are 
characterized by seven transmembrane α-helices, known as the transmembrane domain.  A 
 schematic representation of a GPCR is illustrated in 
regions of the receptor exist in aqueous intra
take the form of random, helical, or 
connects to transmembrane-7 in the intracellular space and the N
connects to transmembrane-1 in the extracellular space.  Trans
connected by three extracellular loops (Exoloops 1
(Cytoloops 1-3) in the cytosolic space.
 
Figure 1.7. Cartoon illustration of a G
 
Figure 1.8 contains a cartoon illus
intracellular signaling cascades are primarily mediated by heterotrimeric GTP
proteins (G-proteins), which are activated or inactivated by conformational changes within 
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Figure 1.7.  The non-
- and extracellular environments and typically 
β-sheet conformations.  The C-terminal segment 
-terminal segment 
membrane helices are 
-3) and three intracellular loops 
22   
-protein coupled receptor viewed from within cell membrane
tration of the GPCR activation mechanism.  The 
transmembrane 
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-binding 
 the receptor.  When a G-protein 
exchanges GDP for GTP and the 
associated  with the intracellular membrane.  The subunits then become free to activate 
various signaling cascades via enzymatic action
phosphatidylinositol signal pathways.
 
Figure 1.8. Cartoon illustration of GPCR activation cycle
 
While it is sufficient in some cases to explain binding affinity and efficacy, the model 
of GPCR activation as a linear sequence of events in which the receptor acts as a “molecular 
17 
is activated by a receptor conformational change, it 
α subunit dissociates from the β-γ subunits, which stay 
—typically, cAMP, diacylglycerol, and/or 
22  
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 switch” when a ligand (L) binds is simplistic and n
dynamics of the process (Figure 1.
dynamic nature of the conformational state of the receptor protein.  An improved model 
called the cubic ternary complex shown i
approach to understanding GPCR functioning and considers the equilibrium of multiple 
combinations of ligand, receptor, 
receptors exist in a dynamic equilibrium of conformational states.
 
Figure 1.9. Models of receptor occupancy/activation
 
For the purpose of understanding the activity of the cannabinoids studied in this 
dissertation, a simplified approach to the cubic ternary model may b
the considerations of interactions with G
18 
ot an entirely accurate depiction of the 
9A).  The process is more thoroughly described by the 
n Figure 1.9B demonstrates a more refined 
and effector proteins, as well as taking into account that 
25   
 
e taken which omits 
-proteins. As illustrated in Figure 1.1
 
0, it provides 
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a means to understanding the so-called inverse agonism of some of the compounds 
discussed.  This model may be understood on the basis that, in the absence of ligand, the 
receptors exist in a dynamic equilibrium of active and inactive states (R vs. R*); this 
consequently results in some basal level of transduction of second messengers even when a 
ligand is not present.  The efficacy label that we apply to a ligand is a result of the 
compounds’ ability to stabilize either of these states, thereby biasing the equilibrium 
towards either the active state or the inactive state.  Partial to full agonists are therefore 
defined as compounds that stabilize the active state of the receptor to some degree, and 
inverse agonists are compounds that stabilize the inactive state.  If a ligand stabilizes both 
states approximately equally, thereby maintaining the basal state of the receptor while 
simultaneously blocking the active site, it is said to be an antagonist.  This model provides a 
rational theoretical basis to explain why drugs that are considered inverse agonists at a 
receptor tend to have essentially the opposite physiological effects as agonists at the same 
receptor (i.e. cannabinoid inverse agonists reduce appetite while agonists increase 
appetite). 26  
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Figure 1.10. Constitutive activity in relation to GPCR dynamics27 
 
To further complicate our understanding of GPCR efficacy, recent empirical data has 
demonstrated that certain GPCRs and ligands exhibit a phenomenon known as functional 
selectivity, where a single receptor exhibits ligand-dependent differential activation of 
multiple signal transduction pathways. A key example that is especially relevant to 
Chapter 8 of this dissertation is the activity of the functionally selective 
aminobenzocyclobutene, (R)-2C-B-CB (8.4a) at the 5HT2A receptor.28,29   Figure 1.11 
illustrates functional selectivity via dose-response curves for two related compounds’ 
ability to activate the GPCR 5HT2A with respect to two separate second messengers. The 
panel on the left displays the dose-response relationship for accumulation of inositol 
phosphates (PI) and on the right arachadonic acid (AA) release.  Looking at the panel on 
 the left, both compounds have approximately the same efficacy with respect to 
accumulation of inositol phosphates, whereas (R)
at stimulating AA release while DOB exhibits about the same efficacy relative to PI (right 
panel).  Comparing the two compounds, it could be said that DOB is not a functionally 
selective ligand, whereas (R)-2B
second messengers.  
 
Figure 1.11. Comparison of functional selectivity at 5HT2A receptors
 
With the above example of functional selectivity in mind, once again, the 
collaboration between pharmacologists and chemists has been paramount in the 
development of this concept of functional selectivity, which currently exists as the state of 
the art in pharmacology.     
 
1.3 Biogenic amine neurotransmitters and receptors within the CNS
The biogenic amines function as neurotransmitters in the brain.  That is, they are 
endogenous chemicals that transmit signals from (presynaptic) neurons across synapses 
21 
-2C-B-CB is nearly 36-fold less efficacious 
-B-CB is functionally selective with respect to these two 
28 
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and bind to receptors (usually a GPCR) on target (postsynaptic) neurons.22 The biogenic 
amine neurotransmitters mediate a broad scope of mechanisms within the central nervous 
system, and understanding their role has been an attractive area of research for scientists 
interested in understanding the brain for many years. Referring back to Figure 1.2, most of 
the early serendipitous discoveries of CNS-active drugs were later found to manipulate one 
or more of the biogenic amine pathways.  Though a complete discussion of the 
neuroscience of the biogenic amines is well beyond the scope of this introduction, a brief 
overview will follow with the goal of demonstrating why the manipulation of these 
neurotransmitters via exogenous chemical influences has the ability to provide valuable 
insight about the mechanics of the brain and useful pharmacotherapies for treating 
disorders of the mind.       
The biogenic amines relevant to CNS functioning are comprised of three classes of 
neurotransmitters: the catecholamines, which include dopamine (1.6), norepinephrine 
(1.7), and epinephrine (1.8); the indolamines, which include serotonin (1.9) and melatonin 
(1.10); and finally, histamines (1.11).   For the purpose of this dissertation and specifically 
the research described in Chapter 8, only CNS mechanisms associated with the 
neurotransmitters dopamine and serotonin will be discussed in detail. 
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Figure 1.12. The biogenic amine neurotransmitters 
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In the brain, the cell bodies that primarily communicate via dopamine signalling are 
found in the midbrain and are comprised of the mesostriatal, mesolimbocortical, 
periventricular, and tuberohypophyseal systems.  Manipulation of these dopaminergic 
pathways has been found to correlate with behaviors including motor control, cognition, 
and especially rewarding behaviors associated with sex, thirst, and appetite.  It is currently 
hypothesized that dopaminergic mediation is central to all addictive drugs and 
behaviors.30,31 The addictive effects of psychoactive stimulants such as cocaine (1.12), 
amphetamine (1.13), and methamphetamine (1.14) illustrate prototypical examples of 
dopamine’s role in rewards associated with addiction as all of the drugs have been found to 
function by effectively increasing the levels of dopamine at the synapse.32 Consequently, 
pharmacotherapies with the goal of mitigating the behaviors associated with the disease of 
addiction will most certainly target dopaminergic pathways in some way.32 Abnormally low 
dopamine levels resulting in aberrant dopamine function in nigrostriatal pathways has 
been highly implicated in the motor deficits associated with Parkinson’s disease.33 
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Compounds that block dopamine receptors (antagonists), such as 1.3, are effective as 
antipsychotic drugs.34   
 
Figure 1.13.  Stimulants: cocaine, amphetamine, methamphetamine 
 
1.12 1.13 1.14 
 
Serotonergic cells are primarily centralized in two clusters within the brain: the 
caudal system within the medulla and the rostral system in the midbrain. These cells then 
project throughout the rest of the CNS, suggesting that serotonergic signaling is far-
reaching and mediates communication across many regions of the brain.35 Serotonin is the 
primary neurotransmitter associated with behaviors relating to appetite, sleep, and 
aggression (“mood“ in humans).36 It has been found that serotonin reuptake blockers such 
as fenfluramine, (1.15), which increase serotonin at the synapse, are effective in 
significantly reducing appetite.37  Conversely, decreased levels of serotonin at the synapse 
are generally associated with increased aggressiveness.38 Measurements of levels of 
serotonin metabolites in the cerebrospinal fluid and blood of animals and humans can be 
an accurate predictor of a history of aggressive behavior.39,40 Considerable attention has 
also been focused on the production of drugs that modulate serotonergic signaling for the 
purpose of treating depression.  Once again, referring back to Figure 1.3, many of the early 
drugs that were found to be useful in easing the symptoms associated with depression 
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(TCAs, SSRIs, MAOIs) were later found to modulate serotonergic circuits in one or more 
ways. 
 
Figure 1.14. Fenfluramine, an appetite-reducing serotonin-increasing compound 
 
1.15 
 
Unfortunately, the analysis above paints an incomplete and overly simplistic picture 
of the nature of biogenic amine neurotransmitters. The story is complicated significantly by 
the fact that the GPCRs (and other proteins) to which these neurotransmitters bind are 
quite diverse, existing as a multitude of related yet functionally distinct subtypes that are 
fundamentally interwoven physiologically.36,41,42 Furthermore, the emerging evidence that 
these neurotransmitters can also be modulated by “third party” cannabinoids (discussed 
below) further complicates the puzzle.43–46 Therefore, part of our motivation in producing 
the compounds described in the subsequent chapters was to provide additional tools to 
hopefully aid in the continued elucidation of these central mechanisms of the brain.  
 
1.4 Cannabinoids and endocannabinoids 
 
Cannabinoids are molecules that selectively bind to a unique class of G-protein 
coupled receptors.  To date, two subclasses of cannabinoid receptor, CB1 and CB2, have 
been studied in detail.  Additional subtypes of the cannabinoid receptor have been 
26 
 
hypothesized to exist, but are not yet well understood or thoroughly supported 
experimentally.47–49 Cannabinoids and their receptors function in the cell by a unique 
mechanism known as retrograde signaling where, in contrast to classical 
neurotransmitters, cannabinoids are synthesized in the post-synaptic neuron and bind to 
receptors presynaptically in order to suppress neurotransmitter release.50  
Though humans have consumed the cannabis plant for thousands of years, our 
scientific understanding of the receptor system that interacts with the plant’s 
pharmacologically active constituents has only recently begun to be elucidated, and 
cannabinoids currently represent a new frontier in understanding one of the fundamental 
mechanisms of the brain.  In 1964, Δ9-tetrahydrocannabinol (THC, 1.16), the primary 
active component of cannabis, was isolated and synthesized by Gaoni and Mechoulam.51 At 
the time, it was believed that the highly lipophilic molecule interacted nonspecifically with 
cell membranes. Not until twenty years later in the 1980’s did Howlett & Fleming publish 
data which indicated that the receptor that responds to Δ9-THC may be a G-protein-coupled 
receptor.52 However, further elucidation of the receptor was impeded due to the lipophilic 
nature of THC.  This problem was circumvented by Pfizer’s development of a more 
hydrophilic THC synthetic analog, CP-55,940 (1.17).   
 
Figure 1.15. Plant-derived Δ9-tetrahydrocannabinol and the hydrophilic synthetic analog, CP-55,940 
 
1.16 1.17 
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Using radiolabeled CP-55,940 binding site distribution data combined with the 
pattern of mRNA expression of a specific GPCR, the first cannabinoid receptor was 
definitively identified in the rat brain in 1990.53 A second receptor was discovered in 1993 
by The Munro group with 44% sequence similarity that exhibited binding affinity for Δ9-
THC and CP-55,940; this receptor was found to be primarily expressed in the immune 
system, but not the brain.  In order to distinguish between the two receptors, Munro and 
colleagues coined the brain and immune receptors CB1 and CB2, respectively, in 1993.54 
 Despite the mounting data indicating the existence of a receptor system activated by 
plant-derived Δ9-THC, it would be reasonable to assume that the endocannabinoid system 
did not evolve for the purpose of cannabis consumption.  Indeed, not long after the two 
cannabinoid receptors were identified, Mechoulam (who determined the structure of THC 
in 1964) and several others independently isolated the putative endogenous cannabinoid 
receptor ligands, anandamide (1.18, Sanskrit for “bliss”) and 2-arachidonyl glycerol (1.19, 
2-AG).55–57 Although anandamide and 2-AG are the most well studied endocannabinoids, 
many other endogenous molecules have been implicated in cannabinoid signaling. These 
molecules generally consist of amides, esters, and ethers of long chain polyunsaturated 
fatty acids.58 
 
Figure 1.16. Anandamaide and 2-arachidonyl glycerol, the endocannabinoids 
 
1.18 1.19 
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The development of selective agonists and antagonists for CB1 and CB2 allowed 
researchers to definitively distinguish between the two receptors. Synthesized by Sanofi 
Recherche, SR141716A (1.20) was the first CB1 selective inverse agonist.  This compound 
demonstrated nanomolar affinity for CB1 but only micromolar affinity for CB2.59  Four 
years later, SR144528 (1.21) was developed. Compound 1.21 has a 700-fold lower affinity 
for CB1 than CB2.60 Thus, both receptors could be studied in detail independently. 
Figure 1.17. SR141716A and SR144528, selective CB1 and CB2 receptor ligands 
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The role of cannabinoids in the brain is complex and many psychological, 
behavioral, and physical processes are implicated.  Cannabinoids are believed to function 
as “homeostasis regulators” in the body.61 Endocannabinoids are synthesized on-demand 
in post-synaptic neurons and bind to cannabinoid receptors on pre-synaptic neurons, 
thereby tuning down, or attenuating, the rate of anterograde neurotransmission.  As 
illustrated in Figure 1.18, the endocannabinoid 2-AG is shown to regulate glutamate 
neurotransmission by forming a negative feedback loop.  Glutamate is released 
presynaptically and binds to receptors on the postsynaptic neuron, which in turn activates 
enzymes that increase endocannabinoid synthesis from membrane lipids.  The 
endocannabinoids are then released into the synapse where they bind to cannabinoid 
 receptors on the presynaptic neuron.  The ca
to attenuate glutamate vesicle packaging, thereby regulating glutamate release.  
 
Figure 1.18. Schematic of cannabinoid retrograde signaling at the synapse
 
  CB1 receptors are expressed 
range of physiological functions
CB1 receptors inhibits the synaptic release of many neurotransmitters 
aminobutyric acid, glutamate, acetylcholine
of monoamine neurotransmitters such as serotonin and dopamine by way of cannabinoid 
function holds particular promise for the development of new theories about the brain, and 
in turn, novel pharmacotherapies to treat disorders of the mind, given the significant 
behavioral implications of these neurotransmitters
29 
nnabinoid receptor in turn transduces a signal 
62 
throughout much of the CNS and therefore mediate a 
.63 As recent evidence has demonstrated, the activation of
, and the monoamines.45 The indirect regulation 
 as described in Section 1.3
 
 
 
including γ-
.   
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The therapeutic benefits of cannabinoid-mediated therapies have recently begun to 
be realized.  Cannabinoids generally exhibit low toxicity and demonstrate great potential 
for medicinal utility.64 Current cannabinoid based medications generally target the 
peripheral (non-psychoactive) CB2 receptor.  These medications include treatments for 
nausea and vomiting associated with chemotherapy, muscle spasticity associated with 
multiple sclerosis, alleviation of chronic pain, and glaucoma.65 Given the recent findings in 
the cannabinoids’ ability to regulate dopaminergic function, CB1 receptor ligands have 
become attractive targets for addiction pharmacotherapy.66 With this in mind, the research 
in the subsequent chapters was initiated in order to further explore this new frontier in the 
study of the mind and potentially develop compounds that may be medicinally useful in 
treating disorders of the mind by way of modulation of cannabinoid receptors. 
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2 
Diaryl Ether Hybrid Analogs as Cannabinoid Receptor Ligands – 
Rationale, Synthesis and Preliminary Data 
 
2.1 Abstract 
 
Preliminary data regarding the synthesis and utility of diaryl ether derivatives as 
cannabinoid receptor ligands is reported.  Initially, we sought to prepare hybrid analogs of 
BAY 59-3074 and CB25 in order to exploit the favorable properties of each molecule. Both 
compounds have demonstrated partial agonist activity at the CB1 receptor.  Molecular 
features of each compound were combined to synthesize hybrid derivatives in order to 
evaluate their pharmacological potential. Several moderate affinity compounds emerged 
and indicated that hybrid diaryl ethers may be viable as potential cannabinoid receptor 
ligands.   
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Scheme 2.1. Abstract scheme: BAY 59-3074 / CB 25 hybrid analogs 
 
2.2 Introduction 
The initial goal of this project was to develop novel high affinity low efficacy (neutral 
antagonist to partial agonist) CB1 receptor ligands. These compounds will be useful for 
exploring the (relatively unexplored) cannabinoid pharmacophore and specifically 
represent potentially attractive targets for addiction pharmacotherapy.1,2 While 
cannabinoid inverse agonist pharmacotherapies have been explored somewhat rigorously, 
neutral antagonist/partial agonist studies are more sparse, partially due to limited 
availability of useful compounds.  Cannabinoid inverse agonists have been implicated in 
being potentially useful for the treatment of a variety of disorders including obesity and 
addiction, but they tend to have undesirable side effects that include nausea, increased 
nociceptive activity, increased anxiety and depression.3–6 Many of these side effects were 
discovered in the clinical trials for the cannabinoid inverse agonist Rimonabant (2.1).7 It 
has been hypothesized that that low efficacy agonists/neutral antagonists may diminish 
some of the negative properties seen with inverse agonists, especially nausea, while 
retaining some of the desirable qualities of cannabinoid targeted pharmacotherapies.8   To 
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date, there are very few high affinity CB1 selective ligands that exhibit low efficacy profiles, 
and therefore, less is known about the CB1 partial agonist pharmacophore.  The research 
described in the present study was initiated with the goal of making novel high affinity, low 
efficacy cannabinoids available to the research community for further study. 
 
Figure 2.1.  Cannabinoid inverse agonist Rimonabant (SR141716) 
 
2.1 
 
 The compounds BAY 59-3074 (2.2) and CB25 (2.3) exhibit low efficacy agonist 
profiles both in vitro and in vivo as compared to THC. BAY 59-3074 was discovered by 
Bayer Pharmaceutical by screening compound libraries, and so a full SAR of this compound 
was not well established; this compound has only modest affinity at the CB1 receptor with 
a Ki value of 48.3 nM. The compound has demonstrated good bioavailability and blood-
brain barrier (BBB) penetrability.9 
 
Figure 2.2. BAY 59-3074, a CB1 receptor partial agonist 
 
2.2 
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The olivetol derivative CB25 was introduced by the DiMarzo et al. and exhibits high 
affinity (Ki = 5nM) at CB receptors.10,11 CB25 is, however, very lipophilic (ClogP = 6.2) and is 
unlikely to be a viable drug candidate.   
 
Figure 2.3.  CB25, a CB1 receptor partial agonist 
 
2.3 
 
With both of these compounds serving as leads, it was envisaged that perhaps a 
“hybrid derivative” could be developed in order to exploit the desirable properties of each 
molecule. To improve the hydrophilicity and take advantage of the high potency of CB25 
the amide side chain of CB25 was replaced with an aryl moiety similar to BAY 59-3074.   
We therefore sought to develop a synthetic methodology in order to produce compounds 
belonging to the scaffold shown in Figure 2.4 with general features including an electron-
deficient aryl ring coupled to an aryl system bearing hydrophobic alkyl chains and oxygen 
linkages. 
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Figure 2.4.  Preliminary ligand design strategy 
 
 
2.3 Results and Discussion 
 
The synthesis of target compounds was achieved in good to moderate yield and the 
details of these procedures have been described by our group elsewhere.12 Our general 
synthetic strategy is outlined in Scheme 2.2 and began with mono-protection of select 
alkyl-resorcinols 2.4a-g via benzylation using benzyl bromide and sodium hydride.  The 
alkyl-resorcinol precursors 2.4a-g were either commercially available or prepared 
according to previously established methods.12 Given the symmetry of these resorcinol 
compounds, a mixture of mono-benzylation and di-benzylation product was produced 
despite the use of only one stoichiometric equivalent of base, and so unfortunately only 
moderate yields of this early precursor could be obtained. Mono-protected alkyl-
resorcinols 2.5a-g were coupled to the electron-deficient aryl fluoride via a microwave-
assisted nucleophilic aromatic substitution to produce the corresponding diaryl ethers 
2.6a-g in good yield following the protocol established by the Wang group.13 Debenzylation 
via hydrogenolysis removed the benzyl protecting group and afforded the key diaryl ether 
scaffolds 2.7a-g.   
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The phenolic site of diaryl ether 2.7a was subject to further modification in order to 
expand our preliminary SAR. We hypothesized that introducing an ester at this position 
could possibly produce high affinity compounds that more closely mimic the structure of 
BAY 59-3074. Subjecting 2.7a to phase transfer catalysis conditions and an appropriate 
acid halide afforded compounds 2.8b-f as diaryl ether esters.   
  
Scheme 2.2. Synthetic strategy for the synthesis of target compounds 
 
            2.4a-ga      2.5a-g                   2.6a-g 
 
                 2.7a-g  
 
           2.7a        2.8b-f 
 
afor suffixs a-g, R = H, methyl, ethyl, propyl, butyl, pentyl, hexyl, respectively. 
 
 
Tables 2.1 and 2.2 represent a summary of the available bioassay data for the first 
generation of hybrid derivative diaryl ethers synthesized. Compounds 2.7d, 2.7e, 2.7f, 
2.6a, 2.8e demonstrated approximate micromolar affinity for the CB1 receptor, but no high 
41 
 
affinity nanomolar compounds emerged from the present studies.  The results were, 
however, encouraging enough to carry on with the SAR experiments and synthesize more 
compounds. A full analysis and discussion of the bioassay data from Tables 2.1 and 2.2 is 
presented in Chapter 6 within the context of the entire diaryl ether SAR studies. 
 
Table 2.1. In vitro binding data at CB1 and [3H]SR141716A inhibition for alkyl resorcinol series 
 
Cpd Code R CB1b 
(1 μM) 
 
CB1b 
(10 μM) 
 
[3H]SR141716A  
(CB1) Ki (nM)a
 
 
2.7a ARN142 H 3 37  
2.7b ARN156 CH3 16 30 21,055±3217
 
2.7c ARN167 CH2CH3 21 37  
2.7d ARN180 CH2CH2CH3 24 60  
2.7e ARN191 CH2(CH2)2CH3 35 94  
2.7f ARN158 CH2(CH2)3CH3 39 41 293±107 
2.7g ARN190 CH2(CH2)4CH3 nd nd  
a All the values are mean ± SEM of three experiments. b Binding affinities at CB1 receptor 
measured as % inhibition. 
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Table 2.2. In vitro binding data at CB1 and [3H]SR141716A inhibition for alkyl ester series 
 
Cpd Code R CB1b 
(1 μM) 
 
CB1b 
(10 μM) 
 
[3H]SR141716A  
(CB1) Ki (nM)a
 
 
2.6a AS109 Bn 49 56  
2.8b ARN199 COCH3 18 45  
2.8c ARN200 COCH2CH3 25 34  
2.8d ARN201 CO(CH2)2CH3 25 25  
2.8e ARN202 CO(CH2)3CH3 25 49  
2.8f ARN203 CO(CH2)4CH3 7 19  
a All the values are mean ± SEM of three experiments. b Binding affinities at CB1 receptor 
measured as % inhibition. 
 
 
2.4 Conclusion 
A series of BAY 59-3074 / CB 25 hybrid derivatives were synthesized to obtain a 
new class of diaryl ether CB1 receptor ligands. Alkyl ligands 2.6a-2.6g and ester ligands 
2.7b-2.7f were synthesized in good to moderate yield and subsequently evaluated for 
binding affinity at the CB1 receptor.  Several compounds with micromolar affinity for the 
receptor were discovered as a result. Future SAR studies will focus on further manipulation 
of the diaryl ether scaffold for the development of novel high affinity CB1 receptor ligands. 
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2.6 Experimental Section 
General Methods  
All chemicals were purchased from Aldrich Chemical Company unless otherwise noted. 
Anhydrous toluene, tetrahydrofuran (THF), dichloromethane (CH2Cl2), and methanol 
(MeOH) were purchased from Mallinckrodt Baker, Inc and were used under nitrogen 
without any further purification. Thin layer chromatography (TLC) 20 x 20 cm glass plates 
precoated with 250 μm silica gel were purchased from Sorbent Technologies and used to 
monitor reactions via visualization with short-wave UV light, iodine, potassium 
permanganate, phosphomolybdic acid (PMA), 2,4-dinitrophenyl hydrazine or 
Dragondorff’s reagent. Chromatography is in reference to column chromatography on silica 
gel (Silica Gel 60, 230-400 mesh). High-pressure hydrogenations were carried out on a Parr 
apparatus. Proton and carbon NMR were recorded on a Varian-Gemini 300 and 400 MHz 
nuclear magnetic resonance spectrometer, respectively at ambient temperature in 
deuterated chloroform from Cambridge Isotope Laboratories, Inc. 1H NMR chemical shifts 
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are reported in δ values (ppm) with tetramethylsilane (TMS), employed as the internal 
standard. 13C NMR chemical shifts are reported in δ values (ppm) with chloroform-D 
(CDCl3, 77.0 ppm), employed as the internal standard. Elemental analyses were obtained 
from Atlantic Microlabs, Inc.  
 
 
                                   2.4a-g                       2.5a-g 
General Method A: Preparation of monobenzylated 1,3-diols  
The appropriate alkyl resorcinol 2.4a-g (1 equiv.) in DMF was added dropwise to NaH (1 
equiv.) in DMF. The reaction mixture was allowed to stir for 30 minutes at room 
temperature. BnBr (1 equiv.) in DMF was added dropwise to the reaction mixture and 
allowed to stir for 2 h at room temperature. Distilled H2O was added and the mixture was 
extracted with EtOAc. The organic layers were combined, washed with 0.5 N HCl, washed 
with brine, dried over Na2SO4, and evaporated to dryness under reduced pressure.  
 
 
                                         2.5a-g                             2.6a-g 
General Method B: Preparation of Diaryl Ethers 
2-Fluoro-6-(trifluoromethyl)benzonitrile (1 equiv.), alkyl phenol 2.5a-g (1 - 1.2 equiv.), and 
potassium carbonate (2 equiv.) were added to DMSO. Using a microwave power of 300-400 
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W the temperature was ramped from room temperature to the boiling point of DMSO. 
Upon completion of the reaction, it was cooled to room temperature, put into ice water, and 
extracted with Et2O. The organic layers were combined, washed with 0.5 N HCl, washed 
with brine, dried over Na2SO4, and evaporated to dryness under reduced pressure.  
 
 
                                              2.6a-g                                    2.7a-g 
General Method C: Preparation of Debenzylated Diaryl Ethers  
A solution of O-benzyl diaryl ether 2.6a-g (1 equiv.) and 10% Pd/C (50 wt. %) in EtOH (23 
mL) was hydrogenated using a hydrogen balloon at 45 °C. The reaction mixture was 
filtered through celite and evaporated to dryness under reduced pressure.  
 
 
                                        2.7a                                    2.8b-f 
General Method D: Preparation of Esters 
Under argon, the phenol 2.7a (0.53 mmol) was dissolved in DCM and tetrabutylammonium 
iodide (0.27 mmol) and 20M NaOH were added and stirred. At 0 °C, the acid halide (0.63 
mmol) dissolved in DCM was added. The reaction mixture was allowed to stir for 1 h after 
the color change at 0 °C and for another 1h at room temperature. The reaction mixture was 
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diluted with water and extracted with DCM. The organic layers were collected, washed 
with brine, and dried over MgSO4.  
 
 
3-Benzyloxyphenol (2.5a)14,15  
General Method A. The residue was purified by column chromatography (SiO2, gradient of 
hexane, EtOAc/hexane, 1:5, 1:4) to afford 2.5a (0.86 g, 24%) as an amber oil. TLC: Rf 0.46 
(EtOAc/hexane, 1:4): 1H NMR (400 MHz; (CD3)2CO) δ 4.75 (broad s, 1, OH), 5.04 (s, 2H), 
6.43 (tt, J = 1.6 Hz, 2.0 Hz, 1H), 6.49 (t, J = 2.4 Hz, 1H), 6.56 (qq, J = 0.8 Hz, 0.8 Hz, 1H), 7.14 
(t, J = 8.4 Hz, 1H), 7.31-7.44 (m, 5H). 13C NMR (100 MHz; (CD3)2CO) δ 69.7, 102.6, 106.3, 
108.4, 127.8, 128.0(2), 128.7(2), 130.3, 137.8, 158.9, 160.6.  
 
 
3-Benzyloxy-5-methyl-phenol (2.5b)14,15  
General Method A. The residue was purified by column chromatography (SiO2,  
gradient of hexane, EtOAc/hexane, 1:5, 1:4) to afford 2.5b (1.0 g, 29%) as a pale yellow oil. 
TLC: Rf 0.44 (EtOAc/hexane, 1:4): 1H NMR (400 MHz; (CD3)2SO) δ 2.18 (s, 3H), 5.00 (s, 2H), 
6.24 (d, J = 4.4 Hz, 2H), 6.29 (s, 1H), 7.31 (t, J = 4.0 Hz, 3H), 7.35-7.43 (m, 2H), 9.30 (broad s, 
1, OH). 13C NMR (100 MHz; (CD3)2SO) δ 21.3, 69.0, 99.4, 106.4, 108.9, 127.6(2), 127.7, 
128.4(2), 137.4, 139.5, 158.5, 159.6.  
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3-Benzyloxy-5-ethylphenol (2.5c) 14,15  
General Method A. The residue was purified by column chromatography (SiO2, gradient of 
hexane) to afford 2.5c (0.379 g, 18%) as a yellow oil. TLC: Rf 0.47 (EtOAc/hexane, 1:4): 1H 
NMR (400 MHz; CDCl3) δ 1.21 (t, J = 7.6 Hz, 3H), 2.57 (q, J = 7.6 Hz, 2H), 4.61 (broad s, 1, 
OH), 5.02 (s, 2H), 6.31 (q, J = 2.4 Hz, 1H), 6.44 (s, 2H), 7.33-7.44 (m, 5H). 13C NMR (100 
MHz; CDCl3) δ 15.5, 29.1, 70.2, 99.7, 107.4, 107.8, 127.8(2), 128.2, 128.8(2), 137.2, 147.4, 
156.7, 160.3. 
 
 
3-Benzyloxy-5-propylphenol (2.5d) 14,15 
General Method A. The residue was purified by column chromatography (SiO2, gradient of 
hexane) to afford 2.5d (0.256 g, 19%) as a yellow oil. TLC: Rf 0.51 (EtOAc/hexane, 1:4): 1H 
NMR (400 MHz; CDCl3) δ 0.93 (t, J = 7.2 Hz, 3H), 1.50-1.66 (m, 2H), 2.53 (t, J = 7.2 Hz, 2H), 
5.02 (s, 2H), 6.23 (d, J = 2.0 Hz, 1H), 6.23-6.47 (m, 2H), 7.09-7.44 (m, 5H). 13C NMR (100 
MHz; CDCl3) δ 13.9, 24.4, 38.2, 70.5, 104.6, 112.9, 113.0, 127.8(2), 128.4, 128.9(2), 136.6, 
146.7, 160.4, 161.9. 
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3-Benzyloxy-5-butylphenol (2.5e) 14,15 
General Method A. The residue was purified by column chromatography (SiO2, gradient of 
hexane, 1:9, 1:7, 1:5) to afford 2.5e (0.409 g, 26%) as a dark brown oil. TLC: Rf 0.67 
(EtOAc/hexane, 3:7): 1H NMR (400 MHz; CDCl3) δ 1.03-1.08 (m, 3H), 1.42-1.51 (m, 2H), 
1.64-1.72 (m, 2H), 2.62 (dd, J = 7.6 Hz, 2.0, 2H), 5.07 (s, 2H), 6.38 (d, J = 4.4 Hz, 1H), 6.44 (s, 
1H), 6.48 (d, J = 2.4 Hz, 1H), 6.49 (s, 1H), 7.26-7.53 (m, 5H). 13C NMR (100 MHz; CDCl3) δ 
14.3, 22.7, 33.6, 36.1, 70.5, 100.1, 108.4, 108.9, 128.0(2), 128.4, 129.0(2), 137.3, 146.2, 
156.7, 160.3. 
 
 
 
3-Benzyloxy-5-pentyl-phenol (2.5f) 14,15 
General Method A. The residue was purified by column chromatography (SiO2, gradient of 
hexane, EtOAc/hexane, 1:5, 1:4) to afford 2.5f (0.457 g, 31%) as a brown oil. TLC: Rf 0.53 
(EtOAc/hexane, 1:4): 1H NMR (400 MHz; (CD3)2CO) δ 0.89 (t, J = 6.8 Hz, 3H), 1.26-1.34 (m, 
4H), 1.55-1.63 (m, 2H), 2.49-2.56 (m, 2H), 5.02 (s, 2H), 7.30-7.44 (m, 5H), 8.21 (broad s, 1, 
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OH). 13C NMR (100 MHz; (CD3)2CO) δ 13.7, 22.6, 31.1, 31.6, 36.0, 69.6, 99.8, 106.5, 108.4, 
127.7(2), 127.9, 128.6(2), 138.0, 145.3, 158.6, 160.4. 
 
 
3-Benzyloxy-5-hexylphenol (2.5g) 14,15 
General Method A. The residue was purified by column chromatography (SiO2, 
gradient of hexane) to afford 2.5g (0.374 g, 21%) as a light brown oil. TLC: Rf 0.72 
(EtOAc/hexane, 3:7): 1H NMR (400 MHz; CDCl3) δ 0.95 (dt, J = 2.4 Hz, 4.0 Hz, 3H), 1.31-1.40 
(m, 6H), 1.62 (q, J = 7.6 Hz, 2H), 2.56 (t, J = 8.0 Hz, 2H), 5.03 (s, 2H), 5.75 (broad s, 1, OH), 
6.36 (d, J = 8.8 Hz, 1H), 6.38 (t, J = 2.4 Hz, 1H), 6.50 (d, J = 1.2 Hz,1H), 7.35-7.48 (m, 5H). 13C 
NMR (100 MHz; CDCl3) δ 14.3, 22.8, 29.2, 31.2, 31.9, 36.2, 70.2, 99.9, 108.0, 108.6, 127.8(2), 
128.2, 128.8(2), 137.1, 146.0, 156.6, 160.1. 
 
 
2-(3-Benzyloxy-phenoxy)-6-trifluoromethyl-benzonitrile (2.6a)16  
General Method B. The residue was purified by column chromatography (SiO2, 
gradient of hexane, EtOAc/hexane, 1:10, 1:9, 1:4) to afford 2.6a (0.325 g, 23%) as a white 
solid. TLC: Rf 0.60 (EtOAc/hexane, 1:4): 1H NMR (400 MHz; (CD3)2SO) δ 5.16 (s, 2H), 6.82 (t, 
50 
 
J = 8.4 Hz, 1H), 6.94-7.00 (m, 2H), 7.24 (d, J = 11.6 Hz, 1H), 7.33-7.45 (m, 6H), 7.65 (d, J = 
10.0 Hz, 1H), 7.82 (d, J = 10.8 Hz, 1H). 13C NMR (100 MHz; (CD3)2SO) δ 70.1, 107.2(3), 
112.5, 112.8, 120.8(2), 121.1, 127.8(3), 128.1(2), 128.7, 131.2, 135.2, 137.2, 155.9, 160.9, 
161.0. MS (ESI) m/z 392.2 (M + Na), 387.3 (M + H2O), 370.2 (M + 1). Anal. Calcd. For 
C21H14F3NO2: C, 68.29; H, 3.82; N, 3.79. Found: C, 68.21; H, 3.77; N, 3.81. 
 
 
2-(3-Benzyloxy-5-methyl-phenoxy)-6-trifluoromethyl-benzonitrile (2.6b)16  
General Method B. The residue was purified by column chromatography (SiO2, gradient of 
hexane, EtOAc/hexane, 1:5, 1:4) to 2.6b afford (1.35 g, 91%) as a pale yellow oil. TLC: Rf 
0.56 (EtOAc/hexane, 1:5): 1H NMR (400 MHz; (CD3)2CO) δ 2.34 (s, 3H), 5.14 (s, 2H), 6.66 (s, 
1H), 6.73 (s, 1H), 6.84 (s, 1H), 7.25 (d, J = 8.8 Hz, 1H), 7.34 (d, J = 7.2 Hz, 1H), 7.39 (t, J = 7.2 
Hz, 2H), 7.46 (d, J = 7.2 Hz, 2H), 7.65 (d, J = 7.6 Hz, 1H), 7.82 (t, J = 8.4 Hz, 1H). 13C NMR 
(100MHz; (CD3)2CO) δ 20.9, 70.1, 104.3(2), 113.2, 113.5, 120.7(2), 120.8, 121.1, 127.8(2), 
128.1, 128.7(2), 135.2(2), 137.3, 141.9, 155.7, 160.6, 161.7. 
 
 
2-(3-(Benzyloxy)-5-ethylphenoxy)-6-(trifluoromethyl)benzonitrile (2.6c)16 
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General Method B. The residue was purified by column chromatography (SiO2, gradient of 
hexane) to afford 2.6c (0.404 g, 74%) as a pale yellow oil. TLC: Rf 0.71 (EtOAc/hexane, 1:4): 
1H NMR (400 MHz; CDCl3) δ 1.23 (t, J = 7.6 Hz, 3H), 2.63 (q, J = 7.2 Hz, 2H), 5.04 (s, 2H), 6.53 
(t, J = 2.4 Hz, 1H), 6.56 (s, 1H), 6.75 (s, 1H), 7.06 (d, J = 8.8 Hz, 1H), 7.32-7.44 (m, 2H), 7.53 
(t, J = 8.8 Hz, 2H). 13C NMR (100 MHz; CDCl3) δ 15.4, 29.1, 70.5, 104.5(2), 112.4(2), 112.5, 
120.1, 120.2(2), 127.8(2), 128.4, 128.9(2), 134.0(3), 148.2, 155.4, 160.5, 161.8. 
 
 
2-(3-(Benzyloxy)-5-propylphenoxy)-6-(trifluoromethyl)benzonitrile (2.6d)16 
General Method B. The residue was purified by column chromatography (SiO2, gradient of 
hexane) to afford 2.6d (0.279 g, 64%) as a pale yellow oil. TLC: Rf 0.63 (EtOAc/hexane, 
1:4): 1H NMR (400 MHz; CDCl3) δ 0.93 (t, J = 7.6 Hz, 3H), 1.60-1.66 (m, 2H), 2.56 (t, J = 7.2 
Hz, 2H), 5.04 (s, 2H), 6.54 (d, J = 1.6 Hz, 2H), 6.73 (s, 1H), 7.05 (d, J = 8.8 Hz, 1H), 7.32-7.44 
(m, 6H), 7.53 (t, J = 8.4 Hz, 1H). 13C NMR (100 MHz; CDCl3) δ 13.4, 24.4, 38.2, 70.5, 95.7, 
104.6(2), 112.9, 113.0, 115.6, 120.0, 120.1(2), 127.8(2), 128.3, 128.9(2), 134.0, 136.6, 
146.7, 155.3, 160.4, 161.9. 
 
 
2-(3-(Benzyloxy)-5-butylphenoxy)-6-(trifluoromethyl)benzonitrile (2.6e)16 
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General Method B. The residue was purified by column chromatography (SiO2, gradient of 
hexane, EtOAc/hexane 3:7, CH2Cl2/Hexane 3:7) to afford 2.6e (0.244 g, 36%) as a colorless 
oil. TLC: Rf 0.80 (CH2Cl2/hexane, 3:7): 1H NMR (400 MHz; CDCl3) δ 0.94 (t, J = 7.6 Hz, 3H), 
1.28-1.41 (m, 2H), 1.56-1.64 (m, 2H), 2.61 (t, J = 6.8 Hz, 2H), 5.05 (s, 2H), 6.54-6.56 (m, 2H), 
6.75 (s, 1H), 7.07 (d, J = 8.8 Hz, 1H), 7.32-7.45 (m, 6H), 7.53 (t, J = 8.0 Hz, 1H). 13C NMR (100 
MHz; CDCl3) δ 14.1, 22.5, 33.4, 35.9, 70.5, 104.6(2), 112.6, 112.9, 113.0, 120.1, 120.2(2), 
127.8(2), 128.4, 128.9(2), 134.1(2), 136.7, 146.9, 155.3, 160.4, 161.9. 
 
 
2-(3-Benxyloxy-5-pentyl-phenoxy)-6-trifluoromethyl-benzonitrile (2.6f)16 
General Method B. The residue was purified by column chromatography (SiO2, gradient of 
hexane) to afford 2.6f (0.446 g, 72%) as a pale yellow oil. TLC: Rf 0.36 (EtOAc/hexane, 1:9): 
1H NMR (400 MHz; (CD3)2CO) δ 0.88 (dd, J = 3.2 Hz, 6.8 Hz, 3H), 1.29-1.36 (m, 4H), 1.63 (q, J 
= 5.6 Hz, 2H), 2.62 (t, J = 8.0 Hz, 2H), 5.14 (s, 2H), 6.69 (t, J = 2.0 Hz, 1H), 6.75 (t, J = 2.4 Hz, 
1H), 6.86 (t, J = 2.0 Hz, 1H), 7.24 (d, J = 8.8 Hz, 1H), 7.33-7.41(m, 3H), 7.46-7.48 (m, 2H), 
7.63 (d, J = 7.6 Hz, 1H), 7.79-7.83 (m, 1H). 13C NMR (100 MHz; (CD3)2CO) δ 13.7, 30.9, 31.5, 
32.5, 35.8, 70.1, 104.5(2), 112.7(2), 113.0, 120.6(2), 120.9, 127.8(2), 128.1, 128.7(2), 
135.2(2), 137.3, 147.0, 155.6, 160.7, 161.8. 
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2-(3-(Benzyloxy)-5-hexylphenoxy)-6-(trifluoromethyl)benzonitrile (2.6g)16 
General Method B. The residue was purified by column chromatography (SiO2, gradient of 
hexane) to afford 2.6g (0.491 g, 98%) as a yellow oil. TLC: Rf 0.49 (EtOAc/hexane, 3:7): 1H 
NMR (400 MHz; CDCl3) δ 0.90 (t, J = 5.2 Hz, 3H), 1.31 (s, 6H), 1.59 (td, J = 2.8 Hz, 6.0 Hz, 2H), 
2.60 (t, J = 7.6 Hz, 2H), 5.05 (s, 2H), 6.55 (d, J = 1.6 Hz, 2H), 6.75 (s, 1H), 7.07 (d, J = 8.4 Hz, 
1H), 7.32-7.45 (m, 6H), 7.55 (t, J = 8.4 Hz, 1H). 13C NMR (100 MHz; CDCl3) δ 14.3, 22.8, 29.1, 
31.2, 31.9, 36.2, 70.5, 101.0, 104.6(2), 112.9, 113.0, 120.1(2), 120.2, 127.8(2), 128.4, 
128.9(2), 134.1(2), 136.7, 147.0, 155.3, 160.4, 161.9. 
 
 
2-(3-Hydroxy-phenoxy)-6-trifluoromethyl-benzonitrile (2.7a) 
General Method C. The residue was purified by column chromatography (SiO2, 
gradient of hexane, EtOAc/hexane, 1:9, 1:7, 1:5, 1:1) to afford 2.7a (0.199 g, 81%) as a 
white solid. TLC: Rf 0.08 (EtOAc/hexane, 1:4), mp 106–108 °C: 1H NMR (400 MHz; 
(CD3)2CO) δ 6.77-6.71 (m, 2H), 6.80-6.82 (m, 1H), 7.28-7.34 (m, 2H), 7.66 (d, J = 7.6 Hz, 1H), 
7.84-7.88 (m, 1H), 8.81 (broad s, 1, OH). 13C NMR (100 MHz; (CD3)2CO) δ 101.6, 107.6, 
111.1, 112.4, 113.2, 120.8(2), 121.7, 131.3, 135.3(2), 155.9, 159.5, 161.7. 
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2-(3-Hydroxy-5-methyl-phenoxy)-6-trifluoromethyl-benxonitrile (2.7b) 
General Method C. The residue was purified by column chromatography (SiO2, gradient of 
hexane, EtOAc/hexane, 1:9, 1:7, 1:5, 1:1) to afford 2.7b (0.588 g, 57%) as a light brown 
solid. TLC: Rf 0.19 (EtOAc/hexane, 1:4). The oily residue was induced to crystallize by the 
addition of hexane, mp 73-75 °C: 1H NMR (400 MHz; CDCl3) δ 2.29 (s, 3H), 5.79 (broad s, 1, 
OH), 6.42-6.46 (m, 2H), 6.57 (d, J = 0.8 Hz, 1H), 7.10 (d, J = 8.8 Hz, 1H), 7.43 (d, J = 7.6 Hz, 
2H), 7.55-7.59 (m, 1H). 13C NMR (100 MHz; CDCl3) δ 20.8, 101.2, 104.7(2), 111.9(2), 113.8, 
120.6, 121.2, 135.2(2), 141.8, 155.7, 159.2, 161.8. MS (ESI) m/z 292.1 (M - 1). Anal. Calcd. 
for C15H10F3NO2: C, 61.44; H, 3.44; N, 4.78. Found: C, 61.23; H, 3.77; N, 4.54. 
 
 
2-(3-Ethyl-5-hydroxyphenoxy)-6-(trifluoromethyl)benzonitrile (2.7c) 
General Method C. The residue was purified by column chromatography (SiO2, gradient of 
hexane, EtOAc/hexane, 1:9, 1:7, 1:5, 1:3, 1:1) to afford 2.7c (0.279 g, 89%) as a yellow oil. 
TLC: Rf 0.37 (EtOAc/hexane, 1:4): 1H NMR (400 MHz; CDCl3) δ 1.21 (p, J = 13.0 Hz, 3H), 
2.60(q, J = 12.0 Hz, 2H), 5.32 (s, 1H), 6.43 (t, J = 2.4 Hz, 1H), 6.51 (broad s, 1, OH), 6.60 (t, J = 
0.8 Hz, 1H), 7.11 (d, J = 8.4 Hz, 1H), 7.43 (d, J = 7.6 Hz, 1H), 7.57 (q, J = 8.0 Hz, 1H). 13C NMR 
(100 MHz; CDCl3) δ 15.3, 28.9, 105.3(2), 112.2, 112.7, 120.6, 120.3, 120.2(2), 134.2, 134.3, 
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148.5, 155.4, 157.4, 161.8. MS (ESI) m/z 342.1 (M + MeOH), 306.1 (M – O-). Anal. Calcd. for 
C19H18F3NO2: C, 62.54; H, 3.94; N, 4.56. Found: C, 62.44; H, 4.07; N, 4.35. 
 
 
2-(3-Propyl-5-hydroxyphenoxy)-6-(trifluoromethyl)benzonitrile (2.7d) 
General Method C. The residue was purified by column chromatography (SiO2, gradient of 
hexane, EtOAc/hexane, 1:9, 1:7, 1:5, 1:3, 1:1) to afford 2.7d (90.4 mg, 41%) as a yellow oil. 
TLC: Rf 0.52 (EtOAc/hexane, 3:7): 1H NMR (400 MHz; CDCl3) δ 0.92 (t, J = 7.2 Hz, 3H), 1.61 
(q, J = 7.6 Hz, 2H), 2.52 (t, J = 7.6 Hz, 2H), 4.71 (broad s, 1, OH), 6.43 (s, 1H), 6.48 (s, 1H), 
6.57 (s, 1H), 7.09 (d, J = 8.8 Hz, 1H), 7.43 (d, J = 7.6 Hz, 1H), 7.56 (t, J = 8.4 Hz, 1H). 13C NMR 
(100 MHz; CDCl3) δ 13.9, 24.3, 38.0, 100.2(2), 105.4(2), 112.6, 113.5(2), 120.1, 134.5(2), 
146.9, 155.1, 157.6, 162.1. MS (ESI) m/z 364.3 (M + 1), 382.4 (M + H2O), 386.2 (M + Na+). 
Anal. Calcd. for C20H20F3NO2•1/2 H2O: C, 64.51; H, 5.68; N, 3.76. Found: C, 64.62; H, 5.62; N, 
3.64. 
 
 
2-(3-Butyl-5-hydroxyphenoxy)-6-(trifluoromethyl)benzonitrile (2.7e) 
General Method C. The residue was purified by column chromatography (SiO2, gradient of 
hexane, EtOAc/hexane, 1:9, 1:7, 1:5, 1:3, 1:1) to afford 2.7e (86.7 mg, 36%) as a yellow 
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solid. TLC: Rf 0.62 (EtOAc/hexane, 1:4). The oily residue was induced to crystallize by the 
addition of hexane, mp 89-92 °C: 1H NMR (400 MHz; CDCl3) δ 0.91 (q, J = 7.6 Hz, 3H), 1.30-
1.37 (m, 2H), 1.52-1.59 (m, 2H), 2.54 (t, J = 7.2 Hz, 2H), 6.14 (broad s, 1, OH), 6.44 (t, J = 2.4 
Hz, 1H), 6.47 (d, J = 2.0 Hz, 1H), 6.59 (dd, J = 1.6 Hz, 1.2 Hz, 1H), 7.42 (d, J = 7.6 Hz, 1H), 
7.54-7.59 (m, 1H). 13C NMR (100 MHz; CDCl3) δ 14.1, 22.4, 33.3, 35.7, 105.3(2), 112.6, 
113.3, 120.1(2), 120.2(2), 134.2(2), 147.2, 155.3, 157.5, 161.9. MS (ESI) m/z 336.1 (M + 1), 
353.3 (M + H2O), 358.1 (M + Na+). Anal. Calcd. for C18H16F3NO2: C, 64.47; H, 4.81; N, 4.18. 
Found: C, 64.71; H, 4.85; N, 4.06. 
 
 
2-(3-Hydroxy-5-pentyl-phenoxy)-6-trifluoromethyl)-benzonitrile (2.7f) 
General Method C. The residue was purified by column chromatography (SiO2, gradient of 
hexane, EtOAc/hexane, 1:9, 1:7, 1:1) to afford 2.7f (0.141 g, 40%) as a white solid. TLC: Rf 
0.23 (EtOAc/hexane, 1:4). The oily residue was induced to crystallize by the addition of 
hexane, mp 85-86 °C: 1H NMR (400 MHz; CDCl3) δ 0.88 (q, J = 4.4 Hz, 3H), 1.26-1.34 (m, 
4H), 1.54-1.62 (m, 2H), 2.54 (t, J = 7.6, 2H), 5.51 (broad s, 1, OH), 6.44 (t, J = 2.0 Hz, 2H), 
6.49 (d, J = 2.0 Hz, 1H), 6.58 (s, 1H), 7.10 (d, J = 8.4 Hz, 1H), 7.43 (d, J = 8.0 Hz, 1H), 7.54-
7.58 (m, 1H). 13C NMR (100 MHz; CDCl3) δ 14.2, 22.7, 30.9, 31.6, 35.9, 97.6, 105.2, 112.5, 
112.9, 113.1, 115.6(2), 120.2(2), 134.1, 147.3, 155.4, 157.1, 161.8. MS (ESI) m/z 372.2 (M + 
Na+). Anal. Calcd. for C19H18F3NO2: C, 65.32; H, 5.19; N, 4.01. Found: C, 65.50; H, 5.14; N, 
4.01. 
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2-(3-Hexyl-5-hydroxyphenoxy)-6-(trifluoromethyl)benzonitrile (2.7g) 
General Method C. The residue was purified by column chromatography (SiO2, gradient of 
hexane, EtOAc/hexane, 1:9, 1:7, 1:5, 1:3, 1:1) to afford 2.7g (33.2 mg, 8.4%) as a yellow 
solid. TLC: Rf 0.68 (EtOAc/hexane, 3:7). The oily residue was induced to crystallize by the 
addition of hexane, mp 88-91 °C: 1H NMR (400 MHz; CDCl3) δ 0.86- 0.89 (m, 3H), 1.24-
1.33(m, 6H), 1.54-1.60 (m, 2H), 2.54 (t, J = 8.0 Hz, 2H), 5.50 (broad s, 1, OH), 6.43 (t, J = 2.0 
Hz, 1H), 6.49 (s, 1H), 6.58 (s, 1H), 7.10 (d, J = 8.4 Hz, 1H), 7.43 (d, J = 7.6 Hz, 1H), 7.56 (t, J = 
8.4 Hz, 1H). 13C NMR (100 MHz; CDCl3) δ 14.3, 22.8, 29.1, 31.1, 31.8, 36.0, 105.3(2), 
112.6(2), 112.8, 113.2, 120.1, 120.2, 134.1(2), 147.3, 155.4, 157.2, 161.8. MS (ESI) m/z 
364.3 (M + 1), 382.4 (M + H2O), 386.2 (M + Na+). Anal. Calcd. for C20H20F3NO2•1/2 H2O: C, 
64.51; H, 5.68; N, 3.76. Found: C, 64.62; H, 5.62; N, 3.64. 
 
 
3-(2-Cyano-3-(trifluoromethyl)phenozy)phenyl acetate (2.8b) 
General Method D. The residue was purified by flash chromatography (SiO2, 
gradient of hexane, CH2Cl2, EtOAc) to afford 2.8b (46.5 mg, 67%) as a colorless oil. TLC: Rf 
0.30 (EtOAc/hexane, 1:4): 1H NMR (400 MHz; CDCl3) δ 2.30 (s, 3H), 6.91 (t, J = 2.0 Hz, 1H), 
6.98-7.04 (m, 2H), 7.14 (d, J = 8.8 Hz, 1H), 7.43 (dd, J = 8.0 Hz, 8.8 Hz, 2H), 7.60 (t, J = 7.6 Hz, 
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1H). 13C NMR (100 MHz; CDCl3) δ 21.3, 98.6, 112.3, 114.4, 117.7(2), 119.3, 120.3, 120.7(2), 
124.1, 131.0, 134.3(2), 152.1, 155.1, 161.2, 169.2. MS (ESI) m/z 322.3 (M + 1), 344.3 (M + 
Na+), 339.3 (M + H2O). Anal. Calcd. for C16H10F3NO3•1/4 C7H8: C, 61.92; H, 3.51; N, 4.07. 
Found: C, 60.74; H, 3.66; N, 4.07. 
 
 
3-(2-Cyano-3-(trifluoromethyl)phenozy)phenyl propionate (2.8c) 
General Method D. The residue was purified by preparative TLC (SiO2, gradient of 
EtOAc/hexane 1:4) to afford 2.8c (70.8 mg, 61%) as a white solid. TLC: Rf 0.25 
(EtOAc/hexane, 1:4), mp 82-83 °C: 1H NMR (300 MHz; CDCl3) δ 1.23 (t, J = 7.5 Hz, 3H), 2.59 
(q, J = 7.5 Hz, 2H), 6.91 (s, 1H), 6.91-7.04 (m, 2H), 7.13 (d, J = 8.4 Hz, 1H), 7.41-7.49 (m, 2H), 
7.60 (t, J = 8.1 Hz, 1H). 13C NMR (300 MHz; CDCl3) δ 9.16, 27.9, 101.4, 112.4, 114.5, 117.6, 
119.3, 120.2, 120.6, 124.2, 127.8, 131.0, 134.3, 152.3, 155.0, 161.3, 172.8. MS (ESI) m/z 
454.1 (M + 1). Anal. Calcd. for C17H12F3NO3•1/4 H2O: C, 60.09; H, 3.71; N, 4.12. Found: C, 
60.20; H, 3.49; N, 4.16. 
 
 
3-(2-Cyano-3-(trifluoromethyl)phenoxy)phenyl butyrate (2.8d) 
General Method D. The residue was purified by preparative TLC (SiO2, gradient of 
EtOAc/hexane 1:4) to afford 2.8d (0.128 g, 69%) as a pale yellow oil. TLC: Rf 0.54 (EtOAc/ 
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CH2Cl2, 1:4): 1H NMR (400 MHz; CDCl3) δ 1.03 (t, J = 7.6 Hz, 3H), 1.77 (sextet, J = 7.6 Hz, 2H), 
2.54 (t, J = 7.6 Hz, 2H), 6.90 (t, J = 2.4 Hz, 1H), 6.97-7.04 (m, 2H), 7.13 (d, J = 8.4 Hz, 1H), 
7.42-7.48 (m, 2H), 7.57-7.62 (m, 1H). 13C NMR (100 MHz; CDCl3) δ 13.8, 18.6, 36.4, 101.7, 
112.4, 114.5, 117.6, 119.3, 120.2, 120.5, 120.6, 131.0, 134.3(2), 152.2, 155.0, 161.3, 172.0. 
MS (ESI) m/z 350.3 (M + 1), 372.3 (M + Na+), 367.4 (M + H2O). Anal. Calcd. for 
C20H20F3NO2•1/2 H2O: C, 64.51; H, 5.68; N, 3.76. Found: C, 64.62; H, 5.62; N, 3.64. 
 
 
3-(2-Cyano-3-(trifluoromethyl)phenoxy)phenyl pentanoate (2.8e) 
To a stirred solution of phenol (23a) (57 mg, 0.20 mmol) in Et3N (5 mL) valeryl chloride 
(29 μL, 0.24 mmol, 1.2 equiv) was added and refluxed for 2 h. The solvent was removed 
under reduced pressure. The residue was purified by column chromatography (SiO2, 
gradient of hexane, hexane/ CH2Cl2 1:1, CH2Cl2, (CH3)2CO) to afford 2.8e (57.1 mg, 78%) as 
a white solid. TLC: Rf 0.50 (EtOAc/hexane, 1:4), mp 44-46 °C: 1H NMR (400 MHz; CDCl3) δ 
0.96 (t, J = 7.2 Hz, 3H), 1.39-1.48 (m, 2H), 1.69-1.76 (m, 2H), 2.56 (t, J = 7.2 Hz, 2H), 6.90 (t, J 
= 2.4 Hz, 1H), 6.97-7.03 (m, 2H), 7.13 (d, J = 8.8 Hz, 1H), 7.41-7.48 (m, 2H), 7.57-7.61 (m, 
1H). 13C NMR (100 MHz; CDCl3) δ 13.9, 22.4, 27.1, 34.2, 101.3, 112.4, 114.5, 117.7, 119.4, 
120.2, 120.6, 120.7, 123.7, 131.0, 134.3, 152.3, 155.0, 161.3, 172.2. MS (ESI) m/z 454.1 (M + 
1). Anal. Calcd. for C20H20F3NO2•1/2 H2O: C, 64.51; H, 5.68; N, 3.76. Found: C, 64.62; H, 5.62; 
N, 3.64. 
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3-(2-Cyano-3-(trifluoromethyl)phenoxy)phenyl hexanoate (2.8f) 
General Method D. The residue was purified by preparative TLC (SiO2, gradient of 
EtOAc:hexane 1:4) to afford 2.8f (58.0 mg, 74%) as a colorless oil. TLC: Rf 0.56 
(EtOAc/hexane, 1:4): 1H NMR (400 MHz; CDCl3) δ 0.91-0.94 (m, 3H), 1.36-1.40 (m, 4H), 
1.71-1.76 (m, 2H), 2.55 (t, J = 7.2 Hz, 2H), 6.90 (t, J = 2.4 Hz, 1H), 6.97-7.03 (m, 2H), 7.13 (d, 
J = 8.4 Hz, 1H), 7.42-7.48 (m, 2H), 7.59 (t, J = 8.0 Hz, 1H). 13C NMR (100 MHz; CDCl3) δ 14.1, 
22.5, 24.7, 31.4, 34.4, 112.3, 114.5, 117.6, 119.3, 120.2, 120.6(2), 120.7, 123.7, 131.0, 134.3, 
152.2, 155.0, 161.3, 172.1. MS (ESI) m/z 378.3 (M + 1), 400.4 (M + Na+). Anal. Calcd. for 
C20H18F3NO3: C, 63.66; H, 4.81; N, 3.71. Found: C, 63.84; H, 4.90; N, 3.65. 
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3 
General Method for the Synthesis of Phloroglucinol Monoaryl Ethers 
Towards the Development of CB1 Receptor Ligands 
 
3.1 Abstract 
 
A novel 1,3,5-trihydroxybenzene core diaryl ether scaffold was developed in order to 
establish a library of precursor compounds for a cannabinoid structure activity 
relationship study.  A variety of novel functionalized phloroglucinol monoaryl ethers have 
been synthesized in two steps under mild conditions by coupling substituted aryl fluorides 
with 3,5-dimethoxyphenol followed by conversion of the methyl ethers to phenols.  Target 
compounds were synthesized under simple reaction conditions via nucleophilic aromatic 
substitution (SNAr) in N-methylpyrrolidine and cesium carbonate. Subsequent boron 
tribromide mediated demethylation gave a series of monoaryl ethers in good overall yields. 
The compounds presented here represent a relatively unexplored substructure of 
molecules and may be used as substrates in exploring a variety of chemical applications. 
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Scheme 3.1 Abstract scheme, the synthesis of phloroglucinol monoaryl ethers 
 
3.2 Introduction 
In our efforts to synthesize novel analogues of the cannabinoid partial agonists BAY 
59-3074 and CB-25 (Figure 3.1), we have developed a simple, catalyst-free procedure for 
the synthesis of phloroglucinol monoaryl ethers. To our knowledge, no formal report exists 
describing the synthesis of phloroglucinol monoaryl ethers. The structures presented here 
represent a relatively unexplored substructure of compounds that were synthesized 
specifically for evaluation of the cannabinoid pharmacophore, but may also find utility 
elsewhere. 
 
Figure 3.1. Cannabinoid partial agonists BAY 59-3074 and CB-25 
          
                                      2.2                                                                                               2.3 
 
Several methods have been reported for the preparation of diaryl ethers, many of 
which rely on copper catalysts.1,2 We have chosen to proceed through uncatalyzed 
nuclephilic aromatic substitution (SNAr) promoting conditions for the sake of simplicity. 
F
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Reactions that proceed via an SNAr mechanism represent one of the more attractive 
methods for diaryl ether synthesis due to mild reaction conditions typically employed to 
affect the desired coupling.3,4 The preparation of the diaryl ether precursor 3.2 to BAY 59-
3074 was achieved via uncatalyzed conditions in good yield in N-methylpyrrolidone (NMP) 
using KOH as a base (Scheme 3.2).5 Other reports have also demonstrated NMP to be 
advantageous in the synthesis of diaryl ethers.6 As a solvent, NMP is ideal for these 
uncatalyzed coupling reactions since it possesses a high boiling point (203 °C) and large 
dielectric constant (32.2). Based upon these results we initially explored the uncatalyzed 
conditions developed for the synthesis of 3.2 for the aryl ether coupling reaction of aryl 
fluoride 3.3 with phloroglucinol (3.4). Unfortunately, the direct arylation of 3.4 proved to 
be less straightforward. The uncatalyzed conditions led to a complex mixture of mono- and 
diaryl ethers as well as an intractable mixture of C-arylation products (Scheme 3.3). In 
addition, the removal of the excess phloroglucinol made the isolation and purification of 
the coupling products cumbersome and tedious. 
 
Scheme 3.2 Attempted direct arylation of phloroglucinol 
 
           3.2 
                       
                          3.3              3.4  
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In light of these results, we sought to develop a stoichiometric uncatalyzed method 
for the preparation of the desired phloroglucinol monoaryl ethers. To this end, a two-step 
process was envisaged that would involve initial aryl ether formation via coupling a 
substituted aryl fluoride with a protected phloroglucinol derivative 3.5 followed by a 
deprotection step to give the phloroglucinol monoaryl ether (Scheme 3.3). 3,5-
Dimethoxyphenol (3.5) seemed to be a particularly amenable substrate for the uncatalyzed 
coupling reaction due to electron-donating methoxy groups that would activate the phenol 
toward SNAr nucleophilic addition. The methyl ethers could then be readily removed to 
furnish the phloroglucinol derivative. Cesium carbonate was selected as the base for the 
reaction since it has been widely used for the generation of phenoxide salts in diaryl ether 
coupling reactions due to its functional group tolerance and good solubility in organic 
solvents.7–10 
 
Scheme 3.3 Two-step synthesis of phloroglucinol monoaryl ethers 
 
              3.5       3.6a – 3.13a 
 
                                        3.6b – 3.13b  
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3.3 Results and Discussion 
As summarized in Table 3.1 the uncatalyzed coupling reactions of substituted aryl 
fluorides with 3.5 gave the corresponding diaryl ethers 3.6a – 3.13a in good to high yields. 
The coupling reactions presented here support an SNAr mechanism. Substrates that 
possessed strong activating groups such as nitrile (3.6a and 3.12a) and nitro (3.13a) gave 
nearly quantitative yields, presumably via formation of an intermediate Meisenheimer 
complex.11 However, weaker activating groups like halogen (Cl, Br, I) also gave good yields 
when multiple halogen substituents were present. Only aryl fluorides that did not contain 
electron withdrawing groups or were mono-halogenated (3.14a - 3.16a) were 
unreactive.12 
 
Table 3.1 Uncatalyzed arylation of 3,5-dimethoxyphenol (3.5) 
 
3.6a - 3.13a 
Cpd Code X Y Z Product (yield, %) 
3.6a AMS115 CN CF3 H 99 
3.7a AMS191 Cl H Cl 84 
3.8a AMS209 Cl Cl H 59 
3.9a AMS211 H Cl Cl 60 
3.10a AMS235 Br H Br 51a 
3.11a DP173 I H Cl 62 
3.12a DP171 H H CN 94 
3.13a AMS123 H H NO2 94 
3.14a AMS213a H Cl H (NR)b 
3.15a AMS213b H H H (NR)b 
3.16a AMS213c H H Me (NR)b 
a Mixture of isomers.  b NR: no reaction, starting material recovered 
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The coupling to m-chlorofluorobenzene was not at all reactive (3.14a), yet reactions 
of fluorobenzenes bearing dichloro substitution (3.7a – 3.9a) and dibromo substitution 
(3.10a) proceeded in good yields. Neither fluorotoluene nor fluorobenzene were reactive 
under the conditions presented (3.15a, 3.16a). Additionally, clear selectivity was 
demonstrated for nucleophilic attack at the fluorine-substituted carbon over other 
halogenated sites. In all examples, including where mixed aryl halides were employed 
(3.11a), the predominant product was always formed chemoselectively by substitution at 
the fluorinated carbon. 
The dimethoxy diaryl ethers 3.6a – 3.13a were converted into the phloroglucinol 
derivatives 3.6b – 3.13b using boron tribromide. This demethylation process has been 
well covered in the literature.13,14 However, it is worth noting that special care must be 
taken with the quench/hydrolysis procedure in order to achieve high yields. It was found 
that slowly dripping the reaction mixture into an excess of stirred cold water produced the 
best results. All of the reactions proceeded cleanly and in high yield (>89%) with the 
exception of the nitrile 3.6a. The demethylation step gave a mixture of side products that 
made it necessary to purify the phloroglucinol derivative (Table 3.2, 3.6b) by column 
chromatography. All other compounds were isolated in sufficient purity for subsequent use 
directly from the workup with no chromatography. 
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Table 3.2 Monoaryl phloroglucinol derivatives 
 
3.6b – 3.13b 
Cpd Code X Y Z Product (yield, %) 
3.6b AMS149 CN CF3 H 82 
3.7b AMS193 Cl H Cl 97 
3.8b AMS217 Cl Cl H 97 
3.9b AMS219 H Cl Cl 97 
3.10b AMS239 Br H Br 89a 
3.11b AMS241 I H Cl 95 
3.12b AMS223 H H CN 98 
3.13b AMS221 H H NO2 92 
a Mixture of isomers. 
 
3.4 Conclusion 
In conclusion, an efficient, safe, and scalable method for the preparation of 
phloroglucinol monoaryl ethers has been developed. The uncatalyzed aryl coupling 
reaction was chemoselective and furnished the diaryl ethers cleanly with few side 
reactions. Further manipulation of this unique molecular scaffold toward the development 
of novel cannabinoid receptor ligands will be reported elsewhere. 
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3.6 Experimental Section 
General methods 
All chemicals were purchased from Aldrich Chemical Company and used as received unless 
otherwise noted. TLC: silica gel (250 μm); visualization with UV light, I2, or 
phosphomolybdic acid. Chromatography: silica gel 60 Å (230–400 mesh). 1H NMR (400 
MHz) and 13C NMR (100 MHz) were recorded on a Varian 400 MHz NMR spectrometer at 
ambient temperature in CDCl3 or DMSO-d6. 1H NMR chemical shifts are reported as δ values 
(ppm) relative to TMS. 13C NMR chemical shifts are reported as δ values (ppm) relative to 
CDCl3 (77.0 ppm) or DMSO-d6 (39.5 ppm). Melting points were recorded on a Mel-temp 
apparatus and are uncorrected. Atlantic Microlab, Inc., Norcross, GA performed all CHN 
microanalyses.  
 
 3.5               3.6a – 3.13a 
 
General Method A. (diaryl ether formation). To 3,5-dimethoxyphenol (1.1 equiv) 
dissolved in NMP (0.7-1.4 mL/mmol) was added Cs2CO3 (3 equiv).  A rubber septum was 
attached to the reaction flask and a nitrogen atmosphere was established by evacuation 
and back filling with nitrogen, repeated three times.  The flask was placed in a 50°C oil bath 
for 30 minutes resulting in a dark brown phenoxide solution.  Aryl fluoride (1 equiv.) was 
syringed into the solution and the reaction was allowed to stir at 50-110 °C for 3-36h. 
Reaction temperature was adjusted to not exceed the boiling point aryl fluoride used.  
Reactions were monitored by TLC to determine apparent completion.  The reaction 
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mixtures were cooled to room temperature and added to H2O (20 mL).  The resulting 
suspension was extracted with toluene (3 x 15 mL).  The pooled organic extracts were 
washed with H2O (15 mL), brine (15 mL) then dried over MgSO4 and filtered.  The toluene 
was distilled off under reduced pressure on a rotoevaporator.  The resulting residue was 
purified by column chromatography or triturated with H2O (10 mL), filtered, and washed 
with water then dried.  Compounds isolated by trituration were of adequate purity to be 
used for further synthesis.    
 
 
 3.6a – 3.13a         3.6b – 3.13b 
 
General Method B. (BBr3 promoted demethylation) A solution of dimethoxy diaryl 
ether 3.6a – 3.13a (1 equiv.) was dissolved in anhydrous CH2Cl2 (5 mL/mmol) and stirred 
under N2 at 0 °C for 15 min. With vigorous stirring, BBr3 (3–5 equiv) was carefully syringed 
into the solution over 15 min. The ice bath was removed and the mixture was stirred for 90 
min at r.t. The reaction mixture was carefully transferred to an addition funnel and added 
dropwise to H2O (50 mL) at 0 °C with continuous stirring over 20 min. The resulting 
suspension was extracted with EtOAc (4 × 40 mL). The combined organic extracts were 
washed with H2O (50 mL), brine (50 mL), then dried (MgSO4), and filtered. The solvent was 
removed under reduced pressure to afford a viscous oil. The oily residue was lyophilized 
under high vacuum to afford the phloroglucinol aryl ethers 3.6b-3.13b as solids in pure 
form. 
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2-(3,5-dimethoxyphenoxy)-6-(trifluoromethyl)benzonitrile (3.6a)  
General Method A. 3,5-dimethoxyphenol (3.4 g, 22 mmol) was reacted with Cs2CO3 (9.8 g, 
30 mmol) and 2-fluoro-6-(trifluoromethyl)benzonitrile (3.7 g, 20 mmol) in NMP (15 mL) at 
65 °C for 4 h. Purification by trituration and filtration afforded 3.6a (6.4 g, 99 %) as a shiny 
white solid; mp 95-97 °C: 1H NMR (400MHz; CDCl3) δ: 7.57 (t, J = 8.0 Hz, 1H) 7.44 (d, J = 
8.0Hz, 1H) 7.13 (d, J = 8 Hz, 1H) 6.36 (dd, J = 2.0, 2.0Hz, 1H), 6.25(t, J = 2.0Hz, 2H), 3.78 (s, 
6H). 13C NMR (100 MHz; CDCl3) δ: 162.2, 161.5, 156.1, 134.4, 134.1, 123.8, 121.1, 120.4, 
112.6, 100.8, 98.9, 97.9, 55.7.   
 
 
2,4-dichloro-1-(3,5-dimethoxyphenoxy)benzene (3.7a).  
General Method A. 3,5-dimethoxyphenol (3.4 g, 22 mmol) was reacted with Cs2CO3 (9.8 g, 
30 mmol) and 2,4-dichloro-1-fluorobenzene (3.3 g, 20 mmol) in NMP (15 mL) at 120 °C for 
2 h.  Purification by flash chromatography (10% ethyl acetate/hexane) afforded 3.7a (5.0 g, 
84 %) as a white solid; mp 44-45°C: 1H NMR (400MHz; CDCl3) δ: 7.48 (d, J = 2.0 Hz, 1H) 
7.19(dd, J = 8.0, 2.0 Hz, 1H) 6.96 (d, J = 8.0Hz, 1H) 6.22(dd, J = 2.0, 2.0 Hz, 1H) 6.10(t, J = 2.0 
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Hz 2H) 3.74 (s, 6H). 13C NMR (100 MHz; CDCl3) δ: 161.9, 158.7, 151.2, 130.7, 129.7, 128.3, 
127.0, 122.1, 96.7, 96.0, 55.7.  
 
 
1,2-dichloro-3-(3,5-dimethoxyphenoxy)benzene (3.8a).  
General Method A. 3,5-dimethoxyphenol (3.4 g, 22 mmol) was reacted with Cs2CO3 (9.8 g, 
30 mmol) and 1,2-dichloro-3-fluorobenzene (3.3 g, 20 mmol) in NMP (20 mL) at 110 °C for 
20 h.  Purification by flash chromatography (10% ethyl acetate/hexane) afforded 3.8a (3.5 
g, 59%) as a shiny white solid; mp 43-44 °C: 1H NMR (400MHz; CDCl3) δ: 7.26 (dd, J = 8.0, 
2.0 Hz, 1H) 7.15 (t, J = 8.0 Hz, 1H) 6.94 (dd, J = 8.0, 2.0 Hz 1H) 6.24 (dd, J = 2.0, 2.0 Hz, 1H) 
6.13(d, J = 2.0 Hz, 2H)  3.76 (s, 6H). 13C NMR (100 MHz; CDCl3) δ: 162.0, 158.6, 154.9, 134.2, 
127.8, 125.7, 125.2, 119.0, 97.0, 96.1, 55.7.   
 
 
1,2-dichloro-4-(3,5-dimethoxyphenoxy)benzene (3.9a).  
General Method A. 3,5-dimethoxyphenol (1.9 g, 12 mmol) was reacted with Cs2CO3 (5.4 g, 
17 mmol) and 1,2-dichloro-4-fluorobenzene (1.9 g, 11 mmol) in NMP (10 mL) at 120 °C for 
2 h. Purification by flash chromatography (10% ethyl acetate/hexane) afforded 3.9a (2.0 g, 
60%) as a white solid; mp 57-58°C: 1H NMR (400MHz; CDCl3) δ: 7.37 (d, J = 8.0 Hz, 1H) 7.12 
(d, J = 2.0 Hz, 1H) 6.88 (dd, J = 8.0, 2.0 Hz, 1H) 6.27 (dd, J = 2.0, 2.0 Hz, 1H) 6.17 (t, J = 2.0 Hz, 
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2H) 3.76(s, 6H). 13C NMR (100 MHz; CDCl3) δ: 162.0, 158.2, 156.5, 131.2, 120.8, 118.5, 
115.6, 98.0, 96.6, 55.7.   
 
 
2,4-dibromo-1-(3,5-dimethoxyphenoxy)benzene (3.10a).  
General Method A. 3,5-dimethoxyphenol (1.1 g, 7.3 mmol) was reacted with Cs2CO3 (3.3 g, 
10 mmol) and 2,4-dibromo-1-fluorobenzene (1.7 g, 6.7 mmol, 90% purity*) in NMP (10 
mL) at 65 °C for 36 h. Purification by flash chromatography (10% ethyl acetate/hexane) 
afforded 3.10a (1.2 g, 51%) as a mixture of isomers* as a clear oil: 1H NMR (400MHz; 
CDCl3) δ: 7.76 (d, J = 2.4 Hz, 1H) 7.37(dd, J = 8.0, 2.4 Hz, 1H) 6.88 (d, J = 8.0Hz, 1H) 6.24(t, J 
= 4.0 Hz, 1H) 6.12(d, J = 2.0 Hz, 2H) 3.74 (s, 6H). 13C NMR (100 MHz; CDCl3) δ: 162.0, 158.5, 
153.0, 136.2, 131.9, 122.1 117.0, 116.0, 97.0, 96.1, 55.7. 
*starting material contained a 10% mixture of dibromofluorobenzene isomers  
 
 
2-chloro-1-(3,5-dimethoxyphenoxy)-4-iodobenzene (3.11a).  
General Method A. 3,5-dimethoxyphenol (0.66 g, 4.3 mmol) was reacted with Cs2CO3 (1.7 
g, 5.1 mmol) and 2-chloro-1-fluoro-4-iodobenzene (1.1 g, 4.2 mmol) in NMP (10 mL) at 68 
°C for 24 h. Purification by trituration and filtration afforded 3.11a (1.0 g, 62%) as a tan-
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red solid; mp 72-74°C: 1H NMR (400MHz; CDCl3) δ: 7.77 (d, J = 2.0 Hz, 1H) 7.50(dd, J = 8.0, 
2.0 Hz, 1H) 6.76 (d, J = 8.0Hz, 1H) 6.24(dd, J = 2.0, 2.0 Hz, 1H) 6.13(d, J = 2.0 Hz, 2H) 3.74 (s, 
6H). 13C NMR (100 MHz; CDCl3) δ: 162.0, 158.4, 153.7, 139.1, 137.2, 122.7, 97.0, 96.2, 55.7.  
 
 
4-(3,5-dimethoxyphenoxy)benzonitrile (3.12a).  
General Method A. 3,5-dimethoxyphenol (1.1 g, 7.3 mmol) was reacted with Cs2CO3 (3.3 g, 
10 mmol) and 4-fluorobenzonitrile (0.81 g, 6.7 mmol) in NMP (10 mL) at 60°C for 48h. 
Purification by trituration and filtration afforded 3.12a (1.6 g, 94%) as a light orange solid; 
mp 67-68°C: 1H NMR (400MHz; CDCl3) δ: 7.60 (d, J = 8.0 Hz, 2H) 7.03 (d, J = 8.0 Hz, 2H) 6.32 
(t, J = 2.0 Hz, 1H) 6.21 (d, J = 2.0 Hz, 2H) 3.76(s, 6H). 13C NMR (100 MHz; CDCl3) δ: 162.1, 
161.5, 156.8, 134.8, 119.0, 118.4, 106.8, 99.0, 97.4, 55.7.   
 
 
1,3-dimethoxy-5-(4-nitrophenoxy)benzene (3.13a).  
General Method A. 3,5-dimethoxyphenol (1.1 g, 7.3 mmol) was reacted with Cs2CO3 (3.3 g, 
10 mmol) and 1-fluoro-4-nitrobenzene (0.95 g, 6.7 mmol) in NMP (10 mL) at 65 °C for 2 h. 
Purification by trituration and filtration afforded 3.13a (1.75 g, 94%) as a light yellow 
solid; mp 116-118°C: 1H NMR (400MHz; CDCl3) δ: 8.20 (d, J = 8.0 Hz, 2H) 7.05 (d, J = 8.0 Hz, 
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2H) 6.34 (t, J = 4.0 Hz, 1H) 6.24 (d, J = 2.0 Hz, 2H) 3.78(s, 6H). 13C NMR (100 MHz; CDCl3) δ: 
163.3, 162.2, 156.7, 126.1, 117.5, 115.6, 99.6, 97.7, 55.8.   
 
 
1-(3-chlorophenoxy)-3,5-dimethoxybenzene (3.14a).  
General Method A. 3,5-dimethoxyphenol (1.1 g, 7.3 mmol) was reacted with Cs2CO3 (3.3 g, 
10 mmol) and 1-chloro-3-Fluorobenzene (0.86 g, 6.7 mmol) was added in NMP (10 mL) at 
62 ⁰C for 23 h. No product formation was observed. The reaction was repeated in a sealed 
tube reactor, but again no product formation was evident.   
 
 
(1,3-dimethoxy-5-phenoxybenzene (3.15a).   
General Method A. 3,5-dimethoxyphenol (0.67 g, 4.3 mmol) was reacted with Cs2CO3 (1.7 
g, 5.1 mmol) and fluorobenzene (0.38 g, 3.9 mmol) was added in NMP (10 mL) at 55 ⁰C for 
24 h. No product formation was observed. 
 
 
(1,3-dimethoxy-5-(p-tolyloxy)benzene (3.16a).  
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General Method A. 3,5-dimethoxyphenol (0.67 g, 4.3 mmol) was reacted with Cs2CO3 (1.7 
g, 5.1 mmol) and fluorotoluene (0.43 g, 3.9 mmol) was added in NMP (10 mL) at 65 ⁰C for 
24 h. No product formation was observed. 
 
 
2-(3,5-dihydroxyphenoxy)-6-(trifluoromethyl)benzonitrile (3.6b).  
General Method B. To a stirring solution of 3.6a (4.0 g, 12 mmol) in methylene chloride 
(60 mL) at 0 °C was carefully added BBr3 (5.9 mL, 62 mmol).  The resulting oily residue was 
purified by flash chromatography (50% ethyl acetate/hexane) affording 3.6b (3.0 g, 82%) 
as a white solid; mp: 178–180 °C: 1H NMR (400MHz; DMSO-d6) δ: 9.66 (s, 2H) 7.81(t, J = 8.0 
Hz, 1H) 7.62(d, J = 8.0 Hz, 1H) 7.31(d, J = 8.0 Hz, 1H) 6.17(s, 1H) 6.00(s, 2H). 13C NMR (100 
MHz; DMSO-d6) δ: 161.5, 160.5, 156.5, 136.2, 132.7, 124.3, 122.3, 121.4, 113,2, 100.7, 
100.0, 98.7. Anal. Calcd for C14H8F3NO3: C, 56.96; H, 2.73; N, 4.74. Found: C, 56.90; H, 2.83; 
N, 4.54. 
 
 
5-(2,4-dichlorophenoxy)benzene-1,3-diol (3.7b).  
General Method B. To a stirring solution of 3.7a (0.19 g, 0.64 mmol) in methylene chloride 
(3.5 mL) at 0 °C was carefully added BBr3 (0.32 mL, 3.4 mmol).  The resulting oily residue 
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was frozen with liquid nitrogen then subjected to vacuum affording 3.7b (0.17 g, 97%) as a 
tan solid; mp: 79–81 °C: 1H NMR (400MHz; DMSO-d6) δ: 9.45 (br s, 2H) 7.71 (d, J = 2.0 Hz, 
1H) 7.40(dd, J = 8.0, 2.0 Hz, 1H) 7.11 (d, J = 8.0 Hz, 1H) 5.98(dd, J = 8.0, 2.0 Hz, 1H) 5.76(d, J 
= 2.0 Hz, 2H). 13C NMR (100 MHz; DMSO-d6) δ: 160.1, 158.7, 151.3, 130.7, 129.4, 129.2, 
126.6, 123.5, 98.8, 96.5. Anal. Calcd for C12H8Cl2O3: C, 53.17; H, 2.97. Found: C, 53.21; H, 
2.80. 
 
 
5-(2,3-dichlorophenoxy)benzene-1,3-diol (3.8b).  
General Method B. To a stirring solution of 3.8a (0.19 g, 0.64 mmol) in methylene chloride 
(3.5 mL) at 0 °C was carefully added BBr3 (0.32 mL, 3.4 mmol).  The resulting oily residue 
was frozen with liquid nitrogen then subjected to vacuum affording 3.8b (0.17 g, 97%) as 
an off-white solid; mp: 104–106 °C: 1H NMR (400MHz; DMSO-d6) δ: 9.46 (s, 2H) 7.45(dd, J = 
4.0, 2.0 Hz, 1H) 7.36(t, J = 8.0 Hz, 1H) 7.08 (dd, J = 8.0, 2.2 Hz, 1H) 5.98(dd, J = 2.0, 2.0 Hz, 
1H) 5.77(d, J = 2.0 Hz, 2H). 13C NMR (100 MHz; DMSO-d6) δ: 160.2, 158.5, 153.8, 133.4, 
129.6, 126.4, 124.4, 120.5, 99.0, 96.6. Anal. Calcd for C12H8Cl2O3: C, 53.17; H, 2.97. Found: C, 
53.01; H, 3.00. 
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5-(3,4-dichlorophenoxy)benzene-1,3-diol (3.9b).  
General Method B. To a stirring solution of 3.9a (0.19 g, 0.64 mmol) in methylene chloride 
(3.5 mL) at 0 °C was carefully added BBr3 (0.32 mL, 3.4 mmol).  The resulting oily residue 
was frozen with liquid nitrogen then subjected to vacuum which afforded 3.9b (0.16 g, 
92%) as an off-white solid; mp: 91 – 92 °C: 1H NMR (400MHz; DMSO-d6) δ: 9.49 (br s, 2H) 
7.59(dd, J = 8.0, 2.0 Hz, 1H) 7.26(d, J = 2.0 Hz, 1H) 6.99 (dd, J = 8.0, 2.0 Hz, 1H) 6.02(br s, 
1H) 5.85(d, J = 2.0 Hz, 2H). 13C NMR (100 MHz; DMSO-d6) δ: 160.2, 158.0, 156.9, 132.5, 
132.1, 125.9, 121.0, 119.6, 99.5, 98.0. Anal. Calcd for C12H8Cl2O3: C, 53.17; H, 2.97. Found: C, 
53.17; H, 3.17. 
 
 
5-(2,4-dibromophenoxy)benzene-1,3-diol (3.10b).  
General Method B. To a stirring solution of 3.10a (0.4 g, 1.0 mmol) in methylene chloride 
(5.0 mL) at 0 °C was carefully added BBr3 (0.5 mL, 5.3 mmol).  The resulting oily tan residue 
was frozen with liquid nitrogen and subjected to vacuum, which afforded 3.10b (0.33 g, 
89%) as a red semi-solid: 1H NMR (400MHz; DMSO-d6) δ: 9.45 (s, 2H) 7.94(d, J = 2.0 Hz, 
1H) 7.66(dd, J = 8.0, 2.0 Hz, 1H) 7.02 (d, J = 8.0 Hz, 1H) 5.97(t, J = 2.0 Hz, 1H) 5.75(d J = 2.0 
Hz, 2H). 13C NMR (100 MHz; DMSO-d6) δ: 160.1, 158.6, 153.0, 136.1, 132.9, 123.6, 117.1, 
116.3, 98.8, 96.6. Anal. Calcd for C12H8Br2O3: C, 40.04; H, 2.24. Found: C, 39.71; H, 2.44. 
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5-(2-chloro-4-iodophenoxy)benzene-1,3-diol (3.11b).   
General Method B. To a stirring solution of 3.11a (0.25 g, 0.64 mmol) in methylene 
chloride (3.5 mL) at 0 °C was carefully added BBr3 (0.32 mL, 3.4 mmol).  The resulting oily 
tan residue was frozen with liquid nitrogen and subjected to vacuum which afforded 3.11b 
(0.22 g, 95%) as a brown solid; mp: 75 – 77 °C: 1H NMR (400MHz; DMSO-d6) δ: 9.44 (s, 2H) 
7.90(d, J = 2.0 Hz, 1H) 7.66(dd, J = 8.0, 2.0 Hz, 1H) 6.88 (d, J = 8.0 Hz, 1H) 5.98(t, J = 2.0 Hz, 
1H) 5.76(d, J = 2.0 Hz, 2H). 13C NMR (100 MHz; DMSO-d6) δ: 160.1, 158.5, 152.3, 138.8, 
138.1, 126.8, 124.0, 98.9, 96.6, 88.7. Anal. Calcd for C12H8ClIO3: C, 39.75; H, 2.22. Found: C, 
39.50; H, 2.50. 
 
 
4-(3,5-dihydroxyphenoxy)benzonitrile (3.12b).  
General Method B. To a stirring solution of 3.12a (0.70 g, 2.7 mmol) in methylene chloride 
(15 mL) at 0 °C was carefully added mmol BBr3 (1.3 mL, 13 mmol).  The resulting oily 
residue was frozen with liquid nitrogen then subjected to vacuum, which afforded 3.12b 
(0.6 g, 98%) as an orange solid; mp: 158–160 °C: 1H NMR (400MHz; DMSO-d6) δ: 9.57 (br s, 
2H) 7.79(d, J = 8.0 Hz, 2H) 7.08(d, J = 8.0 Hz, 2H) 6.10(dd, J = 2.0, 2.0 Hz 1H) 5.92(d, J = 2.0 
Hz, 2H). 13C NMR (100 MHz; DMSO-d6) δ: 161.6, 160.3, 156.8, 135.2, 119.4, 118.3, 105.6, 
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100.1, 98.9. Anal. Calcd for C12H8Cl2O3: C, 68.67; H, 3.99; N, 6.16. Found: C, 68.51; H, 4.11; N, 
6.02. 
 
 
5-(4-nitrophenoxy)benzene-1,3-diol (3.13b).  
General Method B. To a stirring solution of 3.13a (2.0 g, 7.7 mmol) in methylene chloride 
(30 mL) at 0 °C was carefully added BBr3 (2.5 mL, 27 mmol).  The resulting oily residue was 
frozen with liquid nitrogen then subjected to vacuum, which afforded 3.13b (1.6 g, 89%) as 
a light yellow solid; mp: 127–129 °C: 1H NMR (400MHz; DMSO-d6) δ: 9.62 (br s, 2H) 8.22 (d, 
J = 8.0 Hz, 2H) 7.11(d, J = 8.0 Hz, 2H) 6.12(br s, 1H) 5.94(br s, 2H). 13C NMR (100 MHz; 
DMSO-d6) δ: 163.5, 160.4, 156.6, 142.8, 126.7, 118.1, 100.4, 99.2. Anal. Calcd for C12H8Cl2O3: 
C, 58.30; H, 3.67; N, 5.67. Found: C, 58.81; H, 3.99; N, 5.29. 
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4 
Modification of Phloroglucinol Monoaryl Ethers Towards the 
Development of CB1 Receptor Ligands 
 
4.1 Abstract 
Guided by preliminary data on the utility of alkyl diaryl ethers as potential 
cannabinoid receptor ligands, it was hypothesized that novel phloroglucinol monoaryl 
ether core compounds would show binding affinity at the CB1 receptor. Phloroglucinol 
monoaryl ethers described in Chapter 3 were transformed to the corresponding mixture of 
mono and di-alkyl ethers in one synthetic step utilizing uncatalyzed Williamson ether 
synthesis conditions in ether N-methylpyrrolidine or acetonitrile. Though the dialkyl ethers 
were not our target compounds, some were isolated and characterized and made available 
for bioassay in the interest of expanding the structure activity relationship studies.  Some 
attempts were made to optimize starting conditions in order to favor the production of 
mono-alkylated product, but were not particularly successful due to the complex kinetics of 
the reaction. The compounds presented here were ultimately subjected to biological 
assessment to determine binding affinity at the cannabinoid receptor in order to verify the 
aforementioned hypothesis.   
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Scheme 4.1 Abstract scheme, alkylation of phloroglucinol monoaryl ethers 
 
4.2 Introduction 
The compounds described herein were synthesized with the goal of further 
demonstrating that modification of a diaryl ether scaffold would have an effect on binding 
affinity at the CB1 receptor.  Guided in part by the preliminary efforts to synthesize novel 
analogs of the cannabinoid partial agonists BAY 59-3074 and CB25 (see Chapter 2), a 
simple, catalyst-free procedure for the alkylation of phloroglucinol monoaryl ethers was 
developed.   
In order to synthesize the desired third-generation compounds, Williamson Ether 
Synthesis conditions were utilized to transform the previously described phloroglucinol 
monoaryl ethers to the corresponding alkyl ethers.1 This method was chosen due to its 
broad scope and simplicity.  The reaction proceeds via SN2 mechanism between an in situ 
generated phenoxide anion nucleuphile and a primary alkyl halide (Scheme 4.2).2   
Previous reports have demonstrated the utility of cesium salts for phenoxide generation, 
and therefore cesium carbonate was chosen as the base for our procedure.3 Additionally, 
consistent with most SN2 mediated processes, the reaction has been proven to proceed well 
in polar aprotic solvents due to their ability to effectively solvate the free nucleuphile.2 
Given our previous success with N-methylpyrrolidone (NMP), the solvent was initially 
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chosen for this reaction as well, however, due to apparent solubility issues with certain 
substrates, acetonitrile was used instead with acceptable results.1 
 
Scheme 4.2 General Williamson Ether Synthesis mechanism      
 
 
4.3 Results and Discussion 
As summarized in Table 1, uncatalyzed William Ether Synthesis conditions afforded 
the desired mono alkyl ethers in moderate to low yield, which is typical for reactions of this 
nature.4 Lower product yield was largely a result of the complex kinetics of the reaction, 
and are partially described in Scheme 4.3:  The reactive nature of phloroglucinol mono 
aryl ether under alkaline conditions can be attributed in part to anionic delocalization of 
the phenoxide ion and therefore several competing side reactions were possible in the 
presence of alkyl halide; any intermediate product still bearing a phenolic hydroxyl group 
is capable of further deprotonation under basic conditions.  The most facile side reaction 
was apparently formation of the di-alkyl ether; as demonstrated in Tables 4.1 and 4.2, 
recovery of the di-alkyl ethers either exceeded or was close to that of the mono-alkyl 
ethers. Furthermore, given that Ka2 > Ka1, it is not surprising that a significant amount of di-
alkyl ether would be produced. To a lesser extent C-alkylation was also theoretically 
possible, demonstrated by the resonance structures of generated phenoxide ions.  Initially, 
out of interest in broadening the scope of the SAR studies, these di-alkyl ethers 4b-8b were 
isolated and characterized in addition to the target mono-alkyl ethers.  However, the highly 
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lipophilic di-alkyl ethers demonstrated little promise as cannabinoid receptor ligands and 
were not isolated and characterized in subsequent reactions.  Though no C-alkylated 
products were formally characterized, the analysis of TLC and NMR spectra of crude 
reaction mixtures provided strong evidence of a mixture of C-alkylated products in trace 
amounts. 
  
Scheme 4.3. Partial kinetics of the alkylation of phloroglucinol monoaryl ethers 
 
In an attempt to favor the formation of the desired mono-alkyl ether, the 
stoichiometry was manipulated in some examples such that there was an excess of 
phloroglucinol monoaryl ether.  Statistically, this would lead to a higher probability of the 
first alkylation occurring.  Though reaction conditions were not rigorously experimentally 
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optimized, it was found that approximately one-half equivalent of base and two equivalents 
of alkyl halide relative to phloroglucinol monoaryl ether produced acceptable mono-alkyl 
ether formation.  Small changes to the ratios of starting materials were made across the 
reactions attempted, however, statistically significant changes in product yield were not 
observed.  Conceivably, other variables such as reaction temperature, reaction time, phase 
of the moon and volatilization of alkyl halide also influenced product yield.  In general, 
unreacted starting material could be recovered from all of the reactions attempted for 
recycling if desired.   Given that the ultimate goal of this project was to make compounds 
available for biological screening, requiring relatively little material, further optimization 
was deemed unnecessary in the interest of time.  
 NMP was initially chosen as the solvent for these reactions given it’s favorable 
properties as a polar aprotic solvent and based on our previous success using it for 
nucleophilic aromatic substitution conditions.  The synthesis of products 4.1 - 4.4 was 
relatively facile in NMP. Unexpectedly, however, producing the desired mono and di-alkyl 
ethers 4.5 – 4.8 from the corresponding di-chloro substituted phloroglucinol mono aryl 
ether became increasingly difficult using the same reaction conditions.  Curiously, product 
recovery systematically decreased with increasing carbon chain length of the alkyl halide 
used whereas this trend was not observed in the corresponding examples of products 4.1 - 
4.4.  A reasonable explanation for this trend could not be imagined. It was later found that 
substituting acetonitrile for NMP as the solvent circumvented these somewhat confounding 
results.   
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Table 4.1 Alkylation of phloroglucinol mono aryl ethers in NMP 
 
Cpd Code X Y Z R1 R2 Yield (%)a 
4.1a AMS151 CN CF3 H H C3H7 18 
4.1b AMS150 CN CF3 H C3H7 C3H7 47 
4.2a AMS159 CN CF3 H H C4H9 24 
4.2b AMS158 CN CF3 H C4H9 C4H9 40 
4.3a AMS205 CN CF3 H H C5H11 17 
4.3b AMS204 CN CF3 H C5H11 C5H11 nib 
4.4a AMS167 CN CF3 H H C6H13 34 
4.4b AMS166 CN CF3 H C6H13 C6H13 22 
4.5a AMS195 Cl H Cl H C3H7 15 
4.5b AMS194 Cl H Cl C3H7 C3H7 nib 
4.6a AMS197 Cl H Cl H C4H9 10 
4.6b AMS196 Cl H Cl C4H9 C4H9 nib 
4.7a AMS199 Cl H Cl H C5H11 14 
4.7b AMS198 Cl H Cl C5H11 C5H11 nib 
4.8a AMS215 Cl H Cl H C6H13 trace 
a Isolated yield. bProduct formation evident by TLC analysis, but not isolated 
or further characterized.   
 
As summarized in Table 4.2, products synthesized in an acetonitrile solvent system 
were reliably afforded in 19% - 26% yield.   Product 4.8a, which could not be isolated using 
NMP (Table 4.1), was produced in 24% yield using acetonitrile (Table 4.2).  While 
maximal yields were observed using NMP, the results were highly variable even under very 
similar reaction conditions.  Conversely, the reactions carried out in acetonitrile produced 
slightly lower yields, but the experiments were very consistent and reliably reproducible.  
It is therefore recommended that any subsequent reactions be carried out in acetonitrile. 
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Table 4.2. Alkylation of phloroglucinol mono aryl ethers in acetonitrile 
 
Cpd Code X Y Z R1 R2 Yield (%)a 
4.8a AMS215 Cl H Cl H C6H13 24 
4.9a AMS2251 Cl Cl H H C3H7 23 
4.10a AMS2252 Cl Cl H H C4H9 22 
4.11a AMS2253 Cl Cl H H C5H11 20 
4.12a AMS2254 Cl Cl H H C6H13 27 
4.13a AMS2271 H Cl Cl H C3H7 22 
4.14a AMS2272 H Cl Cl H C4H9 19 
4.15a AMS2273 H Cl Cl H C5H11 22 
4.16a AMS2274 H Cl Cl H C6H13 23 
4.17a RS43 H H NO2 H C4H9 20 
4.18a RS39 H H NO2 H C5H11 18 
4.19a RS37 H H NO2 H C6H13 13 
a Isolated yield.  
 
4.4 Conclusion 
A simple method for the preparation of phloroglucinol monoaryl alkyl ethers from 
phloroglucinol monoaryl ethers has been developed.  The compounds were synthesized 
with the ultimate goal of testing their activity at the cannabinoid CB1 receptor.  
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4.6 Experimental Section 
 
 
General Method A  (Williamson-type alkylation) To phloroglucinol monoaryl ether (1.0 
- 2.5 equiv.) dissolved in acetonitrile or N-methylpyrrolidinone (5 – 10 mL/mmol) was 
added Cs2CO3 (1.0 – 3.0 equiv).  A condenser was placed onto the flask and the mixture was 
allowed to stir for 1 hour at 70 °C, which evolved CO2 gas and generated a dark colored 
phenoxide solution.  Finally, alkyl iodide or alkyl bromide (1.0 – 3.0 equiv.) was added 
through the condenser via syringe.  The reaction was allowed to stir at 70°C overnight.   
The reaction mixture was cooled to room temperature then poured over H2O (10 mL) 
resulting in a red colored suspension. HCl (6N) was added dropwise until the solution 
appeared slightly acidic on pH paper.  The resulting aqueous mixture was extracted with 
Et2O (3 x 15 mL).  Pooled organic extracts were washed once with brine, dried over MgSO4 
and concentrated under reduced pressure on a rotoevaporator. The resulting residue was 
purified by preparative thin layer chromatography.   
 
 
2-(3-hydroxy-5-propoxyphenoxy)-6-(trifluoromethyl)benzonitrile (4.1a) 
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General Method A.  2-(3,5-dihydroxyphenoxy)-6-(trifluoromethyl)benzonitrile (0.10 g, 
0.34 mmol) was reacted with Cs2CO3 (0.19 g, 0.60 mmol) in NMP (1.5mL) for one hour then 
1-iodopropane (0.10 g, 0.61 mmol) was added dropwise. Purification by preparative thin 
layer chromatography (20% ethyl acetate/hexane), Rf = 0.25, afforded 4.1a (20 mg, 18%) 
as an off-white waxy solid, mp 65-66 °C: 1H NMR (400 MHz; CDCl3): δ  7.54 (t, J = 8.1 Hz, 
1H), 7.41 (d, J = 7.8 Hz, 1H), 7.13 (d, J = 8.4 Hz, 1H), 6.31 (t, J = 2.2 Hz, 1H), 6.19 (t, J = 2.1 Hz, 
1H), 6.14 (t, J = 2.1 Hz, 1H), 3.84 (t, J = 6.6 Hz, 2H), 1.76 (d, J = 7.3 Hz, 2H), 1.00 (t, J = 7.4 Hz, 
3H). 13C NMR (100 MHz; CDCl3): δ 161.78, 161.75, 159.6, 156.0, 135.6, 134.0, 122.8, 120.4, 
120.10, 120.04, 112.6, 100.5, 99.8, 98.73, 98.69, 70.0, 22.7, 10.7.  Anal. Calcd. for 
C17H14F3NO3 : C, 60.54; H, 4.18; N, 4.15. Found: C; 60.76; H, 4.29; N, 3.95. 
 
 
2-(3,5-dipropoxyphenoxy)-6-(trifluoromethyl)benzonitrile (4.1b)  
General Method A.  The production of 4.1b was a competing reaction with 4.1a and was 
therefore prepared concurrently.  4.1b (60 mg, 47%) was isolated as the higher-Rf band on 
the preparative chromatography plate as a fluffy white solid, mp 61 - 61 °C.  1H NMR (400 
MHz; CDCl3): δ  7.57 (t, J = 8.1 Hz, 1H), 7.43 (d, J = 7.8 Hz, 1H), 7.14 (d, J = 8.5 Hz, 1H), 6.35 
(s, 1H), 6.22 (d, J = 1.9 Hz, 2H), 3.87 (t, J = 6.5 Hz, 4H), 1.78 (dq, J = 14.0, 7.0 Hz, 4H), 1.01 (t, 
J = 7.4 Hz, 6H). 13C NMR (100 MHz; CDCl3) δ: 161.7, 161.6, 156.1, 134.3, 134.1, 123.8, 121.0, 
120.4, 120.2(q, 5Hz), 112.5, 101.0, 99.3, 98.9, 70.1, 22.1, 10.7.  Anal. Calcd. for C20H20F3NO3 : 
C, 63.32; H, 5.31; N, 3.69. Found: C; 63.03; H, 5.36; N, 3.59.  
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2-(3-butoxy-5-hydroxyphenoxy)-6-(trifluoromethyl)benzonitrile (4.2a)  
General Method A. 2-(3,5-dihydroxyphenoxy)-6-(trifluoromethyl)benzonitrile  (0.25 g, 
0.85 mmol) was reacted with Cs2CO3 (0.20 g, 0.61 mmol) in NMP (7.5 mL) for one hour 
then 1-iodobutane (0.10 g, 0.61 mmol) was added dropwise. Purification by preparative 
thin layer chromatography (30% ethyl acetate/hexane), Rf = 0.3, afforded 4.2a (52 mg, 24 
%) as a tan solid, mp 56-58 °C:  1H NMR (400 MHz; CDCl3): δ  7.57 (t, J = 8.2 Hz, 1H), 7.43 (d, 
J = 7.8 Hz, 1H), 7.15 (d, J = 8.6 Hz, 1H), 6.30 (s, 1H), 6.19 (d, J = 1.0 Hz, 2H), 5.91 (s, 1H), 3.89 
(t, J = 6.4 Hz, 2H), 1.73 (quintet, J = 7.1 Hz, 2H), 1.45 (dq, J = 14.9, 7.4 Hz, 2H), 0.95 (t, J = 7.3 
Hz, 3H). 13C NMR (100 MHz; CDCl3): δ 161.8, 161.6, 158.4, 156.1, 134.7, 134.3, 123.7, 121.0, 
120.46, 120.34, 112.6, 100.3, 99.8, 99.5, 68.4, 31.3, 19.4, 14.0. 
 
 
2-(3,5-dibutoxyphenoxy)-6-(trifluoromethyl)benzonitrile (4.2b)   
General Method A.  The production of 4.2b was a competing reaction with 4.2a and was 
prepared concurrently.  4.2b  (100 mg, 40%) was isolated as the higher-Rf band on the 
preparative chromatography plate as a tan solid, mp 36 - 37 °C.  1H NMR (400 MHz; CDCl3): 
δ  7.57 (t, J = 8.2 Hz, 1H), 7.43 (d, J = 7.8 Hz, 1H), 7.15 (d, J = 8.6 Hz, 1H), 6.35 (s, 1H), 6.22 (s, 
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2H), 3.91 (t, J = 6.5 Hz, 4H), 1.74 (dt, J = 14.4, 7.0 Hz, 4H), 1.47 (dq, J = 15.0, 7.5 Hz, 4H), 0.96 
(t, J = 7.4 Hz, 6H). 13C NMR (100 MHz; CDCl3) δ: 161.7, 161.6, 156.1, 134.3, 134.1, 123.8, 
121.0, 120.4, 120.2(q, 5Hz), 112.5, 101.0, 99.3, 98.9, 68.3, 31.4, 19.4, 14.0.   
 
 
2-(3-hydroxy-5-(pentyloxy)phenoxy)-6-(trifluoromethyl)benzonitrile (4.3a) 
General Method A. 2-(3,5-dihydroxyphenoxy)-6-(trifluoromethyl)benzonitrile (0.25 g, 
0.85 mmol) was reacted with Cs2CO3 (0.10 g, 0.31 mmol) in NMP (6.0 mL) for one hour 
then 1-bromopentane (0.15 g, 1.0 mmol) was added dropwise. Purification by preparative 
thin layer chromatography (30% ethyl acetate/hexane) afforded 4.3a (54 mg, 17 %) as a 
white solid, mp 76-78 °C: 1H NMR (400 MHz; CDCl3): δ 7.58 (t, J = 8.2 Hz, 1H), 7.45 (d, J = 
7.8 Hz, 1H), 7.16 (d, J = 8.4 Hz, 1H), 6.29 (t, J = 2.1 Hz, 1H), 6.22 (t, J = 2.1 Hz, 1H), 6.18 (t, J = 
2.1 Hz, 1H), 3.90 (t, J = 6.5 Hz, 2H), 1.76 (dt, J = 14.2, 7.0 Hz, 2H), 1.44-1.36 (m, 4H), 0.93 (t, J 
= 7.1 Hz, 3H). 13C NMR (100 MHz; CDCl3): δ 161.9, 161.4, 158.0, 156.3, 134.08, 134.05, 
126.4, 120.53, 120.45, 120.40, 109.9, 100.2, 99.67, 99.57, 99.48, 68.7, 29.0, 28.3, 22.6, 14.2  
Anal. Calcd. for C19H18F3NO3 : C, 62.46; H, 4.97; N, 3.83. Found: C; 62.16; H, 5.02; N, 3.77. 
 
 
2-(3,5-bis(pentyloxy)phenoxy)-6-(trifluoromethyl)benzonitrile (4.3b) 
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General Method A. The production of 4.3b was a competing reaction with 4.3a and was 
prepared concurrently.  Formation of 4.3b was evident by TLC analysis Rf = 0.8 (25 % ethyl 
acetate/hexane), but not isolated or further characterized. 
 
 
2-(3-(hexyloxy)-5-hydroxyphenoxy)-6-(trifluoromethyl)benzonitrile (4.4a) 
General Method A. 2-(3,5-dihydroxyphenoxy)-6-(trifluoromethyl)benzonitrile (0.25 g, 
0.85 mmol) was reacted with Cs2CO3 (0.20 g, 0.61 mmol) in NMP (7.5 mL) for one hour 
then 1-iodohexane (0.13 g, 0.61 mmol) was added dropwise according to general 
procedure C. Purification by preparative thin layer chromatography (30% ethyl 
acetate/hexane) afforded 4.4a (80 mg, 34 %) as a white waxy solid, mp 80-82 °C: 1H NMR 
(400 MHz; CDCl3): δ  7.58 (t, J = 8.2 Hz, 1H), 7.45 (d, J = 7.5 Hz, 1H), 7.16 (d, J = 8.6 Hz, 1H), 
6.30 (t, J = 2.0 Hz, 1H), 6.21 (t, J = 2.0 Hz, 1H), 6.19 (t, J = 2.0 Hz, 1H), 5.40 (s, 1H), 3.90 (t, J = 
6.6 Hz, 2H), 1.75 (quintet, J = 7.3 Hz, 2H), 1.47-1.39 (m, 2H), 1.36-1.30 (m, 4H), 0.90 (t, J = 
6.7 Hz, 3H). 13C NMR (100 MHz; CDCl3) δ: 161.8, 161.6, 158.5, 156.1, 134.6, 134.3, 123.7, 
121.0, 120.4, 120.3(q, 5Hz), 112.6, 100.3, 99.8, 99.4, 68.7, 31.7, 29.2, 25.8, 22.8, 14.2. Anal. 
Calcd. for C20H20F3NO3 : C, 63.32; H, 5.31; N, 3.69. Found: C; 64.29; H, 5.85; N, 3.44. 
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2-(3,5-bis(hexyloxy)phenoxy)-6-(trifluoromethyl)benzonitrile (4.4b)  
General Method A.  The production of 4.4b was a competing reaction with 4.4a and was 
therefore prepared concurrently.  4.4b  (62 mg, 22 %) was isolated as the higher-Rf band 
on the preparative chromatography plate a pink solid, mp 30 - 32 °C.  1H NMR (400 MHz; 
CDCl3): δ  7.57 (t, J = 8.2 Hz, 1H), 7.41 (d, J = 7.7 Hz, 1H), 7.14 (d, J = 8.6 Hz, 1H), 6.34 (t, J = 
2.0 Hz, 1H), 6.21 (d, J = 2.1 Hz, 2H), 3.89 (t, J = 6.5 Hz, 4H), 1.74 (dt, J = 14.5, 7.0 Hz, 4H), 
1.46-1.39 (m, 4H), 1.31 (dt, J = 7.2, 3.6 Hz, 8H), 0.88 (t, J = 6.9 Hz, 6H). 13C NMR (100 MHz; 
CDCl3): δ 161.72, 161.61, 156.1, 134.5, 134.2, 123.8, 121.1, 120.45, 120.26(q, 5Hz), 112.5, 
100.9, 99.2, 98.9, 68.5, 31.7, 29.3, 25.9, 22.8, 14.2. 
 
 
3-(2,4-dichlorophenoxy)-5-propoxyphenol (4.5a)  
General Method A.  5-(2,4-dichlorophenoxy)benzene-1,3-diol (0.27 g, 1.0 mmol) was 
reacted with Cs2CO3 (0.33 g, 1.0 mmol) in NMP (7.5 mL) for one hour then 1-iodopropane 
(0.26g, 1.5 mmol) was added dropwise according to general procedure C. Purification by 
preparative thin layer chromatography (30% ethyl acetate/hexane) afforded 4.5a (46 mg, 
15%) as an amber oil. 1H NMR (400 MHz; CDCl3): δ  7.45 (d, J = 2.5 Hz, 1H), 7.19 (dd, J = 8.7, 
2.5 Hz, 1H), 6.97 (d, J = 8.7 Hz, 1H), 6.16 (t, J = 2.1 Hz, 1H), 6.08 (t, J = 2.1 Hz, 1H), 6.00 (t, J = 
2.1 Hz, 1H), 5.31 (s, 1H), 3.84 (t, J = 6.6 Hz, 2H), 1.76 (q, J = 7.2 Hz, 2H), 1.00 (t, J = 7.4 Hz, 
3H)..13C NMR (100 MHz; CDCl3): δ 161.6, 158.8, 157.8, 151.0, 130.6, 129.8, 128.3, 127.1, 
122.4, 97.8, 97.6, 97.3, 70.0, 22.7, 10.7 
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2,4-dichloro-1-(3,5-dipropoxyphenoxy)benzene (4.5b)  
General Method A. The production of 4.5b was a competing reaction with 4.5a and was 
prepared concurrently.  Formation of 4.5b was evident by TLC analysis Rf = 0.8 (20 % ethyl 
acetate/hexane), but not isolated or further characterized. 
 
 
3-butoxy-5-(2,4-dichlorophenoxy)phenol (4.6a)  
General Method A.  5-(2,4-dichlorophenoxy)benzene-1,3-diol (0.25 g, 0.92 mmol) was 
reacted with Cs2CO3 (0.35 g, 1.1 mmol) in NMP (7.5 mL) for one hour then 1-iodobutane 
(0.37g, 2.0 mmol) was added dropwise according to general procedure C. Purification by 
preparative thin layer chromatography (20% ethyl acetate/hexane) afforded 4.6a (30 mg, 
10 %) as a light yellow solid, mp 69-71 °C:  1H NMR (400 MHz; CDCl3): δ  7.45 (d, J = 2.5 Hz, 
1H), 7.20 (dd, J = 8.7, 2.5 Hz, 1H), 6.98 (d, J = 8.7 Hz, 1H), 6.15 (t, J = 2.2 Hz, 1H), 6.08 (t, J = 
2.1 Hz, 1H), 6.00 (t, J = 2.2 Hz, 1H), 5.07 (s, 1H), 3.88 (t, J = 6.5 Hz, 2H), 1.72 (dt, J = 14.6, 7.0 
Hz, 2H), 1.45 (dq, J = 15.0, 7.5 Hz, 2H), 0.95 (t, J = 7.4 Hz, 3H). 13C NMR (100 MHz; CDCl3): δ 
161.6, 158.9, 157.6, 151.0, 130.7, 129.8, 128.3, 127.2, 122.4, 97.7, 97.5, 97.3, 68.2, 31.4, 
19.4, 14.0.  Anal. Calcd. for C16H16Cl2O3 : C, 58.73; H, 4.93. Found: C; 58.76; H, 5.03. 
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2,4-dichloro-1-(3,5-dibutoxyphenoxy)benzene (4.6b)  
General Method A. The production of 4.6b was a competing reaction with 4.6a and was 
prepared concurrently.  Formation of 4.6b was evident by TLC analysis, Rf = 0.8 (20 % 
ethyl acetate/hexane), but not isolated or further characterized. 
 
 
3-(2,4-dichlorophenoxy)-5-(pentyloxy)phenol (4.7a)  
General Method A.  5-(2,4-dichlorophenoxy)benzene-1,3-diol (0.25 g, 0.92 mmol) was 
reacted with Cs2CO3 (0.35 g, 1.1 mmol) in NMP (7.5 mL) for one hour then 1-bromopentane 
(0.31 g, 2.0 mmol) was added dropwise according to general procedure C. Purification by 
preparative thin layer chromatography (30% ethyl acetate/hexane) afforded 4.7a (43 mg, 
14 %) as a light yellow solid, mp 56-60 °C: 1H NMR (400 MHz; CDCl3): δ  7.44 (d, J = 2.5 Hz, 
1H), 7.18 (dd, J = 8.7, 2.5 Hz, 1H), 6.96 (d, J = 8.7 Hz, 1H), 6.17-6.01 (m, 3H), 3.86 (t, J = 6.6 
Hz, 2H), 1.73 (quintet, J = 7.0 Hz, 2H), 1.44-1.31 (m, 4H), 0.92 (t, J = 7.0 Hz, 3H). 13C NMR 
(100 MHz; CDCl3) δ: 161.5, 158.8, 157.8, 151.0, 130.6, 129.7, 128.3, 127.1, 122.3, 97.9, 97.6, 
97.3, 68.5, 29.0, 28.3, 22.6, 14.2.   
 
98 
 
 
1-(3,5-bis(pentyloxy)phenoxy)-2,4-dichlorobenzene (4.7b)  
General Method A. The production of 4.7b was a competing reaction with 4.7a and was 
prepared concurrently.  Formation of 4.7b was evident by TLC analysis, Rf = 0.8 (20 % 
ethyl acetate/hexane), but not isolated or further characterized. 
 
 
3-(2,4-dichlorophenoxy)-5-(hexyloxy)phenol (4.8a)  
General Method A.  5-(2,4-dichlorophenoxy)benzene-1,3-diol (0.25 g, 0.92 mmol) was 
reacted with Cs2CO3 (0.20 g, 0.61 mmol) in NMP (7.5 mL) for one hour then 1-iodohexane 
(0.32 g, 1.5 mmol) was added dropwise. Purification by preparative thin layer 
chromatography (15% ethyl acetate/hexane) resulted in a trace amount of 4.8a. 
General Method A.  5-(2,4-dichlorophenoxy)benzene-1,3-diol (0.25 g, 0.92 mmol) was 
reacted with Cs2CO3 (0.20 g, 0.61 mmol) in acetonitrile (7.5 mL) for one hour then 1-
iodohexane (0.32 g, 1.5 mmol) was added dropwise. Purification by preparative thin layer 
chromatography (15% ethyl acetate/hexane) afforded 4.8a (80 mg, 24 %) as a light yellow 
oil:  1H NMR (400 MHz; CDCl3): δ  7.44 (d, J = 2.4 Hz, 1H), 7.18 (dd, J = 8.7, 2.5 Hz, 1H), 6.97 
(d, J = 8.7 Hz, 1H), 6.15 (s, 1H), 6.08 (s, 1H), 6.01 (s, 1H), 3.86 (t, J = 6.6 Hz, 2H), 1.74 (dd, J = 
14.1, 7.2 Hz, 2H), 1.41 (dt, J = 14.2, 7.0 Hz, 2H), 1.31 (dt, J = 6.6, 3.5 Hz, 4H), 0.89 (t, J = 6.5 
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Hz, 3H). 13C NMR (100 MHz; CDCl3) δ: 161.6, 158.8, 157.7, 151.0, 130.7, 129.8, 128.3, 127.1, 
122.3, 97.9, 97.6, 97.3, 68.5, 31.7, 29.3, 25.9, 22.8, 14.2. 
 
 
3-(2,3-dichlorophenoxy)-5-propoxyphenol (4.9a)  
General Method A.  5-(2,3-dichlorophenoxy)benzene-1,3-diol (0.25 g, 0.92 mmol) was 
reacted with Cs2CO3 (0.15 g, 0.46 mmol) in acetonitrile (7.0 mL) for one hour then 1-
iodopropane (0.34 g, 2.0 mmol) was added dropwise. Purification by preparative thin layer 
chromatography (15% ethyl acetate/hexane) afforded 4.9a (65 mg, 23 %) as an amber oil:  
1H NMR (400 MHz; CDCl3): δ  7.24 (dd, J = 8.1, 1.5 Hz, 1H), 7.13 (t, J = 8.2 Hz, 1H), 6.93 (dd, J 
= 8.2, 1.5 Hz, 1H), 6.17 (t, J = 2.2 Hz, 1H), 6.10 (t, J = 2.1 Hz, 1H), 6.03 (t, J = 2.1 Hz, 1H), 5.77 
(s, 1H), 3.83 (t, J = 6.6 Hz, 2H), 1.76 (sextet, J = 7.1 Hz, 2H), 0.99 (t, J = 7.4 Hz, 3H). 13C NMR 
(100 MHz; CDCl3) δ: 161.5, 158.6, 157.9, 153.8, 134.4, 127.8, 125.8, 125.4, 119.3, 98.2, 97.8, 
97.5, 70.0, 22.9, 10.7.  Anal. Calcd. for C15H14Cl2O3 : C, 57.53; H, 4.51. Found: C; 57.51; H, 
4.62. 
 
 
3-butoxy-5-(2,3-dichlorophenoxy)phenol (4.10a)  
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General Method A.  5-(2,3-dichlorophenoxy)benzene-1,3-diol (0.25 g, 0.92 mmol) was 
reacted with Cs2CO3 (0.15 g, 0.46 mmol) in acetonitrile (7.0 mL) for one hour then 1-
iodobutane (0.41 g, 2.2 mmol) was added dropwise. Purification by preparative thin layer 
chromatography (15% ethyl acetate/hexane) afforded 4.10a (65 mg, 22 %) as an amber 
oil: 1H NMR (400 MHz; CDCl3): δ  7.24 (dd, J = 8.1, 1.5 Hz, 1H), 7.13 (t, J = 8.2 Hz, 1H), 6.93 
(dd, J = 8.2, 1.4 Hz, 1H), 6.17 (t, J = 2.1 Hz, 1H), 6.10 (t, J = 2.1 Hz, 1H), 6.03 (t, J = 2.1 Hz, 1H), 
5.83 (s, 1H), 3.87 (t, J = 6.5 Hz, 2H), 1.71 (dt, J = 14.5, 7.0 Hz, 2H), 1.45 (dt, J = 15.1, 7.5 Hz, 
2H), 0.94 (t, J = 7.4 Hz, 3H).13C NMR (100 MHz; CDCl3) δ: 161.5, 158.6, 157.7, 153.7, 134.4, 
127.8, 125.9, 125.3, 119.3, 98.2, 97.8, 97.6, 68.3, 31.3, 19.4, 14.0. Anal. Calcd. for 
C16H16Cl2O3: C, 58.73; H, 4.93. Found: C; 58.90; H, 5.11. 
 
 
3-(2,3-dichlorophenoxy)-5-(pentyloxy)phenol (4.11a)  
General Method A.  5-(2,3-dichlorophenoxy)benzene-1,3-diol (0.25 g, 0.92 mmol) was 
reacted with Cs2CO3 (0.15 g, 0.46 mmol) in acetonitrile (7.0 mL) for one hour then 1-
bromopentane (0.28 g, 1.8 mmol) was added dropwise. Purification by preparative thin 
layer chromatography (15% ethyl acetate/hexane) afforded 4.11a (62 mg, 20 %) as an 
amber oil:  1H NMR (400 MHz; CDCl3): δ  7.24 (dd, J = 8.1, 1.0 Hz, 1H), 7.13 (t, J = 8.2 Hz, 1H), 
6.93 (dd, J = 8.2, 1.0 Hz, 1H), 6.17 (t, J = 2.0 Hz, 1H), 6.10 (t, J = 1.9 Hz, 1H), 6.03 (t, J = 1.9 Hz, 
1H), 5.81 (s, 1H), 3.86 (t, J = 6.6 Hz, 2H), 1.73 (quintet, J = 7.0 Hz, 2H), 1.41-1.32 (m, 4H), 
0.91 (t, J = 7.0 Hz, 3H). 13C NMR (100 MHz; CDCl3) δ: 161.5, 158.6, 157.7, 153.7, 134.4, 
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127.8, 125.9, 125.3, 119.3, 98.2, 97.8, 97.6, 68.6, 29.0, 28.3, 22.6, 14.2. Anal. Calcd. for 
C17H18Cl2O3: C, 59.84; H, 5.32. Found: C; 59.96; H, 5.41. 
 
 
3-(2,3-dichlorophenoxy)-5-(hexyloxy)phenol (4.12a)  
General Method A.  5-(2,3-dichlorophenoxy)benzene-1,3-diol (0.25 g, 0.92 mmol) was 
reacted with Cs2CO3 (0.15 g, 0.46 mmol) in acetonitrile (7.0 mL) for one hour then 1-
iodohexane (0.43 g, 2.0 mmol) was added dropwise. Purification by preparative thin layer 
chromatography (15% ethyl acetate/hexane) afforded 4.12a (87 mg, 27 %) as an amber 
oil: 1H NMR (400 MHz; CDCl3): δ  7.24 (dd, J = 8.1, 1.1 Hz, 1H), 7.13 (t, J = 8.2 Hz, 1H), 6.92 
(dd, J = 8.2, 1.2 Hz, 1H), 6.17 (t, J = 2.1 Hz, 1H), 6.10 (t, J = 2.1 Hz, 1H), 6.03 (t, J = 2.0 Hz, 1H), 
5.95 (s, 1H), 3.86 (t, J = 6.6 Hz, 2H), 1.73 (dt, J = 14.5, 7.1 Hz, 2H), 1.41 (dt, J = 14.7, 7.2 Hz, 
2H), 1.31 (dd, J = 7.1, 3.6 Hz, 4H), 0.89 (t, J = 6.9 Hz, 3H). 13C NMR (100 MHz; CDCl3) δ: 
161.5, 158.6, 157.7, 153.7, 134.4, 127.8, 125.9, 125.3, 119.3, 98.3, 97.8, 97.6, 68.6, 31.8, 
29.3, 25.9, 22.8, 14.2. Anal. Calcd. for C18H20Cl2O3: C, 60.86; H, 5.67. Found: C; 60.91; H, 5.76. 
 
 
3-(3,4-dichlorophenoxy)-5-propoxyphenol (4.13a)  
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General Method A.  5-(3,4-dichlorophenoxy)benzene-1,3-diol (0.20 g, 0.74 mmol) was 
reacted with Cs2CO3 (0.12 g, 0.37 mmol) in acetonitrile (7.0 mL) for one hour then 1-
iodopropane (0.30 g, 1.8 mmol) was added dropwise. Purification by preparative thin layer 
chromatography (25% ethyl acetate/hexane) afforded 4.13a (51 mg, 22 %) as an amber 
oil:  1H NMR (400 MHz; CDCl3): δ  7.35 (d, J = 8.8 Hz, 1H), 7.10 (d, J = 2.8 Hz, 1H), 6.86 (dd, J 
= 8.8, 2.8 Hz, 1H), 6.19 (t, J = 2.1 Hz, 1H), 6.14 (t, J = 2.1 Hz, 1H), 6.08 (t, J = 2.1 Hz, 1H), 5.79 
(s, 1H), 3.83 (t, J = 6.6 Hz, 2H), 1.76 (sextet, J = 7.1 Hz, 2H), 1.00 (t, J = 7.4 Hz, 3H).13C NMR 
(100 MHz; CDCl3) δ: 161.6, 158.3, 157.8, 156.2, 133.4, 131.2, 127.0, 121.0, 118.6, 99.3, 98.6, 
98.3, 70.1, 22.6, 10.7.  Anal. Calcd. for C15H14Cl2O3 : C, 57.53; H, 4.51. Found: C; 57.01; H, 
4.64. 
 
 
3-butoxy-5-(3,4-dichlorophenoxy)phenol (4.14a)  
General Method A.  5-(3,4-dichlorophenoxy)benzene-1,3-diol (0.20 g, 0.74 mmol) was 
reacted with Cs2CO3 (0.12 g, 0.37 mmol) in acetonitrile (7.0 mL) for one hour then 1-
iodobutane (0.36 g, 2.0 mmol) was added dropwise. Purification by preparative thin layer 
chromatography (25% ethyl acetate/hexane) afforded 4.14a (46 mg, 19 %) as an amber 
oil:  1H NMR (400 MHz; CDCl3): δ  7.35 (d, J = 8.8 Hz, 1H), 7.10 (d, J = 2.8 Hz, 1H), 6.86 (dd, J 
= 8.8, 2.8 Hz, 1H), 6.20 (t, J = 2.1 Hz, 1H), 6.13 (t, J = 2.0 Hz, 1H), 6.08 (t, J = 2.1 Hz, 1H), 5.91 
(s, 1H), 3.87 (t, J = 6.5 Hz, 2H), 1.72 (dt, J = 14.4, 7.0 Hz, 2H), 1.46 (dt, J = 15.1, 7.5 Hz, 2H), 
0.95 (t, J = 7.4 Hz, 3H).13C NMR (100 MHz; CDCl3) δ: 161.6, 158.3, 157.8, 156.2, 133.4, 131.2, 
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127.0, 121.0, 118.6, 99.3, 98.6, 98.3, 68.3, 31.3, 19.4, 14.0.  Anal. Calcd. for C16H16Cl2O3: C, 
58.73; H, 4.93. Found: C; 58.39; H, 5.02. 
 
 
3-(3,4-dichlorophenoxy)-5-(pentyloxy)phenol (4.15a)  
General Method A.  5-(3,4-dichlorophenoxy)benzene-1,3-diol (0.20 g, 0.74 mmol) was 
reacted with Cs2CO3 (0.12 g, 0.37 mmol) in acetonitrile (7.0 mL) for one hour then 1-
bromopentane (0.25 g, 1.6 mmol) was added dropwise. Purification by preparative thin 
layer chromatography (25% ethyl acetate/hexane) afforded 4.15a (55 mg, 22 %) as a light 
yellow oil:  1H NMR (400 MHz; CDCl3): δ  7.37 (d, J = 8.8 Hz, 1H), 7.11 (d, J = 2.8 Hz, 1H), 6.87 
(dd, J = 8.8, 2.8 Hz, 1H), 6.19 (t, J = 2.2 Hz, 1H), 6.13 (t, J = 2.1 Hz, 1H), 6.07 (t, J = 2.1 Hz, 1H), 
5.15 (s, 1H), 3.88 (t, J = 6.6 Hz, 2H), 1.75 (quintet, J = 7.1 Hz, 2H), 1.45-1.35 (m, 4H), 0.92 (t, J 
= 7.1 Hz, 3H).13C NMR (100 MHz; CDCl3) δ: 161.7, 158.3, 157.8, 156.2, 133.4, 131.2, 127.0, 
121.0, 118.7, 99.1, 98.6, 98.2, 68.5, 29.0, 28.3, 22.6, 14.2. Anal. Calcd. for C17H18Cl2O3: C, 
59.84; H, 5.32. Found: C; 59.84; H, 5.40. 
 
 
3-(3,4-dichlorophenoxy)-5-(hexyloxy)phenol (4.16a)  
General Method A.  5-(3,4-dichlorophenoxy)benzene-1,3-diol (0.20 g, 0.74 mmol) was 
reacted with Cs2CO3 (0.12 g, 0.37 mmol) in acetonitrile (7.0 mL) for one hour then 1-
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iodohexane (0.39 g, 1.8 mmol) was added dropwise.  Purification by preparative thin layer 
chromatography (25% ethyl acetate/hexane) afforded 4.16a (60 mg, 23 %) as a light 
yellow oil: 1H NMR (400 MHz; CDCl3): δ  7.35 (d, J = 8.8 Hz, 1H), 7.11 (d, J = 2.8 Hz, 1H), 6.86 
(dd, J = 8.8, 2.8 Hz, 1H), 6.19 (t, J = 2.2 Hz, 1H), 6.14 (t, J = 2.1 Hz, 1H), 6.07 (t, J = 2.1 Hz, 1H), 
5.62 (s, 1H), 3.88 (d, J = 6.6 Hz, 2H), 1.74 (dt, J = 14.5, 7.1 Hz, 2H), 1.45-1.38 (m, 2H), 1.35-
1.30 (m, 4H), 0.90 (t, J = 6.9 Hz, 3H).13C NMR (100 MHz; CDCl3) δ: 161.6, 158.3, 157.7, 156.2, 
133.4, 131.2, 127.0, 121.0, 118.6, 99.1, 98.6, 68.6, 31.8, 29.3, 25.9, 22.8, 14.2. Anal. Calcd. for 
C18H20Cl2O3: C, 60.86; H, 5.67. Found: C; 60.80; H, 5.71. 
 
 
3-butoxy-5-(4-nitrophenoxy)phenol (4.17a)  
General Method A.  5-(4-nitrophenoxy)benzene-1,3-diol (0.25 g, 1.0 mmol) was reacted 
with Cs2CO3 (0.17 g, 1.0 mmol) in acetonitrile (7.0 mL) for one hour then 1-iodobutane 
(0.37 g, 2.0 mmol) was added dropwise. Purification by preparative thin layer 
chromatography (25% ethyl acetate/hexane) afforded 4.17a (60 mg, 20 %) as a yellow oil: 
1H NMR (400 MHz; CDCl3): δ  8.20 (d, J = 9.4 Hz, 2H), 7.05 (d, J = 9.4 Hz, 2H), 6.27 (s, 1H), 
6.21 (s, 1H), 6.15 (s, 1H), 5.00 (s, 1H), 3.90 (t, J = 6.5 Hz, 2H), 1.74 (quintet, J = 7.2 Hz, 2H), 
1.50-1.45 (m, 2H), 0.96 (t, J = 7.3 Hz, 3H). 13C NMR (100 MHz; CDCl3): δ 163.2, 161.9, 158.0, 
156.7, 143.0, 126.1, 117.7, 100.4, 99.7, 99.3, 68.3, 31.3, 19.4, 14.0. Anal. Calcd. for 
C16H17NO5: C, 63.36; H, 5.65; N, 4.62. Found: C; 62.70; H, 5.89; N, 4.42. 
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3-(4-nitrophenoxy)-5-(pentyloxy)phenol (4.18a)  
General Method A.  5-(4-nitrophenoxy)benzene-1,3-diol (0.25 g, 1.0 mmol) was reacted 
with Cs2CO3 (0.17 g, 1.0 mmol) in acetonitrile (7.0 mL) for one hour then 1-bromopentane 
(0.30 g, 2.0 mmol) was added dropwise. Purification by preparative thin layer 
chromatography (25% ethyl acetate/hexane) afforded 4.18a (55 mg, 18 %) as a yellow oil:  
1H NMR (400 MHz; CDCl3): δ  8.20-8.16 (m, 2H), 7.06-7.02 (m, 2H), 6.28 (t, J = 2.1 Hz, 1H), 
6.20 (t, J = 2.1 Hz, 1H), 6.16 (t, J = 2.1 Hz, 1H), 3.89 (t, J = 6.6 Hz, 2H), 1.79-1.72 (m, 2H), 
1.44-1.38 (m, 4H), 0.91 (t, J = 7.1 Hz, 3H). 13C NMR (100 MHz; CDCl3) δ: 163.2, 161.8, 158.1, 
156.7, 142.9, 126.1, 117.7, 100.4, 99.7, 99.3, 68.6, 29.0, 28.3, 22.6, 14.2.  
 
 
3-(hexyloxy)-5-(4-nitrophenoxy)phenol (4.19a) 5-(4-nitrophenoxy)benzene-1,3-diol 
(0.25 g, 1.0 mmol) was reacted with Cs2CO3 (0.17 g, 1.0 mmol) in acetonitrile (7.0 mL) for 
one hour then 1-iodobutane (0.42 g, 2.0 mmol) was added dropwise. Purification by 
preparative thin layer chromatography (25% ethyl acetate/hexane) afforded 4.19a (42 mg, 
13 %) as a light yellow oil:  1H NMR (400 MHz; CDCl3): δ  8.21-8.17 (m, 2H), 7.06-7.02 (m, 
2H), 6.28 (t, J = 2.2 Hz, 1H), 6.20 (t, J = 2.1 Hz, 1H), 6.16 (t, J = 2.1 Hz, 1H), 3.89 (t, J = 6.6 Hz, 
2H), 1.75 (dt, J = 14.5, 7.1 Hz, 2H), 1.46-1.41 (m, 2H), 1.35-1.32 (m, 4H), 0.89 (t, J = 6.8 Hz, 
3H). 13C NMR (100 MHz; CDCl3) δ: 163.2, 161.8, 158.1, 156.7, 142.9, 126.1, 117.7, 100.4, 
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99.7, 99.3, 68.6, 31.7, 29.2, 25.9, 22.8, 14.2.  Anal. Calcd. for C18H21NO5: C, 65.24; H, 6.39; N, 
4.23. Found: C; 64.47; H, 6.40; N, 4.07. 
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5 
Synthesis of Indole aryl ethers as Cannabinoid Receptor Ligands 
 
5.1 Abstract 
A synthetic method has been developed to prepare the novel indole aryl ether 
analog of a napthoyl indole with known cannabinoid receptor activity.  This compound was 
synthesized in order to test the hypothesis that the ether analog would also exhibit binding 
affinity at the CB1 receptor.  The compound was synthesized in 4-steps with an overall 
unoptomized yield of 10%. Bioassay of the new compound demonstrated that it exhibited 
nanomolar binding affinity at the CB1 receptor.     
 
Scheme 5.1. Abstract scheme: proposed structure for novel indole naphthol ether cannabinoids 
 
5.1              5.2 
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5.2 Introduction 
The non-classical napthoyl indole cannabinoids came about as a result of an 
interesting serendipitous discovery in the 1980’s.  A series of unexpected connections led 
to an entirely new, structurally distinct class of cannabinoid receptor ligands (Scheme 
5.2). The drug Indometacin (5.3) was discovered in 1963.  It became (and still is) a 
prescribed non-steroidal anti-inflammatory drug (NSAID) that works by reducing 
prostaglandin production by nonselective inhibition of the enzymes cyclooxygenase 1 and 
2.  In the 1980’s, researchers at the pharmaceutical company Sterling-Winthrop were 
searching for new analgesic NSAIDS and had synthesized some derivatives of 5.3.1 One of 
those compounds was Pravadoline (5.4), which worked similarly by inhibiting COX and so 
it demonstrated anti-inflammatory and analgesic properties.  The analgesic properties of 
5.4 were, however, unexpectedly high—at doses more than 10 times lower than the 
effective anti-inflammatory dose the compound displayed strong analgesic activity in rats, 
and therefore, a COX-mediated mechanism was unlikely.2 In a logical step, the researchers 
administered 5.4 in combination with naloxone, an opioid receptor antagonist, to 
determine if the compound was reducing pain sensitivity in rats by interacting with opioid 
receptors, but the analgesic property remained so opioid activity was also unlikely.  The 
researchers were unconvinced and tested the compound in vitro using radioligand 
displacement at opioid receptors but it did not bind at up to 10 µM concentrations.  
Furthermore, subsequent extensive testing in isolated tissue preparations and in 
radioligand binding assays had ruled out the interaction of 5.4 with muscarinic, 
cholinergic, adrenergic, serotonin, opioid, purinergic, dopaminergic, histaminergic, 
109 
 
glutaminergic, VIP, NPY, somatostatin, bombesin, GABAergic, neurokinin, bradykinin, and 
prostaglandin receptors.3,4 
 
Scheme 5.2. From prescription NSAIDs to the first aminoalkyl indole cannabinoids 
 
5.3     5.4          5.5 
 
 In order to further explore this curious non-opioid antinociceptive NSAID, the 
researchers at Sterling-Winthrop conducted a structure activity relationship study of 
Pravadoline analogs resulting in several compounds that were devoid of the ability to 
inhibit prostaglandin synthesis (non NSAID) but still clearly demonstrated antinociceptive 
ability.  For the first time, it was hypothesized (in passing) that the antinociceptive 
mechanism might be associated with binding to the recently characterized cannabinoid 
receptor.2 A publication from the same group several months later produced another SAR 
study with the goal of supporting the hypothesis that the Pravadoline-derived compounds 
were cannabinoid receptor ligands by identifying molecular features that inhibit 
neuronally stimulated contractions in mouse vas deferens (MVD), an assay that responds 
well to cannabinoids, while minimizing the NSAID activity.4 The most potent compound at 
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inhibiting MVD contractions to emerge from this study was WIN 55,212-2 (5.5). Finally, 3H-
labeled 5.5 was used to demonstrate that the binding site distribution in the brain was 
functionally equivalent with the THC (5.7) derivative, CP-55940 (5.6) cannabinoid binding 
site.4 And so, a new class of cannabinoid receptor ligands was born.  The aminoalkylindole 
5.5 is still a ubiquitous and useful tool in cannabinoid research today. 
 
Figure 5.1. Synthetic THC derived cannabinoid, CP-55940 
 
5.6 
 
  In the year 1994 following the introduction of WIN 55,212-2, Huffman et al. 
published an SAR demonstrating that compounds built around a napthoyl indole core bind 
to the same receptor as THC (“CB1” receptor was a relatively new term and doesn’t actually 
appear in the paper, though it is the receptor that he was referring to).5 Prompted by the 
fact that WIN 55,212 bared little apparent structural resemblance to THC or CP-55940, 
Huffman sought to identify molecular features required for binding affinity at the 
cannabinoid receptor by analyzing and comparing both THC and WIN 55,212-2 (Scheme 
5.3). Using computer aided molecular modeling, it was shown that the two compounds 
could be aligned and superimposed.  Doing so placed the 5-carbon alkyl chain of THC near 
the nitrogen atom of the indole on 5.5.  It was therefore hypothesized that napthoyl indoles 
111 
 
bearing hydrophobic alkyl chains at the indole nitrogen would show cannabinoid activity.  
The napthoyl indole 5.1 was the most potent of the series with a Ki value of 9.5 nM. 
 
Scheme 5.3. Huffman’s rationale for designing the aminoalkyl napthoyl indoles 
 
 
The goals of the proceeding work were to develop a synthetic procedure able to 
produce a compound that would expand the SAR study conducted by Huffman as well as 
our own model of diaryl ether cannabinoids.  Noting that 5.1 is essentially a diaryl ketone, 
we envisaged that the carbonyl linkage could simply be substituted by an ether linkage 
yielding alkylindole aryl ether 5.2 reminiscent of our previously described diaryl ethers.  
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Scheme 5.4. Indole aryl ether design strategy 
 
  5.1                     5.2 
 
 
Though our synthetic procedure was used only to produce one representative 
compound, we hypothesize that upon substitution of the appropriate starting reagents, 
similar methodology could be used to produce a variety of compounds of the same form as 
5.8, thereby significantly expanding the structure activity relationship studies. 
 
Figure 5.2. Indole aryl ether general scaffold 
 
5.8 
 
5.3 Results and Discussion 
As illustrated by the retrosynthesis in Scheme 5.5, we envisioned that indole 5.9 
would be the key precursor to our target, 5.2, and could be produced by applying Fischer 
Indole Synthesis methodology to phenylhydrazone 5.10. From key precursor 5.9, SN2-
113 
 
mediated alkylation at the relatively basic amine was predicted to be facile, as it was the 
same approach used by Huffman to produce 5.1.6   
 
Scheme 5.5. Retrosynthesis to target compound 5.2 
 
                                               5.9                                                              5.10 
 
With the retrosynthesis described above in hand, the synthesis of target compound 
5.2 was mostly straightforward (Scheme 5.6). The SN2 product of 2-naphthol and 
chloroacetone afforded ketone 5.11 in high yield and acceptable purity directly from the 
workup. Phenylhydrozone 5.10 was readily afforded by the condensation of phenyl 
hydrazine with ketone 5.11 in benzene and was used subsequently without further 
purification.  The indole synthesis reaction to 5.9 proceeded with moderate difficulty. The 
workup was somewhat tedious (refer to Experimental Section for further details) and the 
resulting crude residue required careful column chromatography in order to isolate 5.9 in 
reasonable purity, though conceivably the reaction could be optimized for better results.  
Alkylation of 5.9 was analogous to procedures described by Huffman previously and 
preceded without difficulty.6   
114 
 
Scheme 5.6. Synthetic route to target compound 5.2 
 
 5.11 5.10 
 
5.9  5.2 
 
It is also worth noting that very few literature examples exist describing the 
synthesis of indoles bearing ether linkages at the 3-position, and thus 5.9 represents a 
relatively unique novel scaffold that probably deserves some further attention in the 
future.  The reaction presented here was based on an example found in patent literature 
that provided the synthesis of an indole somewhat related to 5.9.7 In the example 
presented, the reaction was carried out a room temperature and mediated by 
stoichiometric amounts of phosphorus trichloride, which are atypical conditions for a 
classical Fischer Indole synthesis, and likely proceeds via a unique mechanism that differs 
in several ways.  As proposed by Todesco et al., the reaction is likely mediated through a 
diazaphophole intermediate, ultimately ending with a Wittig-like elimination of NH2PCl2 to 
produce the indole.8    For product 5.9, the proposed mechanism is illustrated in Scheme 
5.7.  
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Scheme 5.7. Proposed indole synthesis mechanism to key precursor 5.9 
 
      5.10   
 
          5.9 
 
Radioligand displacement studies of 5.2 at CB1 receptors demonstrated a Ki value of 
245 nM, suggesting that the compound has moderate to high binding affinity. A full analysis 
and discussion of the bioassay data from compound 5.2 is presented in Chapter 6 within 
the context of the entire diaryl ether SAR studies. 
 
5.4 Conclusion 
We have demonstrated for the first time that N-alkyl indole aryl ethers may 
represent a new class of potent cannabinoid receptor ligands. Though our novel synthetic 
strategy was used only to produce one representative compound, we hypothesize that 
upon substitution of the appropriate starting reagents, similar methodology could be used 
to produce a variety of compounds resulting in an interesting cannabinoid SAR study. 
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5.6 Experimental Section 
 
All chemicals were purchased from Aldrich Chemical Company and used as received 
unless otherwise noted. TLC: silica gel (250 μm); visualization with UV light, I2, or 
phosphomolybdic acid. Chromatography: silica gel 60 Å (230–400 mesh). 1H NMR (400 
MHz) and 13C NMR (100 MHz) were recorded on a Varian 400 MHz NMR spectrometer at 
ambient temperature in CDCl3 or DMSO-d6. 1H NMR chemical shifts are reported as δ values 
(ppm) relative to TMS. 13C NMR chemical shifts are reported as δ values (ppm) relative to 
CDCl3 (77.0 ppm) or DMSO-d6 (39.5 ppm). Melting points were recorded on a Mel-temp 
apparatus and are uncorrected. Atlantic Microlab, Inc., Norcross, GA performed all CHN 
microanalyses.  
 
 
1-(naphthalen-1-yloxy)propan-2-one (5.11) 
 To a solution of 1-napthol (7.2 g, 0.05 mol) in DMF (40 mL) was added Cs2CO3 (16 g, 0.05 
mol) at room temperature and a nitrogen atmosphere was established.  The initial pink 
solution became blue/green and opaque after 15 minutes of stirring.  Chloroacetone (4 mL, 
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0.05mol) was added via syringe slowly, resulting in an exothermic reaction.  The reaction 
stirred at room temperature for 5h, over which time it became a dirty brown-green color.  
The resulting suspension was dumped into H2O (75 mL) and extracted with Et2O (2 x 75 
mL).  Combined ether extracts were washed once with NaOH (1N, 50 mL), brine (100 mL) 
and dried over Na2SO4.  The extract was filtered and concentrated to afford 5.11 (7.9 g, 
78%) as a thick amber oil that slowly formed flower shaped crystals upon sitting overnight.  
The compound was used subsequently without further purification. 1H NMR (CDCl3; 400 
MHz) δ: 8.35 - 8.37 (m, 1H), 7.82 - 7.85 (m, 1H), 7.38 – 7.55 (m, 3H), 7.36 (t, J = 8.0 Hz, 1H), 
6.66 – 6.67 (m, 1H), 4.67(s, 2H), 2.38 (s, 3H). 13C NMR (100 MHz; CDCl3) δ: 206.3, 153.7, 
134.9, 127.8, 127.0, 125.9, 122.1, 121.6, 105.1, 73.4, 27.1. 
 
 
 
1-(1-(naphthalen-1-yloxy)propan-2-ylidene)-2-phenylhydrazine (5.10) 
 5.11 (2.0 g, 10 mmol) and phenylhydrazine (1.0 g, 9.0 mmol) were dissolved in benzene 
(10 mL).  The clear orange solution became cloudy.  The reaction was carried out under 
nitrogen for 1h.  The reaction mixture was dried over Na2SO4, filtered and concentrated 
under reduced pressure on the rotary evaporator followed by high-vacuum overnight 
resulting in approximately 3 g of viscous red oil.  The compound was used without further 
purification or characterization. 
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2-methyl-3-(naphthalen-1-yloxy)-1H-indole (5.09) 
 Compound 5.10 (3.0 g, 10 mmol) was dissolved in dry DCM (25 mL).   PCl3 (1.8 mL, 21 
mmol) was syringed into the reaction and the mixture was allowed to stir at room 
temperature under nitrogen for 24h. The reaction was quenched by slowly introducing H2O 
(~0.5 mL) and resulted in the formation of copious amounts of gaseous HCl.  The reaction 
was allowed to stir for about 30 minutes until gas evolution ceased.  The reaction mixture 
was brown with some black solids.  NaOH (4N) was added until the pH of the solution 
appeared approximately neutral on pH paper.  The entire mixture was concentrated under 
reduced pressure on a rotoevaporator.  The resulting aqueous brown slurry was added to 
water (100 mL) and extraction was attempted with Et2O.  Suspended solids greatly 
impeded the extraction.*  The aqueous mixture was extracted with four more volumes of 
Et2O (100 mL).  Combined organic extracts were washed with water followed by brine then 
dried over MgSO4.  Filtration and concentration resulted in 1.07 g of reddish brown oil.  The 
oil was purified by column chromatography (10-20% EtOAc in Hexanes).  The fractions 
corresponding to TLC: Rf = 0.6 in 20% EtOAc/Hexanes proved to be 5.09 (0.6 g, 22%) as a 
red oil.  1H NMR (400 MHz; CDCl3): δ  8.60-8.57 (m, 1H), 7.87 (dd, J = 6.7, 2.8 Hz, 1H), 7.69 
(br s, 1H), 7.60-7.54 (m, 2H), 7.51-7.46 (m, 2H), 7.33-7.31 (m, 1H), 7.22 (d, J = 8.1 Hz, 1H), 
7.15 (ddd, J = 8.1, 7.1, 1.0 Hz, 1H), 7.01 (ddd, J = 7.9, 7.1, 0.9 Hz, 1H), 6.67 (dd, J = 7.7, 0.8 Hz, 
1H), 2.36 (s, 3H). 
 
119 
 
*It is recommended that the workup/extraction outlined above be modified should 
this experiment be repeated.  Quenching on ice would probably be wise.  Filtration of the 
initial reaction mixture would probably result in a cleaner workup and an extraction 
solvent other than Et2O might be better. 
  
 
 
2-methyl-3-(naphthalen-1-yloxy)-1-pentyl-1H-indole (5.2) 
5.09 (0.6 g, 2.2 mmol) was added to a stirred suspension of freshly powdered KOH (0.65 g, 
11 mmol) in DMSO (2.5 mL).  1-bromopentane (0.56 mL, 4.4 mmol) was added and the 
reaction stirred at 80°C for 24h.  The reaction mixture was poured into H2O (10 mL) and 
extracted with ethyl acetate (3 x 10mL).  Combined organic extracts were washed with 
water, brine, then dried over Na2SO4.  Concentration of the extract resulted in 0.6 g of red 
oil.  Flash column chromatography on silica (10:1 pet. ether/ EtOAc) yielded slightly 
impure 5.2 (0.4 g, 55 %) as a red oil.* In order to further purify the product, 200mg of this 
oil was subjected to preparative TLC (7% EtOAc/ Hexanes).  A yellow-colored band at 
approximately Rf = 0.5 was isolated affording 5.2 (180 mg, 90%) as a yellow oil that 
spontaneously crystallized to a tan solid. 1H NMR (400 MHz; CDCl3 ): δ  8.61-8.58 (m, 1H), 
7.90-7.86 (m, 1H), 7.61-7.54 (m, 2H), 7.47 (d, J = 8.2 Hz, 1H), 7.35 (dt, J = 8.3, 0.8 Hz, 1H), 
7.28 (d, J = 7.8 Hz, 1H), 7.22 (t, J = 8.0 Hz, 1H), 7.17 (ddd, J = 8.3, 7.1, 1.2 Hz, 1H), 7.00 (ddd, J 
= 7.9, 7.0, 0.9 Hz, 1H), 6.64 (dd, J = 7.7, 0.9 Hz, 1H), 4.12 (t, J = 7.4 Hz, 2H), 1.81 (dt, J = 14.7, 
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7.4 Hz, 2H), 1.42-1.37 (m, 4H), 0.93 (t, J = 7.0 Hz, 3H). 13C NMR (100 MHz, CDCl3) δ 155.4, 
134.9, 133.93, 133.92, 127.8, 126.7, 126.2, 125.7, 122.5, 121.3, 121.2, 119.3, 117.6, 109.5, 
107.6, 81.4, 75.8, 43.7, 30.3, 29.5, 22.8, 22.8, 14.3, 9.2.  
Anal. Calcd. for C24H25NO : C, 83.93; H, 7.34; N, 4.08. Found: C; 83.34; H, 7.35; N, 4.02.  
*Flash column chromatography in 100% petroleum ether would probably work to isolate 
pure 5.2 in one run rendering additional purification unnecessary.  
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6 
Bioassay and Structure Activity Relationship Studies of Diaryl Ethers at 
the CB1 Receptor and the Discovery of a Novel High Affinity Low 
Efficacy Compound 
 
6.1 Abstract 
Compounds consisting of a diaryl ether core described in the previous four chapters 
were evaluated for activity at the cannabinoid CB1 receptor and binding affinity data for 34 
new compounds is reported.  The compounds were initially screened by radioligand 
displacement at two concentrations.  Several moderate affinity (Ki ~ 1 μM) compounds 
emerged from initial studies and helped identify some functionality necessary for binding 
which helped drive the research forward.    Subsequent bioassay led to the discovery of one 
very high affinity compound, AMS167, with a Ki value of 1.2 nM.  This compound was 
subject to further testing where it was revealed that it behaved as a low efficacy compound.  
In support of a neutral antagonist / inverse agonist efficacy profile, AMS167 was found to 
block the behavioral effects of cannabinoid agonists in rats.  With the available data, a 
partial structure activity relationship was discussed for diaryl ether cannabinoids.   
6.2 Introduction 
Low efficacy ligands that bind to the cannabinoid receptor represent an attractive 
target for various pharmacotherapies to treat CNS-related disorders including obesity and 
123 
 
addiction.1,2 Furthermore, there are very few high affinity CB1 selective ligands that exhibit 
low efficacy profiles, and therefore, less is known about the CB1 partial agonist 
pharmacophore.   
This report describes the structure activity relationships of side-chain modified 
diaryl ether hybrid derivatives of BAY 59-3074 (2.2) and CB25 (2.3) as summarized in 
Chapter 2.  These hybrid derivative compounds were studied to determine structural 
features necessary for better binding affinity and improved solubility while retaining a 
partial agonist efficacy profile relative to their parent compounds.   
 Compounds exhibiting reasonable inhibition at two concentrations were advanced 
to full binding affinity studies and the corresponding Ki values were reported.  Several 
moderate affinity (Ki < 1 μM) and one high affinity compound (Ki = 1.2 nM) emerged.  The 
high affinity compound, AMS167, was advanced to efficacy studies and found to behave as a 
inverse agonist/neutral antagonist regarding locomotor activity in rats.   
Scheme 6.1 outlines the ligand design rationale that was guided by the bioassay 
data presented here.   In first-generation diaryl ether cannabinoids described in Chapter 2, 
it was evident that alkyl group R played a role in favorable interaction with the CB1 
receptor. Also, the relatively low activity of second generation esters suggested the 
possibility that a phenolic hydroxyl group may be important for favorable binding, a 
hypothesis that is supported by the structural features of known cannabinoids such as THC 
(1.16) and CP-55,940 (1.17).3 Third generation phloroglucinol-derived compounds were 
designed in interest of ideally decreasing lipophilicity by converting the alkyl side chains to 
alkyl ethers while simultaneously retaining the phenolic hydroxyl group with the ultimate 
goal of increasing binding affinity compared to their first generation analogs.  Given that 
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compounds with high log P values are generally associated with poor blood-brain barrier 
penetrability, the more hydrophilic compounds would likely make better drug candidates.4 
Comparing representative second and third generation compounds, approximately 10 % 
reduction in calculated Log P was accomplished (Figure 6.1). In order to further expand 
our SAR, compounds bearing a variety of different substitutions (X, Y, Z) on the electron 
deficient aryl ring were also synthesized (Chapters 3-4). 
 
Figure 6.1. Calculated Log P constants for representative first and third generation compounds 
 
                                  2.7f                       4.3a 
 
 
 
In addition to our rational design approach, several compounds were tangentially 
synthesized throughout the course of the project and were also evaluated for activity at 
CB1 receptors.  Most of the so-called “wild card” compounds did not exhibit high activity, 
but did provide valuable insight about what would not work as a viable drug candidate.  
One alkyl indole aryl ether compound, 5.2, did display good binding affinity and will likely 
be the subject of further attention by our group (Chapter 5).   
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Scheme 6.1 Overview of ligand design strategy for diaryl ether cannabinoids      
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6.3 Results and Discussion 
Biological screening of our first generation of diaryl ether cannabinoids confirmed 
that the novel scaffold held promise for the discovery of potent compounds.  Of the 
compounds screened, the highest binding affinity was in approximately the low 
micromolar range in radioligand displacement assays.  From the data illustrated in Table 
6.1, it became clear that a hydrophobic alkyl group of three or more carbons was necessary 
for binding at the CB1 receptor.  Compound 2.7a bared no alkyl chain and at 1 μM 
concentration demonstrated little to no substitution for radioligands.  Conversely, alkyl 
substituted compounds 2.7d,e demonstrated clear, albeit moderate, binding affinity, and 
displaced more than 50% radioligand at a concentration between 1 and 10 μM.  This trend 
was somewhat unsurprising, as hydrophobic alkyl chains are a reoccurring motif in many 
prototypical cannabinoid receptor ligands, such as THC (1.16), CP-55,940 (1.17), and JWH-
007 (5.1).   
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Table 6.1. SAR for first generation diaryl ether cannabinoids 
 
Cpd Code R CB1b 
(1 μM) 
 
CB1b 
(10 μM) 
 
[3H]SR141716A  
(CB1) Ki (nM) 
 
2.7a ARN142 H 3 37 >> 10,000c 
2.7b ARN156 CH3 16 30 21,055 ± 3217a 
2.7c ARN167 CH2CH3 21 37 >> 10,000c 
2.7d ARN180 CH2CH2CH3 24 60 < 10,000 c 
2.7e ARN191 CH2(CH2)2CH3 35 94 < 10,000 c 
2.7f ARN158 CH2(CH2)3CH3 39 41 293 ± 107a 
2.7g ARN190 CH2(CH2)4CH3 nd nd - 
a All the values are mean ± SEM of three experiments. b Binding affinities at CB1 receptor 
measured as % inhibition. c Estimated Ki based on concentration range of 50% inhibition. 
 
 Given the encouraging results from our first generation compounds outlined in 
Table 6.1, a second generation of compounds was synthesized with the intent of more 
closely mimicking the BAY 59-3074 (2.2) scaffold by the introduction of alkyl ester 
functionality which simultaneously produced compounds with better water solubility. Also, 
like BAY 59-3074, second generation diaryl ethers were devoid of a phenolic hydroxyl 
group, though this possibly had a detrimental effect on binding affinity. Bioassay of second 
generation compounds is illustrated in Table 6.2.  None of the compounds from the ester 
series displayed significant binding affinity.  Compound 2.8e demonstrated the most 
appreciable binding affinity of the ester series with an estimated modest 10μM inhibition 
constant.  Interestingly, a notable drop-off in binding affinity occurred when the 
hydrophobic alkyl chain increased from five carbons to six carbons in compounds 2.8e and 
2.8f, respectively, which is somewhat anomalous compared to trends usually observed 
with cannabinoids. Nevertheless, the esters tested did not possess high enough binding 
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affinity to warrant further study. A related compound, 2.6a, characterized by benzyl ether 
functionality at the site of modification, was also tested within this series. Surprisingly, 
2.6a, with an estimated inhibition constant of approximately 1 μM, demonstrated higher 
binding affinity than all of the esters, 2.8b-f, tested.  Consequently, benzyl ethers built on 
the scaffold of 2.6a may be the subject of future attention.  Several possible conclusions 
may be drawn from the results of the bioassay of second generation compounds. Despite 
their close similarity to BAY 59-3074, alkyl esters 2.8b-f were surprisingly devoid of 
activity, suggesting that electrostatic difference between an ester and a sulfonate ester was 
significant enough to impact binding affinity.  Given that phenolic hydroxyl groups 
represent a common motif in many cannabinoid receptor ligands, the absence of this 
functionality in the compounds tested may have had a negative impact on binding affinity.  
Nevertheless, neither high affinity BAY 59-3074 nor moderate affinity benzyl ether 2.6a 
possessed phenolic hydroxyl groups, so they may not be entirely necessary for binding 
affinity.  
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Table 6.2. SAR for second generation diaryl ether cannabinoids 
 
Cpd Code R CB1a 
(1 μM) 
 
CB1a 
(10 μM) 
 
2.6a AS109 Bn 49 56 
2.8b ARN199 COCH3 18 45 
2.8c ARN200 COCH2CH3 25 34 
2.8d ARN201 CO(CH2)2CH3 25 25 
2.8e ARN202 CO(CH2)3CH3 25 49 
2.8f ARN203 CO(CH2)4CH3 7 19 
a Binding affinities at CB1 receptor measured as % inhibition. 
 
Bioassay of representative third generation phloroglucinol derived cannabinoids is 
presented in Table 6.3.  The design of the compounds in this series was based partially on 
first generation compounds, with the key modification being the insertion of an ether 
linkage where the alkyl group attached to the aromatic ring in first generation compounds.  
In doing so, the phenolic hydroxyl group was retained and water solubility was increased. 
Full binding affinity curves for compounds 4.1a, 4.2a, and 4.4a were carried out (Figure 
6.2); subsequently, precise inhibition constants were determined. Compound 4.4a 
demonstrated highest binding affinity of all compounds tested, with an inhibition constant 
of 1.2 nM.   The data demonstrated a clear trend that binding affinity increased as the 
length of the alkyl chain increased. Compound 4.4a, with a six-carbon alkyl chain, 
demonstrated thousand-fold increased in binding affinity over the four-carbon analog, 4.2a 
and the three-carbon analog 4.1a exhibited 3-fold lower binding affinity than 4.2a.  The 
shape of the binding affinity curve (Figure 6.2) for 4.4a (AMS-167) suggested that the 
compound was possibly interacting with multiple receptor sites, evidenced by the shallow 
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slope and plateau in the curve between 1 nM and 100 nM, however the details of this 
somewhat unusual curve remains yet to be fully explained.5     
 
Table 6.3. Binding affinity data for third generation diaryl ether cannabinoids 
 
Cpd Code R CB1b 
(1 μM) 
 
CB1b 
(10 μM) 
 
[3H]SR141716A  
(CB1) Ki (nM) 
 
6.1 AMS137 CH3 0 14 >> 10,000c 
4.1a AMS151 CH2CH2CH3 2 59 3530 ± 976a 
4.2a AMS159 CH2(CH2)2CH3 14 78 1230 ± 125a 
4.3a AMS205 CH2(CH2)3CH3 51 52 < 1,000c 
4.4a AMS167 CH2(CH2)4CH3 65 85 1.2 ± 0.5a 
a All the values are mean ± SEM of three experiments. b Binding affinities at CB1 receptor measured as % 
inhibition. c Estimated Ki based on concentration range of 50% inhibition. 
 
 
131 
 
Figure 6.2.  Binding affinity curves for select third generation compounds 
 
 
Given the favorable binding affinity data of compound 4.4a, the analogs outlined in 
Tables 6.4, 6.5, and 6.6 were synthesized with the goal of exploring the impact of chlorine 
substitution on the otherwise experimentally untouched electron deficient aromatic ring of 
the diaryl ether scaffold. Aromatic dichloro-substitution patterns have been observed in 
some known cannabinoid receptor ligands, including Rimonabant (2.1), so it was possible 
that our new compounds would also benefit from a similar favorable interaction with the 
receptor.  Unfortunately, the results of the biological screening were largely unsuccessful 
and inconclusive.  The removal of the trifluoromethyl and nitrile functionality seen in 
previously examples negatively impacted the water solubility of the new compounds and 
consequently, made bioassay very difficult.  Only one compound of the series, 4.8a, was 
successfully screened (Table 6.4).  With a six-carbon alkyl ether, 4.8a was essentially the 
dichloro analog of potent compound 4.4a.   The analog 4.8a demonstrated moderate 
binding affinity, but much lower than that of 4.4a.  Overall, diaryl ethers bearing dichloro 
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substitution did not represent good drug candidates and further analysis of these 
compounds was abandoned.  
 
Table 6.4. Binding affinity data for third generation compounds bearing 2,4-dichloro substitution  
 
Cpd Code R CB1a 
(1 μM) 
 
CB1a 
(10 μM) 
 
[3H]SR141716A  
(CB1) Ki (nM) 
 
4.8a AMS215 CH2(CH2)4CH3 51 52 < 1000b 
a Binding affinities at CB1 receptor measured as % inhibition. b Estimated Ki based on concentration 
range of 50% inhibition. 
 
 
Table 6.5. Binding affinity data for third generation compounds bearing 3,4-dichloro substitution  
 
Cpd Code R CB1 
(1 μM) 
 
CB1 
(10 μM) 
 
4.9a AMS2251 CH2CH2CH3 IRa NIb 
4.10a AMS2252 CH2(CH2)2CH3 IRa NIb 
4.11a AMS2253 CH2(CH2)3CH3 IRa NIb 
4.12a AMS2254 CH2(CH2)4CH3 IRa NIb 
a IR: Inconsistent Results bNI No Inhibition at 10 μM, solubility was a problem 
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Table 6.6. Binding affinity data for third generation compounds bearing 2,3-dichloro substitution 
 
Cpd Code R CB1 
(1 μM) 
 
CB1 
(10 μM) 
 
4.13a AMS2271 CH2CH2CH3 IRa NIb 
4.14a AMS2272 CH2(CH2)2CH3 IRa NIb 
4.15a AMS2273 CH2(CH2)3CH3 IRa NIb 
4.16a AMS2274 CH2(CH2)4CH3 IRa NIb 
a IR: Inconsistent Results bNI No Inhibition at 10 μM, solubility was a problem 
 
 Serendipity and luck are sometimes a theme in drug design and medicinal 
chemistry.6 As such, some of the synthetic by-products that were made alongside the target 
compounds were also screened at cannabinoid receptors for activity.  A summary of these 
so-called “wild card” compounds is illustrated in Table 6.7.  Unfortunately, we did not get 
lucky with any high affinity compounds.  Nevertheless, these compounds did provide 
valuable insight to our structure activity relationship studies.  The compounds in Table 6.7 
represent di-alkyl analogs of the very active mono-alkyl phloroglucinol-derived compounds 
shown in Table 6.3.  Interestingly the di-alkyl compounds were largely devoid of activity, 
suggesting once again that the phenolic hydroxyl group likely plays a role in favorable 
interaction with the receptor.  An alternative hypothesis is that these compounds were 
simply too lipophilic to be properly assayed, similar to the problem with the di-chloro 
compounds described previously.   
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Table 6.7. Binding affinity data for “wildcard” compounds bearing di-alkyl ether substitution patterns 
 
Cpd Code R CB1a 
(1 μM) 
 
CB1a 
(10 μM) 
 
[3H]SR141716A  
(CB1) Ki (nM) 
 
3.6b AMS147 H 0 19 >> 10,000b 
3.6a AMS115 CH3 0 32 > 10,000b 
4.1b AMS150 CH2CH2CH3 37 49 ~10,000b 
4.2b AMS158 CH2(CH2)2CH3 26 42 > 10,000b 
4.3b AMS204 CH2(CH2)3CH3 nd nd - 
4.4b AMS166 CH2(CH2)4CH3 17 19 > 10,000b 
a Binding affinities at CB1 receptor measured as % inhibition. b Estimated Ki based on concentration 
range of 50% inhibition. 
 
Tangentially, a project was initiated in order to explore alkyl indole aryl ethers 
represented by compound 5.2. This compound was synthesized in order to test the 
hypothesis that the ether analog of the known CB1 receptor ligand 5.1 would also exhibit 
binding affinity at the CB1 receptor (refer to Chapter 5 for further details).  Though 
compound 5.2 seemed largely structurally distinct from our previously synthesized diaryl 
ethers, several common features could be noticed.  Namely, both compounds consisted of 
two planar aromatic systems linked by an oxygen atom.  Further, one of those aromatic 
systems was anchored to a five-carbon hydrophobic alkyl chain.  Compound 5.2 was 
synthesized and subjected to binding affinity studies at the CB1 receptor, the results of 
which are illustrated in Table 6.8 and Figure 6.3.  With a Ki value of 246 nM, compound 
5.2 demonstrated good binding affinity, however its parent analog, napthoyl indole 6.1, 
had about 25-fold higher binding affinity with a Ki of 9 nM.3 We envisage that further 
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refinement of this scaffold could potentially yield potent compounds.  Furthermore, no 
efficacy data exists for alkyl indole aryl ethers like 5.2.  While parent compound 5.1 
demonstrated full agonist efficacy at the CB1 receptor, it is possible that the diaryl ether 
analogs related to 5.2 could display diminished efficacy while retaining binding affinity.  It 
is likely that analogs of 5.2 will be the subject of future attention. 
 
Table 6.8. Binding affinity data for novel alkyl indole aryl ether 5.2 
 
Cpd Code CB1b  
(1 μM) 
 
CB1b  
(10 μM) 
 
[3H]SR141716A  
(CB1) Ki (nM)a 
 
5.2 AMS183 54 75 246 ± 101 
a All the values are mean ± SEM of three experiments. b Binding affinities at 
CB1 receptor measured as % inhibition.  
 
 
Figure 6.3. Binding affinity curve for novel alkyl indole aryl ether 5.2 
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With its high affinity for the CB1 receptor, 4.4a (AMS167) became our new lead 
compound.  In order to determine if the compound had bioavailability and to make an 
assessment of its apparent efficacy, the compound’s effect on the locomotor activity in rats 
was studied.  It has been previously established that cannabinoid receptor agonists have a 
sedative effect in animal models.7,8 Consistently, administration of the potent cannabinoid 
agonist WIN 55,212-2 (5.5) reduced the distance traveled by rats over a given time period 
as illustrated in Figure 6.4.  AMS167, administered alone, did not demonstrate a significant 
change in locomotor activity over control at either 1 mg/kg or 5 mg/kg doses.  However, 
when AMS167 was co-administered with WIN 55,212-2, locomotor activity was no longer 
attenuated as with WIN 55,212-2 alone.  Furthermore, increased dosage of AMS167 
relative to WIN 55,212-2 led to apparent complete blockage of its effects on locomotion by 
returning activity to within the same range as the control.  From this study, we have 
concluded that 4.4a, (AMS167) has good bioavailability and blood brain barrier 
penetrability as it clearly had an effect on animal behavior.  The compound antagonized the 
effects of cannabinoid agonist WIN 55,212-2, suggesting that 4.4a was binding to the CB1 
receptor and demonstrating reduced efficacy.  From this, we may conclude that 4.4a was 
either behaving as a neutral antagonist or possibly an inverse agonist at CB1 receptors.  
Further efficacy studies will be required to determine the compounds effect on CB1 
receptor second messengers.  Additionally, continued animal studies are currently 
underway in order to determine the effect of 4.4a on conditioned place preference in rats 
and will be published elsewhere. 
 Figure 6.4. In vivo activity of compound 4.4a (AMS167)
 
In summary, with compo
activity for diaryl ether cannabinoids is presented in 
the molecule highlighted.  The molecule possessed an electron deficient aryl ring that was 
borrowed from the BAY 59-3074 scaffold.  Substitution of the nitrile and trifluoromethyl 
groups for chlorine atoms had a negative impact on binding affinity and solubility. An 
electron-rich phloroglucinol-core aryl ring was connected to the electron deficient aryl ri
by ether linkage.  It was found that blocking the phenolic hydroxyl group had a significant 
negative impact on binding affinity, suggesting that hydrogen bond interaction is required 
for proper binding.  A hydrophobic alkyl ether linkage was found to ha
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und 4.4a serving as our lead, a partial analysis of structure
Figure 6.5, with the key features of 
ve a positive impact 
 
-
ng 
 on binding affinity. Further, a chain length of five to six carbons was found to produce 
optimal binding.  Removal of the ether linkage by attaching the alkyl group directly to the 
electron-rich ring had a negative impact on binding.  
of 4.4a yielded a high affinity, low efficacy cannabinoid receptor ligand. 
 
Figure 6.5.  Structural features of lead compound 4.4a
6.4 Conclusion 
A structure activity relationship for diaryl ether cannabinoids has been established.  
Through three generations of modification, several structural features have been identified 
on diaryl ether scaffolds that are necessary for binding affinity at the cann
receptor.  One high affinity compound and several moderate affinity compounds were 
produced.  The high affinity compound represents new class of cannabinoids and is 
currently serving as our lead.  Further pharmacological analysis of this compou
reported elsewhere.   
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6.6 Experimental Section 
CB1 binding assay. Cerebellum was dissected on ice and suspended in 10 volumes of ice-
cold buffer (50 mM Tris-HCl, 3 mM MgCl2, 0.1 M EDTA, pH 7.4) and homogenized for 20 sec 
with a polytron (setting 6).  The homogenates were centrifuged at 31000 x g for 10 min at 4 
°C, the supernatants discarded and the tissue resuspended in buffer and centrifuged again.  
The final pellet was resuspended at a concentration of 5 mg wet weight/mL. Triplicate 
samples of membranes were incubated in buffer for 2 h at 30 °C in a final volume of 1 mL 
buffer (50 mM Tris-HCl, 3 mM MgCl2 , 0.1 mM EDTA, 100 mM NaCl, pH 7.7 with NaOH) in 
the presence of 0.5 nM [3H]SR 141716A and 30 µM GDP.  Non-specific binding was 
determined as binding in the presence of 1 µM CP 55,940.  The incubation was terminated 
by rapid filtration through Whatman GF/B glass fiber filter paper (presoaked in cold Tris 
buffer).  The filters were rinsed 3 times, each with 5 mL Tris buffer containing 0.1% BSA 
and transferred to scintillation vials. Beckman Ready Value Scintillation Cocktail was added 
to the vials, which were counted the next day at an efficiency of approximately 40%.   
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In vivo in locomotor activity studies.  Compounds were tested for their ability to 
antagonize the locomotor decreasing effects of WIN 55212-2. Male Sprague-Dawley rats 
(Charles River, Wilmington, MA) were used for all studies. Rats were housed two per cage 
in a temperature and humidity-controlled environment under a 12 h light/dark cycle.  Food 
and water were available ad libitum.  Rats were placed in 40.4 x 40.5 x 30.3 cm Plexiglas 
enclosures placed in Digiscan locomotor activity monitors (Omnitech Electronics, 
Columbus, OH).  Panels of infrared beams (16 beams per side) with corresponding 
photodetectors were located on the sides of the chambers, and distance traveled, in 
centimeters, and horizontal activity (expressed as number of beam breaks) was measured 
in 5 min intervals for 60 min post-injection, as described previously.9 Each compound was 
tested with 3 mg/kg WIN 55212-2, to determine whether there are any antagonist effects. 
Initial doses will be determined by comparing the binding affinity of the new compound to 
that of known compounds such as 9-THC and CP 55,940, or the appropriate parent 
compound.  Each dose was administered i.p. in a volume of 1 ml/kg. Time course data was 
analyzed by ANOVA comparing the effects of the test compound to vehicle across time. A 
one-way ANOVA using dose as a variable was used to determine the relationship between 
the antagonist and blockade of the locomotor-decreasing effects of WIN 55,212-2. P values 
less than 0.05 were considered significant.  There were 8 rats/condition for the locomotor 
activity studies.  
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7 
Gram-scale Preparation of AMS-167, A Novel Low Efficacy 
Cannabinoid Receptor Ligand 
 
7.1 Abstract 
In vitro assay for Compound 4.4a (AMS167) appeared to be very promising 
regarding its utility as a high affinity low efficacy cannabinoid receptor ligand.  As such, 
larger-scale preparations were warranted in order to provide sufficient material for further 
study.  Our previously established methods were modified and optimized accordingly and a 
1.6 g batch of compound AMS167 was synthesized in 34 % yield overall in three steps.  
7.2 Introduction 
As a result of the structure activity relationship studies outlined in Chapters 2-5, 
AMS167 emerged as a promising lead compound with binding affinity of 1.2 nM and an 
apparent neutral agonist efficacy profile at the CB1 receptor in vitro.  Animal studies also 
supported the indication that the compound behaved as a neutral antagonist in vivo.  
Additional pharmacology and experiments in animal studies required gram-scale 
quantities of AMS167, so our previous synthetic methods were adjusted accordingly.  Only 
slight modification was required in order to optimize our previously described method for 
the production of this compound on a gram-scale.1 In doing so, the cost of the reaction was 
reduced and the yield was improved. 
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Figure 7.1. AMS167, a novel high affinity cannabinoid neutral antagonist 
 
4.4a 
 
7.3 Results and Discussion 
The nucleophilic aromatic substitution (SNAr) reaction to couple aryl fluoride 3.3 to 
dimethoxyphenol 3.5 proceeded as previously described except potassium hydroxide was 
used to afford the phenoxide intermediate as opposed to cesium carbonate.  This was 
mainly due to the fact that there wasn’t enough cesium carbonate on hand at the time of the 
syntheses. Interestingly, this substitution had no effect on the reaction yield and product 
recovery was nearly quantitative.  Fortuitously, the substitution also reduced the cost of 
the reaction, as cesium carbonate is approximately 3-5x more expensive than potassium 
hydroxide.  In an afternoon of work, it has been demonstrated that the reaction can 
produce up to 16 g of product 3.6a in sufficient purity to be used for further synthesis.      
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Scheme 7.1. Synthesis of AMS167 
 
                    3.3                3.5 3.6a 
 
                  3.6b                                        4.4a 
 
Boron tribromide promoted demethylation of 3.6a to afford the diol 3.6b was 
accomplished by the procedure described by Chapter 3.  This reaction has been 
demonstrated at several scales and results are fairly reproducible with linear scaling of 
reagents. It was not surprising that the demethylation step was affected by the same 
previously observed side reaction and gave a mixture of side products that made it 
necessary to purify the phloroglucinol derivative 3.6b by column chromatography. It is 
suspected, but not confirmed, that boron tribromide undergoes an unfavorable reaction 
with the trifluoromethyl group on 3.6 given a previous report that trifluoromethylarenes 
were converted to tribromomethylarenes using boron tribromide in carbon tetrachloride.2  
Nevertheless, the synthesis of up to 3 g of 3.6b was relatively straightforward.  It is 
suspected that this reaction would work on scales larger than those presented here, 
however working with large quantities of neat boron tribromide is generally undesirable.   
 As described previously in Chapter 4, multiple sites of reactivity and complex 
reaction kinetics affect the alkylation of phloroglucinol derivative 3.6b to produce the 
desired mono-alkylated product 4.4a. The milligram-scale synthesis of 4.4a was modified 
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slightly and scaled accordingly, resulting in an improvement of product recovery from 34 
% to 44 %.  It was hypothesized that an overall excess of the diol 3.6b relative to base and 
alkyl halide would favor mono-alkylated product.  Reagent quantities were controlled such 
that the diol was initially in 2.6-fold molar excess of cesium carbonate and 2.3-fold molar 
excess of iodohexane relative to base.  The reaction was carried out at a lower temperature 
of 50 °C compared to 70 °C previously and for a longer amount of time in an effort to 
reduce side reactions such as C-alkylation.  However, as a result of the longer reaction time, 
it became evident that the somewhat volatile iodohexane had begun to collect on the walls 
of the condenser.  An additional small amount of iodohexane was added after 48 h in order 
to compensate for this apparent loss. Given the complex kinetics of this reaction and that 
several variables were modified at once in the scaled procedure, it would be difficult to 
conclude that any one factor improved the yield.  The only conclusion is that the yield 
improved, and that is good.  Furthermore, this reaction has been repeated using similar 
conditions at the same scale with about the same product recovery. 
 Purification of the crude reaction mixture was straightforward.  Using flash column 
chromatography with an increasing gradient of ethyl acetate in hexanes, dialkyl ether 4.4b 
eluted first, followed by AMS167, and finally about 30 % of unreacted starting material 
3.6b was recovered for recycling.  While the solid white AMS167 isolated from the column 
was of sufficient purity to be used to further study, if desired, the compound could be 
recrystallized overnight from hexanes with about 80% recovery of the crystalline solid.   
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7.4 Conclusion 
 In order to provide a sufficient amount of our promising lead in a cannabinoid 
receptor ligand study, a scaled reaction procedure was developed.  It has been 
demonstrated that 1 - 2 grams of AMS167 can be synthesized in 34% yield in three steps 
using simple reaction conditions in a few days at low cost.   
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7.6 Experimental Section 
 
2-(3,5-dimethoxyphenoxy)-6-(trifluoromethyl)benzonitrile (3.6a) 
Dimethoxyphenol 3.5 (8.5 g, 55 mmol) was dissolved in  NMP (30mL).  Potassium 
hydroxide (4.4 g, 66 mmol based on 85% purity) was crushed to a fine powder with mortar 
and pestle and then added at once to the phenol solution.  The suspension was stirred and 
heated gently for 10 minutes resulting in a grey-green colored phenoxide solution and 
some undissolved KOH.  To the warm suspension, 2-fluoro-6-trifluoromethylbenzonitrile 
3.3 (9.5 g, 50 mmol) was added dropwise (liquefied by gentle warming with heat gun).  The 
reaction was allowed to stir at 65 °C for 3 h, resulting in a granular white solid suspended 
in brown liquid.  TLC (70% hexanes/EtOAc) indicated complete disappearance of 2-fluoro-
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6-trifluoromethylbenzonitrile.  The suspension was brought to room temperature and 
water (100mL) followed by toluene (100mL) was added.  The toluene was collected and 
the brown aqueous layer was extracted with portions of toluene (2 x 100 mL).  Pooled 
organic extracts were washed with 1N NaOH (1N, 100 mL), water (100 mL), brine (100 
mL) then dried over sodium sulfate.  Removal of solvent under reduced pressure on a 
rotoevaporatoar resulted in an off-white waxy solid, to which near-boiling water (60 mL) 
was added. The gooey, inhomogenous mixture was stirred vigorously overnight. The white 
solid was collected and washed with the aid of additional water. After drying completely 
under high vacuum 3.6a (16 g, 99%) as a shiny white solid was isolated, mp 95-97 °C: 1H 
NMR (CDCl3; 400MHz) δ: 7.57 (t, J = 8.0 Hz, 1H) 7.44 (d, J = 8.0 Hz, 1H) 7.13 (d, J = 8.0 Hz, 
1H) 6.36 (s, 1H) 6.25(s, 2H) 3.78 (s, 6H). 13C NMR (100 MHz; CDCl3) δ: 162.2, 161.5, 156.1, 
134.4, 134.1, 123.8, 121.1, 120.4, 112.6, 100.8, 98.9, 97.9, 55.7.   
 
 
2-(3,5-dihydroxyphenoxy)-6-(trifluoromethyl)benzonitrile(3.6b) 
A solution of 3.6a (6.5 g, 20 mmol) in dry methylene chloride (30 mL) in an oven-dried 
flask under a nitrogen atmosphere was cooled on ice.  Neat boron tribromide (8mL, ~80 
mmol) was carefully drawn into a syringe and added via septum to the cold aryl methyl 
ether solution over about 15 minutes.  The orange colored solution was allowed to come to 
room temperature slowly overnight.   The reaction mixture was carefully added to a 
pressure-equalized addition funnel. Methylene chloride (30 mL) was used to rinse the flask 
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and subsequently dilute the reaction mixture in the addition funnel.   The addition funnel 
was placed over a flask containing vigorously stirring cold water (150 mL) and crushed ice.  
The orange boronate-complex solution was added dropwise over about 30 minutes, adding 
additional ice to the flask if necessary.  The mixture was then allowed to stir for one hour to 
complete the hydrolysis.  The very acidic aqueous suspension was neutralized (pH 6 - 7) 
with NaOH (2N) then extracted with EtOAc (3 x 150 mL).  Pooled organic extracts were 
washed with water then brine and dried over sodium sulfate.  The extracts were 
concentrated under reduced pressure on a rotoevaporatoar to furnish an orange oil.  Silica 
was added to the crude residue and it was dry-loaded onto a silica column and purified by 
flash chromatography using 60:40 EtOAc:hexanes.  The product eluted just before a visible 
orange band on the column.  Pooled fractions were concentrated to afford a light yellow oil 
that trapped EtOAc.  Product spontaneously crystallized with the addition of several 
milliliters of hexanes to give 3.6b (4.65 g, 79%) as  a white solid, mp 178 – 180 °C: 1H NMR 
(400MHz; DMSO-d6) δ: 9.66 (s, 2H) 7.81(t, J = 8.0 Hz, 1H) 7.62(d, J = 8.0 Hz, 1H) 7.31(d, J = 
8.0 Hz, 1H) 6.17(s, 1H) 6.00(s, 2H). 13C NMR (100 MHz; DMSO-d6) δ: 161.5, 160.5, 156.5, 
136.2, 132.7, 124.3, 122.3, 121.4, 113,2, 100.7, 100.0, 98.7. Anal. Calcd for C14H8F3NO3: C, 
56.96; H, 2.73; N, 4.74. Found: C, 56.90; H, 2.83; N, 4.54. 
 
 
2-(3-(hexyloxy)-5-hydroxyphenoxy)-6-(trifluoromethyl)benzonitrile (4.4a) 
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To a stirring solution of 3.6b (4.00 g, 13.5 mmol) in NMP (100 mL) was added Cs2CO3 (1.7 
g, 5.2 mmol) and the reaction mixture was brought to 50 °C. 1-Iodohexane (2.3 g, 11 mmol) 
was added via syringe over 1h.  The reaction stirred for 48 h at this temperature then an 
additional (0.2 g, 0.9 mmol) was added and the reaction stirred for an additional 24 h.  The 
tan colored suspension was brought to room temperature and dumped into ice water (100 
mL). The mixture was brought to neutral pH by dropwise addition of HCl (6N, ~2 mL) that 
evolved CO2 gas and precipitated a brown oil.  The aqueous mixture was extracted Et2O (3 x 
75 mL).   Pooled organic layers were washed once with H2O (150 mL), brine (150 mL) then 
dried over Na2SO4 and concentrated.  The resulting oily tan residue was subjected to SiO2 
column chromatography 1:9 EtOAc:Hexanes which eluted dialkyl ether 4.4b (1.2 g, 28%), 
mp 30-32 °C. Continued chromatography with 2:8 EtOAc:Hexanes eluted the desired 
monoalkyl ether AMS167, 4.4a (1.56 g, 44 %). The white solid was recrystallized from 
hexanes; mp 80-82 °C:  1H NMR (400 MHz; CDCl3): δ  7.58 (t, J = 8.2 Hz, 1H), 7.45 (d, J = 7.5 
Hz, 1H), 7.16 (d, J = 8.6 Hz, 1H), 6.30 (t, J = 2.0 Hz, 1H), 6.21 (t, J = 2.0 Hz, 1H), 6.19 (t, J = 2.0 
Hz, 1H), 5.40 (s, 1H), 3.90 (t, J = 6.6 Hz, 2H), 1.75 (quintet, J = 7.3 Hz, 2H), 1.47-1.39 (m, 2H), 
1.36-1.30 (m, 4H), 0.90 (t, J = 6.7 Hz, 3H). 13C NMR (100 MHz; CDCl3) δ: 161.8, 161.6, 158.5, 
156.1, 134.6, 134.3, 123.7, 121.0, 120.4, 120.3(q, 5Hz), 112.6, 100.3, 99.8, 99.4, 68.7, 31.7, 
29.2, 25.8, 22.8, 14.2. 
Continued chromatography with 6:4 EtOAc:Hexanes led to recovery of the diol starting 
material 3.6b (1.2 g, 30 %).       
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8 
Synthesis of Aminobenzocyclobutenes Towards the Development 
of New Monoamine Receptor Ligands 
 
8.1 Abstract 
Aminobenzocyclobutenes (ABCBs) represent a medicinally unexplored class of 
molecules that exhibit the potential to provide valuable insight about the biogenic amine 
neurotransmitter pharmacophore and provide potential treatments for central nervous 
system disorders.  A novel synthetic method has been explored in order to develop a 
general process for the synthesis of rigid ABCB analogs of known phenethylamines (PEAs).  
A key intermediate was determined to be 1-cyanobenzocyclobutene. Several routes to this 
compound were explored and subsequently an optimized procedure was developed 
reliably providing this compound in 65% yield.  Additional reactions were attempted to 
produce phenyl substituted 1-cyanobenzocyclobutenes with mixed success.  Using the 
synthetic approach devised here, from 1-cyanobenzocyclobutene, four novel ABCB 
isomeric analogs of a known pharmacologically active PEA (RS)-phenylpropan-amine were 
synthesized.   
Scheme 8.1. Conformational restriction of ethylamine sidechain in phenethylamines 
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8.2 Introduction 
Substituted phenethylamines represent a structurally simple yet pharmacologically 
diverse set of molecules and, based on the corresponding molecular substitutions, exhibit a 
range of affinities and efficacies upon different sites within the body and especially the CNS.  
Endogenous phenethylamine neurotransmitters include dopamine, epinephrine and 
norepinephrine.  Pharmacologically active exogenous PEAs typically elicit their effects by 
the manipulation of one or more of the biogenic amine neurotransmitter pathways: 
serotonin, dopamine and/or norepinephrine.  Based partially on the extent to which they 
interact with each of these pathways, the physiological effects of substituted PEAs broadly 
fall under three descriptions: stimulants, psychedelics and/or entactogens.   Stimulants 
exert their effects predominantly through the facilitation of norepinephrine and/or 
dopamine activity.1 Psychedelic activity is nearly always correlated with agonism of the 
serotonin 5HT2A receptor, though concurrent interaction with dopamine and 
norepinephrine is also typical.2    The pharmacology of entactogens is slightly less clear, 
though common features include serotonin-releasing ability in addition to dopaminergic 
activity. Entactogens produce subjective physiological effects that resemble, but are 
fundamentally distinct from those of psychedelics or stimulants.3 Some prototypical PEAs 
and their general descriptor class are outlined in Figure 8.1. 
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Figure 8.1. Prototypical substituted phenethylamines 
 
 
PEA 
 
Common name 2C-B Amphetamine MDMA 
Class psychedelic stimulant entactogen 
Code 8.1 8.2 8.3 
 
It was recently hypothesized and subsequently demonstrated by Nichols et al. that 
conformational restriction of the ethylamine side chain in prototypical 5HT2A agonist 2C-B 
(8.1) to produce ABCB 8.4 had a direct effect on ligand binding affinity and its ability to 
activate downstream signaling pathways at the 5HT2A receptor.4 In silico docking 
simulations of 8.1 and the corresponding ABCB 8.4 within a homology model of the 5HT2A 
receptor (Figure 8.2) predicted this activity and specifically that that enantiomer 8.4a 
would direct the protonated amine towards ASP-156 within the receptor leading to a key 
ionic interaction required for binding, suggesting that 8.4a would have very high binding 
affinity.  To test this theoretical model, compounds 8.4a and 8.4b were synthesized and 
evaluated for activity in vitro and in vivo.  The hypothesis was well supported by the data; 
8.4a demonstrated picomolar affinity for 5HT2A and enantiomer 8.4b had a Ki value in the 
low nanomolar range, slightly above the binding affinity for parent compound 8.1.   
 
 Scheme 8.2. Aminobenzocyclobutene analogs of 2C
               8.1 
 
Figure 8.2 Cross-eyed stereo overlay of compounds 8.4a (blue) and 8.4b (green) docked in within the 
putative binding site of a homology model of the 5HT
Perhaps more compelling, the 
conformationally-restricted phenethylamines
on which stereoisomer was tested, meaning they
activation of several downstream signaling pathways: phospholipase C
triphosphate turnover compared to arachidonic acid and
arachidonyl glycerol.6 Most data regarding ligand interactio
comes from phospholipase C (PLC)
selectivity is an emerging concept in pharmacology and
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changes in ligand structure results in the activation of a multitude of downstream signaling 
pathways.6,7 Further, these subtle variations in ligand structure have significant impacts on 
overall in vivo activity of the drugs.8 Our understanding of the connection between the 
ligand/receptor interaction and in vivo activity is not well established.   
In light of the interesting results presented above, the research described in this 
chapter was set in motion with the ultimate goal of exploring the synthesis and 
pharmacology for ABCB analogs of the other two general classes of PEAs, the stimulants 
and entactogens, represented by prototypical compounds 8.2 and 8.3, respectively.  We 
envisage that these compounds could help verify several hypotheses.  In the same way that 
optimal binding is achieved in 5HT2A receptor when the protonated ethylamine side chains 
of PEAs are held outside of the plane of the aromatic ring, ABCB analogs of prototypical 
stimulants and entactogens 8.2 and 8.3 would demonstrate that the optimal binding 
orientation prefers similar placement of the protonated amine at the active sites of other 
targets within the CNS including, but not limited to dopamine, serotonin and 
norepinephrine receptors and/or transporters.  In support of this hypothesis, a recent 
study of the stimulant 8.2 docked at the binding site of the dopamine transporter appears 
to demonstrate this preferred out-of-plane conformation (Figure 8.4).9 Second, the rigid 
ABCB analogs would exhibit greater functional selectivity at receptor sites compared to 
their flexible parent compounds.   Given that the binding of rigid compounds could bias 
receptor towards fewer conformational microstates, it is possible that the rigid compounds 
would differentially affect second messenger pathways for a single receptor compared to 
the flexible analog. 10  
 Figure 8.3. Amphetamine, 8.2, (green) docked within th
Rigid ABCB analogs of PEAs
understanding of multiple receptor pharmaco
scientists in a number of fields including: computational chemists studying 
homology models of the receptor
signaling cascade involved in GPCR
comparing the crystal structures of rigid and flexible analogs, synthetic organic chemists 
interested in benzocyclobutane synthesis, and medicinal chemists developing medications 
for treating psychological disorde
With the above rationale and hypotheses in mind, we set forth to develop a robust 
synthetic methodology capable of producing the ABCB analogs of PEAs 
readily available inexpensive starting materials.   
 
156 
e binding site of the dopamine transporter
 
 will provide important probes capable of furthering our 
phores.  These compounds will be useful to 
s, molecular biologists interested in the molecular 
-mediated neurotransmission, x-ray crystallographers 
rs.  
8.2
 
9  
in silico 
 and 8.3 from 
157 
 
8.3 Results and Discussion 
Retrosynthetic analysis of the target scaffolds illustrated in Scheme 8.3 indicated 
that 1-cyanobenzocyclobutene derivatives 8.5a and 8.5b could potentially be key 
intermediates.  Using a parallel synthetic approach, virtually any ABCB PEA analog, 
including the target compounds 8.15a and 8.16, could potentially be synthesized from 
derivatives of this versatile substrate.  ABCBs bearing alpha-methyl functionality, as in 
8.15a,b, could be produced by a Grignard mediated process from 8.5a,b followed by direct 
reduction of the intermediate imine to the corresponding amine.  Alternatively, hydrolysis 
of the intermediate imine would afford ketone 8.6, precursor to target compound 8.16, 
which could undergo reductive amination with the appropriate (alkyl)amine.  A second 
approach to 8.16 could involve reductive amination on 8.15b using an appropriate 
carbonyl compound.   
 
Scheme 8.3. Retrosynthetic analysis to target compounds from key intermediates 8.5a,b 
 
For suffixes a,b: R1 = H or methylenedioxy, respectively. 
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The retrosynthetic strategy to key intermediates 8.5a,b from commercially 
available starting materials is illustrated in Scheme 8.4.   Both of the imagined routes 
relied on the formation of reactive aryne intermediates to form the strained 4-membered 
carbocycle, the corresponding mechanisms are illustrated in Scheme 8.5. From 2-
bromohydrocinnamonitriles 8.9a,b, strongly basic conditions simultaneously generate the 
aryne and deprotonate the relatively acidic alpha proton with subsequent regioselective 
cyclization to 1-cyanobenzocyclobutenes 8.5a,b.  Alternatively, zwitterionic 
benzenediazonium-2-carboxylates liberate gaseous nitrogen and carbon dioxide upon 
heating to generate arynes, which undergo [2+2] cycloadditions with acrylonitrile to form 
1-cyanobenzocyclobutenes.    
 
Scheme 8.4. Retrosynthetic strategy 8.5a,b from commercially available starting materials  
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Scheme 8.5. Mechanisms to 1-cyanobenzocyclobutenes 
 
 
Both synthetic approaches illustrated by the retrosynthesis in Scheme 8.4 to 
precursor 2-bromohydrocinnamonitriles 8.9a,b were attempted with mixed success 
(Scheme 8.6).  Initially, the SN2 route from bromobenzyl bromide seemed most attractive 
as it could produce the desired 2-bromohydrocinnamonitriles in one synthetic step.  
Unfortunately, using the conditions shown in Scheme 8.6 produced a mixture of the 
desired product and compound 8.10, with separation of the two being quite difficult using 
conventional techniques.  Instead, a two-step procedure from commercially available 2-
bromobenzaldehydes proved to be more reliable.  2-bromocinnamonitriles 8.10a,b were 
produced in good yield by condensation of the corresponding aldehydes with acetonitrile 
under alkaline conditions based on the procedure described by Gokel.11 The reduction of 
the unsaturated nitriles in methanolic pyridine to 8.9a,b was straightforward and has been 
described elsewhere.12  
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Scheme 8.6.  Attempted synthetic routes to 2-bromohydrocinnamonitriles 8.9a,b 
 
The cyclization of 2-bromohydrocinnamonitriles to 1-cyanobenzocyclobutenes 
using sodium amide in liquid ammonia has been described elsewhere.13 As illustrated in 
Scheme 8.7, using a similar approach, key intermediates 8.5a,b were afforded in poor to 
moderate yield.  Sodium amide was generated in situ by the addition of sodium metal to 
liquid ammonia.  It is worth noting that the success of this reaction was highly dependent 
upon conditions being kept absolutely anhydrous throughout the course of the reaction.   
 
Scheme 8.7. Cyclization of 2-bromohydrocinnamonitriles using sodium amide in liquid ammonia  
 
Though target intermediates 8.5a,b were synthesized using the procedure outlined 
in Scheme 8.7, the apparent moisture sensitivity and handling of liquid ammonia led to a 
cumbersome and tedious procedure that yielded an unsatisfactory amount of product for 
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the work involved.  Therefore, an alternative approach to 1-cyanobenzocyclobutenes was 
explored.  Previous reports have shown that 1-cyanobenzocyclobutene may be produced 
from the diazotization product of anthranilic acid followed by cyclization with 
acrylonitrile.4  We explored two possible variations of this procedure, as described in 
Scheme 8.8.  Route II relied on a previously established method using catalytic amounts of 
trifluoroacetic acid and produced the corresponding zwitterion 8.12b directly, which 
cyclized to 8.5a in DCE with a stoichiometric amount of acrylonitrile in moderate yield.14 
The major drawback of Route II was the explosive nature of compound 8.12b.  For safety, 
the product must remain wet, and it is not recommended that the procedure be carried out 
on a scale larger than a few grams.  
 
Scheme 8.8. 1-Cyanobenzocyclobutene from anthranilic acid 
 
 
 Route I represented a more traditional diazotization procedure and resulted in a 
more stable (not so explosive) diazonium salt.  The required zwitterion was generated in 
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situ using propylene oxide as an HCl scavenger during the cyclization reaction.  Several sets 
of reaction conditions and solvent systems were evaluated for the cyclization of 8.12a to 
8.5a: the solvents, DCE (worked, low yield), NMP (unsuccessful, instantly turned to hot red 
gelatinous mess), THF (worked, low yield), excess acrylonitrile as solvent (worked, ~40 % 
yield), toluene (worked well), and benzene (worked well) were evaluated.  Neither stirring 
the reaction at room temperature overnight nor immersion in an ultrasonic bath caused 
significant improvement in product recovery.  It was found that gentle heating at 40-50 °C 
for 4-5h provided the best results and minimal side products as evidenced by TLC.  To 
summarize, gently heating 8.12a in toluene or benzene with propylene oxide and excess 
acrylonitrile for 4 hours reliably produced 8.5a in 60-65% yield.  It’s worth noting that this 
is a significant improvement over similar methods to benzocyclobutenes and is, to our 
knowledge, the first reported use of aromatic solvents systems for  [2+2] cycloadditions to 
1-cyanobenzocyclobutenes.   
A side project with the goal of exploring the regioselectivity and overall generality of 
Route I in Scheme 8.8 was initiated; the same conditions were applied to substituted 
anthranilic acids 8.13 and 8.14 in Scheme 8.9.  Unfortunately, neither of the attempted 
reactions produced acceptable results.  Unexpectedly, neither electron deficient (8.13) nor 
electron rich (8.14) anthranilic acids underwent the cyclization cleanly. Therefore, for 
certain substituted PEA analogs, the cyclization route shown in Scheme 8.7 might be a 
better option. 
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Scheme 8.9.  Unsuccessful attempts at [2+2] cycloadditions on substituted anthranilic acids 
 
                                                          8.13:  X = Y = H; Z = NO2 
                                                          8.14:  X = Y = Z = OMe 
With the success of the reaction shown in Scheme 8.8, Route I, large amounts of 
8.5a could be synthesized quickly and reliably, and attention was focused on exploring the 
final reactions required to produce the target compound 8.15a.  Fortunately, a report 
existed describing an applicable procedure, and so our method was based on the same 
protocol.15 Briefly, methylmagnesium iodide in dry ether reacted with 8.5a to form an 
intermediate imine that was directly reduced using sodium borohydride in methanol 
(Scheme 8.10).   However, unlike parent compound 8.2 with only one stereocenter and 
usually exists as a racemic mixture, compound 8.15a possessed two stereocenters and 
therefore, four distinct compounds were possible—two pairs of enantiomers that were 
diastereomers (Scheme 8.11).   
 
Scheme 8.10. Grignard-mediated methylation and subsequent reduction of 8.5a  
 
8.5a                       8.15a 
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The resulting diastereomers of 8.15a were resolved by careful column 
chromatography on silica.    We found that 2% methanol in methylene chloride with a few 
drops of ammonium hydroxide as a modifier worked as an acceptable mobile phase, 
though some overlap of product fractions was typical.  The chromatography was quite 
tedious and time consuming and the exploration of alternative methods for the purification 
of these compounds is recommended.  Perhaps derivation of the amine, such as Boc 
protection, prior to chromatography would facilitate the separation.   
 
Scheme 8.11. Resolution of 8.15a diastereomers 
 
Each pair of enantiomeric 8.15a freebases (of questionable stability) was 
immediately precipitated as the corresponding sulfate salts by the addition of concentrated 
sulfuric acid to a solution of each in dry isopropanol.   
Upon comparison of the proton NMR spectra for the diastereomers, subtle 
differences in shifts were observed (Figure 8.4), however the data was not sufficient to 
completely characterize the compounds.  For conclusive identification of the absolute 
stereochemistry for each pair of enantiomers isolated, an X-ray crystal structure was 
desired.  We found that the sulfate salts of 8.15a recrystallized well from 10% water in 
 ethanol.  The X-ray crystal structure for the pair of enantiomers that eluted from the 
column first (lower relative polarity) is shown in 
(S,R)/(R,S) enantiomeric pair. 
 
Figure 8.4. Overlayed 1H NMR spectra for 8.15a diastereomers, (RS/SR) red, RR/SS blue
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Figure 8.5, and proved to be the 
 
 
 Figure 8.5. X-ray crystal structure for 8.15a enantiomers (RS/SR) that eluted from the column first
Each pair of enantiomers of 
dopamine and serotonin transporters and the results will be reported elsewhere.  We 
hypothesize that the binding affinity of these compounds will be equal to or greater than 
their parent phenethylamine analogs.
 
8.4 Conclusion 
In summary, a synthetic route to aminobenzocyclobutene analogs of prototypical 
phenethylamines has been explored.  The most strai
cycloaddition reaction with the diazonium salt of anthranilic acid to key intermediate 1
cyanobenzocyclobutene.  The nitrile was methylated using a Grignard
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8.15a was submitted for biological screening at 
 
ghtforward route proceeded via [2 + 2] 
-mediated process 
 
-
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with the resulting imine directly reduced to the corresponding amine, affording the desired 
phenethylamine analog.  Alternative methods were also explored with mixed success; 
several substituted anthranilic acids did not produce the desired 1-
cyanobenzocyclobutene.  Therefore, for products with additional substitution on the 
aromatic ring, an alternative process was recommended.  From 2-
bromohydrocinnamonitriles, the benzocyclobutene core was synthesized with the added 
advantage of regioselectivity.  The work presented here represents an ongoing effort and 
biological screening of target compounds is currently underway and will dictate future 
motivation.  Further exploration and optimization of synthetic methods presented here is 
likely.   
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8.6 Experimental Section 
 
3-(2-bromophenyl)acrylonitrile (8.11a) 
A dry 3-neck round bottom flask was charged with 40 mL anhydrous acetonitrile and 85% 
KOH (5.25 g, 80.0 mmol: based on 85% purity).  A condenser was attached and a nitrogen 
atmosphere was established.  The suspension was brought to reflux and 1-
bromobenzaldehyde (9.25 g, 50.0 mmol) dissolved in dry acetonitrile (20 mL) was added 
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via syringe over a 30 second period.  The reaction was allowed to proceed for an additional 
60 seconds then immediately poured over 100 g of crushed ice.  The resulting aqueous 
suspension was extracted with methylene chloride (3 x 100 mL). Combined organic 
extracts were washed with brine then dried over Na2SO4.  Removal of volatile materials 
under reduced pressure on a rotary evaporator yielded a brown-purple oil which was 
purified by CombiFlash using 10% EtOAc in hexanes isocratic.  Fractions collected proved 
to be 8.11a (4.2 g, 42%) as a shiny white solid, mp 55-56 °C. The product was a 4.5 : 1 
mixture of E:Z isomers, determined by 1H-NMR peak integration.   (E-isomer) 1H NMR (400 
MHz; CDCl3): δ 8.03 (dd, J = 7.8, 1.4 Hz, 1H), 7.65 (dd, J = 8.0, 1.3 Hz, 1H), 7.51 (d, J = 12.0 
Hz, 1H), 7.43 (td, J = 7.6, 1.0 Hz, 1H), 7.30 (td, J = 7.7, 1.6 Hz, 1H), 5.60 (d, J = 12.0 Hz, 1H).  
13C NMR (100 MHz; CDCl3): δ 149.3, 133.9, 132.4, 129.8, 128.2, 127.2, 125.0, 117.9, 99.3 
 
 
3-(2-bromophenyl)propanenitrile (8.9a) 
To a dry 100 mL round bottom flask was added anhydrous pyridine (28 mL) and 
anhydrous methanol (9 mL) then, with stirring, 8.11a  (3.8 g, 18 mmol) was dissolved.  
NaBH4 granules (0.9 g, 24 mmol) were then added over 1 minute.  Some gas evolution was 
observed as the light yellow solution turned orange-red.  A condenser with drying tube 
attached was fixed to the flask and a gentle reflux was established for 2 h.  Upon cooling to 
room temperature, the reaction mixture was dumped over 100 mL HCl (10%) containing 
ice.  Additional HCl (6N) was added dropwise until with mixture appeared acidic on pH 
paper. The pink solution was extracted with diethyl ether (3 x 75 mL).  Combined organic 
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extracts were washed with 10 % HCl (3 x 15 mL) until pink color, suspected to be pyridine, 
disappeared followed by water and brine then dried over Na2SO4.  The extracts were 
concentrated to 8.9a (3.6 g, 94 %) as a light yellow oil of adequate purity for further 
synthesis. 1H NMR (400 MHz; CDCl3): δ 7.57 (d, J = 7.8 Hz, 1H), 7.33-7.28 (m, 2H), 7.19-7.13 
(m, 1H), 3.10 (t, J = 7.4 Hz, 2H), 2.69 (t, J = 7.4 Hz, 2H). 13C NMR (100 MHz; CDCl3): δ 137.4, 
133.4, 131.0, 129.4, 128.2, 124.3, 119.1, 32.3, 17.8 
 
 
3-(6-bromobenzo[d][1,3]dioxol-5-yl)acrylonitrile (8.11b) 
A dry 3-neck round bottom flask was charged with anhydrous acetonitrile (20 mL) and 
freshly powdered KOH (1.0 g, 16 mmol, based on 85 % purity).  A condenser was attached 
and a nitrogen atmosphere was established.  The suspension was brought to reflux and 1-
bromopiperonal (2.3 g, 10 mmol) dissolved in 40 mL dry acetonitrile was added via syringe 
over a 60 second period.  The reaction was allowed to proceed for an additional five 
minutes at reflux then immediately poured over 100 g of crushed ice.  The resulting 
aqueous suspension was extracted with methylene chloride (3 x 40 mL). Combined organic 
extracts were washed with brine then dried over Na2SO4.  Removal of volatile materials 
under reduced pressure on a rotary evaporator yielded a brown fecal looking paste that 
was purified by CombiFlash (15 % EtOAc in hexanes isocratic).  Fractions collected proved 
to be 8.11b (1.9 g, 75%) of a fine yellow powder, mp 168-169 °C.   A small amount of 
unreacted starting material eluted before the product and can be recovered if desired.  1H 
NMR (400 MHz; CDCl3): δ 7.72 (d, J = 16.5 Hz, 1H), 7.06 (s, 1H), 6.96 (s, 1H), 6.04 (s, 2H), 
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5.67 (d, J = 16.5 Hz, 1H). 13C NMR (100 MHz; CDCl3): δ 151.1, 148.9, 148.4, 126.9, 118.2, 
117.9, 113.5, 105.7, 102.8, 96.8. 
 
 
3-(6-bromobenzo[d][1,3]dioxol-5-yl)propanenitrile (8.9b) 
To a dry 50 mL round bottom flask was added anhydrous pyridine (9 mL) and anhydrous 
methanol (3 mL) then, with stirring, 8.11b (1.5 g, 6.0 mmol) was dissolved.  NaBH4 
granules (0.30 g, 7.5 mmol) were then added over 1 minute.  Some gas evolution was 
observed as the light yellow solution turned orange-red.  A condenser with drying tube 
attached was fixed to the flask and a gentle reflux was established for 2 h.  Upon cooling to 
room temperature, the reaction mixture was dumped over 30 mL  HCl (10%) containing 
ice.  Additional HCl (6N) was added dropwise until with mixture appeared slightly acidic on 
pH paper. The pink solution was extracted with diethyl ether (3 x 30 mL).  Combined 
organic extracts were washed with HCl (10 %) until pink color, suspected to be pyridine, 
disappeared followed by brine then dried over Na2SO4.  The extracts were concentrated to 
8.9b (1.3 g, 83%) as a grape-colored oil that solidified upon sitting overnight, mp 77-78 °C.  
The tan solid was of adequate purity for further synthesis. 1H NMR (400 MHz; CDCl3): δ 
7.01 (s, 1H), 6.78 (s, 1H), 5.98 (s, 2H), 2.99 (t, J = 7.3 Hz, 2H), 2.63 (t, J = 7.3 Hz, 2H). 13C 
NMR (100 MHz; CDCl3): δ 148.05, 147.87, 130.3, 119.1, 114.5, 113.2, 110.6, 102.2, 32.2, 
18.0. 
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5,6-dihydrocyclobuta[4,5]benzo[1,2-d][1,3]dioxole-5-carbonitrile 
A 100 mL 3-neck round bottom flask was charged with liquid ammonia (~60 mL) using a 
condenser containing dry ice and acetone.  Sodium lump (0.25 g, 11 mmol) was cut into 
smaller sized chunks and with stirring carefully added to the ammonia, resulting in a deep 
blue colored solution.  A pinch of Fe(NO3)3 ∙ 9H2O was added causing the blue color to 
slowly disappear over about 15 minutes resulting in a cloudy grey-brown suspension 
containing sodium amide.  8.9b (0.5 g, 2 mmol) dissolved in a minimum amount of 
anhydrous THF was then introduced slowly.  The reaction was allowed to stir for 4h in a 
dry ice acetone bath.  Residual NaNH2 was decomposed by careful addition of NH4Cl (~1 g) 
in small portions. External cooling was removed and the ammonia was allowed to 
evaporate overnight.  The brown residue was partitioned between H2O (50 mL) and Et2O 
(50 mL).  The two-phase mixture with suspended solids was filtered through a celite pad 
and washed with additional Et2O.  The organic layer was collected and the aqueous was 
extracted with more with Et2O (2 x 50 mL).  Combined ether extracts were washed with 
water, brine and dried over Na2SO4 then concentrated under reduced pressure to a brown 
oil.  Flash column chromatography (SiO2, 0-10% EtOAc in hexanes) afforded 8.5b (150 mg, 
44%) as a tan oil. TLC: Rf 0.7 (30% EtOAc in hexanes).  1H NMR (400 MHz; CDCl3): δ  6.72 (s, 
1H), 6.64 (s, 1H), 5.92 (s, 2H), 4.09 (dd, J = 5.1, 2.4 Hz, 1H), 3.52 (dd, J = 13.7, 5.3 Hz, 1H), 
3.38 (dd, J = 13.7, 2.5 Hz, 1H). 13C NMR (100 MHz; CDCl3): δ 149.1, 148.0, 135.4, 130.6, 
120.0, 105.4, 104.6, 100.8, 35.1, 27.7. 
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Benzodiazonium 2-carboxylate hydrochloride (Route I, 8.12a)  
A solution of anthranillic acid (2.74 g, 20.0 mmol) in 30 mL of absolute ethanol was cooled 
in an ice bath and treated with 2 mL of concentrated hydrochloric acid.  Cold isoamyl nitrite 
(5.0 mL, 38 mmol) was added dropwise to the stirred solution at 0°C over approximately 
10 minutes.  The color of the solution became deep orange initially then became lighter 
towards the end of the addition.  Approximately 30 mL of diethyl ether was added causing 
the precipitation of the diazonium salt, which was collected and washed with additional ice 
cold ether until the washings were colorless affording 8.12a (3.0 – 3.4 g wet) as a white 
solid. The compound was used immediately without further purification of 
characterization.   
 
 
Benzodiazonium 2-carboxylate (Route II, 8.12b)14 
A solution of anthranillic acid (2.74 g, 20.0 mmol) and trifluoroacetic acid (c. five drops) in 
tetrahydrofuran (30 mL) was prepared in a 100 mL beaker and cooled in an external ice 
bath.  With stirring, isoamyl nitrite (5.0 mL, 38 mmol) was added over about 1 minute.  A 
transient red solid appeared then slowly disappeared.  The mixture continued stirring and 
was allowed to come to room temperature over 1 hour, then cooled to about 10°C.  The 
resulting tan precipitate was carefully collected using vacuum filtration, ensuring that it 
never dried completely, and washed with cold tetrahydrofuran until the washings were 
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colorless affording 8.12b  (2.8 – 3.0 g wet) as a tan solid.  The compound is explosive upon 
scraping and heating and must be used immediately, consequently, no further 
characterization was carried out.   
 
 
bicyclo[4.2.0]octa-1,3,5-triene-7-carbonitrile (8.5a)13 
Method A, from 8.9a:  A 250 mL 3-neck round bottom flask was charged with ~100 mL 
liquid ammonia using a condenser containing dry ice and acetone.  Sodium lump (1.3 g, 55 
mmol) was cut into smaller size chunks and with stirring carefully added to the ammonia, 
resulting in a deep blue colored solution.  A pinch of Fe(NO3)3 ∙ 9H2O was added causing the 
blue color to slowly disappear over about 15 minutes resulting in a cloudy grey-brown 
suspension containing sodium amide.  8.9a (2.1 g, 10 mmol) dissolved in a minimum 
amount of anhydrous THF was then introduced slowly.  The reaction was allowed to stir for 
4h in a dry ice acetone bath.  Residual NaNH2 was decomposed by careful addition of NH4Cl 
(~2-3 g) in small portions. External cooling was removed and the ammonia was allowed to 
evaporate overnight.  The brown residue was partitioned between H2O (100 mL) and Et2O 
(100 mL).  The two-phase mixture with suspended solids was filtered through a celite pad 
and washed with additional Et2O.  The organic layer was collected and the aqueous was 
extracted with more with Et2O (2x 100 mL).  Combined ether extracts were washed with 
water then dried with brine and dried over Na2SO4 then concentrated under reduced 
pressure to a brown oil.  Flash column chromatography on (SiO2, 0-10% EtOAc in hexanes) 
afforded 8.5a (0.4g, 31%) as a light yellow oil. TLC: Rf 0.7 (30% EtOAc in hexanes).  1H NMR 
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(400 MHz; CDCl3): δ  7.36-7.29 (m, 2H), 7.23 (d, J = 7.1 Hz, 1H), 7.14 (d, J = 6.5 Hz, 1H), 4.26 
(dd, J = 5.5, 2.8 Hz, 1H), 3.70 (dd, J = 14.2, 5.6 Hz, 1H), 3.56 (dd, J = 14.1, 2.8 Hz, 1H). 13C 
NMR (100 MHz; CDCl3): δ 143.3, 139.2, 129.7, 128.5, 123.7, 122.8, 119.9, 36.5, 29.1. 
 
Method B, from 8.12a: Wet diazonium chloride 8.12a (3 - 3.5 g, ~20 mmol) was carefully 
transferred to a reaction flask and suspended in toluene (50 mL) and acrylonitrile (30 mL).  
Propylene oxide (2.1 mL, 30 mmol) was introduced and a balloon was stretched over the 
neck of the flask and the reaction was maintained at 40°C overnight. Collection of about 
0.5L of gas signaled reaction completion.  Volatile materials were removed under reduced 
pressure on a rotary evaporator and the residue was subjected to flash column 
chromatography (SiO2 0-10% EtOAc in hexanes) to afford 8.9a (1.7 g, 66%) as a light 
yellow oil. The product eluted as a light yellow band just ahead of an intense blue band on 
the column.  Characterization proved to be identical to the material obtained using Method 
A. 
 
Method C, from 8.12b: Wet diazonium carboxylate 8.12b (2.8 - 3 g, ~20 mmol) was 
carefully transferred to a reaction flask and suspended in dichloroethane (15 mL). 
Acrylonitrile (1.5 g, 28 mmol) was added to the flask and the mixture was gently heated 
and swirled over a hotplate until gas evolution ceased (about 1 hour).    Volatile materials 
were removed under reduced pressure on a rotary evaporator and the residue was 
subjected to flash column chromatography (SiO2, 0-10% EtOAc in hexanes) to afford 8.9a 
(1.0 g, 38%) as a light yellow oil. The product eluted as a broad light yellow band just 
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behind a tight intense yellow band on the column.  Characterization proved to be identical 
to the material obtained using Method A. 
 
 
 
1-(bicyclo[4.2.0]octa-1,3,5-trien-7-yl)ethanamine  (8.15a)  
A 1M solution of methylmagnesium iodide was prepared by slowly introducing methyl 
iodide (3.4 g, 24 mmol) in 24 mL Et2O to Mg turnings (0.58 g, 24 mmol) under dry inert 
conditions and stirring until complete disappearance of Mg occurred, approximately 30 
minutes.  Using a pressure-equalizing addition funnel, 5 mL of the Grignard solution (~5 
mmol MeMgI) was introduced over 30 minutes to a stirring solution of 8.9a (0.65 g, 5 
mmol) in THF (20 mL) on ice, resulting in a banana-colored suspension.  The ice bath was 
removed and the reaction was allowed to stir at room temperature for 2 h.  
Imine reduction: The reaction mixture was cooled to 0°C using an external ice bath and 
hopefully anhydrous methanol (15 mL) was added followed by NaBH4 (473 mg, 12.5 
mmol) and was allowed to stir at room temperature overnight.  The resulting suspension 
was cooled on an ice bath and concentrated HCl was added until the mixture appeared 
slightly acidic on pH paper and was taken up in H2O (50 mL).  Additional concentrated HCl 
was required to ensure that the solution was slightly acidic.  The aqueous extract was 
washed with three volumes of toluene then made alkaline with NaOH (4N) and was 
extracted with toluene (3 x 50 mL).  Combined organic extracts were dried over Na2SO4 
and concentrated to 0.5 g of yellow residue.  Diastereomers were carefully resolved using 
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flash column chromatography (SiO2, 2% MeOH, 0.5% NH4OH, DCM).  The diastereomers 
that eluted from the column first provided (RS/SR)8.15a (100 mg, 27%*) as a transparent 
oil followed by (RR/SS)8.15a (80 mg, 22%*) as a transparent oil.  The sulfate salts of each 
were prepared by dissolving the freebases in 1-2 mL anhydrous isopropanol in a centrifuge 
tube and adding concentrated sulfuric acid (~30 mg).  The tubes were centrifuged and the 
precipitate was isolated.  The sulfate salts may be recrystallized from 10% water in ethanol 
with approximately 60% recovery.   (RS/SR)8.15a: 1H NMR (400 MHz; CDCl3): δ  7.20-7.16 
(m, 2H), 7.12-7.05 (m, 2H), 3.38 (ddd, J = 7.8, 5.4, 2.4 Hz, 1H), 3.26 (dd, J = 14.1, 5.3 Hz, 1H), 
3.10-3.06 (m, 1H), 2.86-2.82 (m, 1H), 1.21 (d, J = 6.4 Hz, 3H). 13C NMR (100 MHz; CDCl3): δ 
144.3, 143.1, 127.8, 127.0, 123.2, 122.6, 51.4, 50.7, 33.4, 21.7.  (RR/SS)8.15a: 1H NMR (400 
MHz; CDCl3): δ  7.22-7.19 (m, 2H), 7.11-7.07 (m, 2H), 3.38 (ddd, J = 7.9, 5.3, 2.5 Hz, 1H), 3.30 
(dd, J = 14.0, 5.2 Hz, 1H), 3.13 (dq, J = 8.1, 6.4 Hz, 1H), 2.94 (dd, J = 13.9, 2.4 Hz, 1H), 1.29 (d, 
J = 6.4 Hz, 3H).  13C NMR (100 MHz; CDCl3): δ 145.9, 144.1, 128.0, 127.1, 123.3, 122.7, 51.0, 
50.2, 33.9, 20.5. 
*yields calculated on the assumption that starting material 8.9a was an equimolar mixture of R and S 
enantiomers.   
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